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ABSTRACT 
Autism is a severe neurodevelopmental disorder. Development of a molecular 
diagnostic screen is an imperative step towards personalized treatments. Gene 
expression profiling using buccal samples was employed to identify susceptibility 
genes and dysregulated signaling pathways. Analyses of differentially regulated genes 
revealed numerous genes that were associated with development and function of the 
nervous and immune systems, circadian rhythm, and ERBB signaling. Amongst the 
affected l?articipants there was a patient with a 3p14.l-p13 deletion, where FOXPJ is 
located. FOXP 2 mutations are responsible for human speech and language disorders. 
Since FOXPl, FOXP2, and FOXP4 require dimerization for transcriptional activity, 
investigating the FOXPl/2/4 molecular network provides insight into the neural 
mechanisms behind language impairments in autism. HEK.293 cells were transfected 
with FOXPJ/214 constructs. QRT-PCR was used to evaluate mRNA expression of 
FOXP2 target genes. Results suggest that specific combinations of FOXPl/2/4 dimers 
may influence the transcription of target genes involved in language acquisition. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1. Introduction to Autism 
1.1.1. Autism Overview 
Autism is a devastating childhood developmental disorder that features social 
interaction deficits, language impairment, and behavioural abnormalities. This disorder is 
one of the most prevalent neurological disorders of childhood, affecting 1 in every 88 
children with a four to one ratio of males to females. 1'2 Autism affects all races, ethnic 
groups, and socioeconomic levels.1 It is a lifelong condition that generates enormous 
financial and personal costs to families and society. 
Autism is not a modern medical disorder, although it has just recently gained vast 
recognition. Swiss psychiatrist Eugen Bleuler introduced the term "autism" in 1911 to 
describe a subset of symptoms of schizophrenia.3 Derived from the Greek word "autos" 
meaning "self', it referenced a persona of extreme withdrawal from social interaction.4 
Subsequently, the definition of autism was largely redefined by Dr. Leo Kanner and Dr. 
Hans Asperger. Kanner published his original account of "early infantile autism" while at 
John Hopkins University in 1943. He conducted a qualitative case study of 11 children 
with common characteristics of social interaction and communication impairments, as 
well as restricted interests and repetitive behaviours.3 Kanner became convinced that 
these behavioural features reflected a syndrome - a specific disorder with a characteristic 
set of symptoms. In the following year at the University of Children's Clinic in Vienna, 
Asperger independently identified a similar condition in four boys that he called "autistic 
psychopathy". Asperger noted that the children, all of whom were male, exhibited a lack 
1 
of empathy, little ability to form friendships, one-sided con~ersations, intense absorption 
in specific interests, and clumsy movements.5 Unfortunately, Asperger's findings were 
largely ignored due to his untranslated work, which was mostly written in German. Dr. 
Loma Wing is credited with widely popularizing the term "Asperger's disorder" in the 
English-speaking medical community and also challenged the previously accepted model 
of autism with the concept of an autism spectrum. 6 In recent years, the idea of an autism 
syndrome has been elaborated to allow for a spectrum - a continuum of disorders 
reflecting shared core characteristics but with slightly different patterns of symptoms. 
The terms 'autism' and 'autism spectrum disorders' are used interchangeably as generic 
descriptions of this spectrum. 
In the past two decades, there has been a dramatic worldwide increase in 
diagnosed autism. Ten years ago, autism had an estimated prevalence of 1 in 250; at 
present, it is believed to affect 1 in 88 children.7 Multiple studies have attributed it to 
greater societal awareness of the condition, the broadening of diagnostic criteria, 
advanced parental age, and more frequent concurrent diagnosis of children with mental 
retardation as also having autism.7 However, these factors only partially account for the 
rise in diagnosed autism. The unexplained increase has mobilized researchers to gain a 
better understanding of the etiology of this disorder in order to develop effective 
diagnostic tools, intervention programs, and treatments. The specific causes of autism are 
unknown, although with further research, genetic factors are becoming more prevalent, 
among other possible causes. There is no cure for autism, but there is evidence to suggest 
2 
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that with early intervention, some children may function independently and successfully 
in a variety of environments. 8 
1.1.2. Symptomatology of Autism 
Autism is an enduring condition that begins in early childhood and generally 
persists throughout the life course.9 It is distinguished not by a single symptom but by a 
characteristic triad of symptoms: deficits in reciprocal social interactions, impairments in 
verbal and nonverbal communication, and restricted or repetitive behaviours (RRBs). 10•11 
Children on the autism spectrum demonstrate the same core deficits, although there is a 
marked variability in the severity of symptoms across affected individuals and over 
time.9•11 
.. 
...... t 
Retrospective literature based on parental reports and observations of home 
videotapes indicate that symptoms of autism exist very early in life. 12•13 One such 
symptom is observable impairment in reciprocal social interactions. In the first year of 
life, infants in whom autism was later diagnosed are more likely to fail in developing 
interest in reciprocal interactions and forming attachments to their primary caregivers. 14 
During preschool years, affected children continue to demonstrate little interest in their 
peers and are frequently described as emotionally remote or disconnected. 14•15 They show 
flat facial affect, do not consistently respond to their own name being called, demonstrate 
lack of showing or pointing out objects of interest to others, and have abnormalities in 
gaze monitoring (i.e., does not direct one's gaze to where someone else is looking.) 13 
Other behavioural factors associated with deficits in reciprocal social interactions include 
3 
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poor eye contact, fewer social interactions, decrease use of gestures, and lack of 
spontaneous or imaginative play.11 -14 
Another hallmark of autism is difficulty with communication. In approximately 
one-third of children with autism, speech never develops beyond the occasional word. 14,16 
Moreover, this language deficit is not accompanied by attempts to compensate through 
alternative modes of communication, such as gesture, signing, or eye contact. 11 The 
remaining two-thirds of affected children develop a varyin.g amount of speech, ranging 
from stereotyped phrases to speech. that is normal in structure, although pragmatics in 
language remain impaired. 14'16 The language of children with autism includes more 
egocentric speech, consisting of echolalia, self-repetition, thinking aloud, and purposeless 
remarks. 17 Their speech tends to have a monotone quality, without the natural lilt that 
aids in communication. 14 In contrast to this picture of pragmatic deficits, the language of 
typically developing children shows pragmatic competence from two years of age. 17 
Furthermore, this deficit in pragmatics is a language abnormality unique to autism. This 
notion is supported by the fact that non-autistic developmentally delayed clinical groups 
appear to possess pragmatic competence, in comparison to their autistic counterparts. 17 
This has led to the prevailing view that children with autism use language instrumentally 
but not communicatively. 
The third feature that defines autism is RRBs. Children with autism demonstrate 
inflexible adherence to specific non-functional routines or rituals and often become upset 
at being interrupted. Also included in this category are stereotyped and repetitive motor 
mannerisms, such as hand or finger flapping, toe walking, or complex whole body 
4 
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movements. Other behaviours include overly focused, preoccupying interests, such as 
schedules, calendars, or weather forecasts. 11 
Other associated symptoms, such as gastrointestinal problems, immune system 
irregularities, motor impairments, and sleep disturbances are common but not essential 
for a diagnosis. 18'19 The heterogeneous presentation of symptoms emerges gradually and 
with inconsistent patterns. In general, symptoms appear to manifest in one of three 
patterns: early onset (i.e., at or around the first birthday), late onset (i.e., after the first 
birthday), or regression (i.e., a period of normal development followed by a loss of 
previously mastered skills).20'21 In addition, the co-occurrence of autism with another 
medical condition is quite frequent. For example, 1-4% of children with autism have 
tuberous sclerosis and 1-2% have fragile X syndrome.22'23 Thus, the symptoms of autism 
may also coexist with symptoms that result from co-morbid disorders. 
1.1.3. Screening and Diagnosis of Autism 
A diagnosis of autism is based on descriptions and observations of behaviour. The 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV), published by the American Psychiatric Association, is an 
international classification guide, which lists the diagnostic cFiteria for autism. According 
to DSM-IV, pervasive developmental disorders (PDD) is the diagnostic umbrella 
classification for "autism-like" behaviours, which includes the prototypic autistic 
disorder, Asperger's disorder, Rett syndrome, and pervasive developmental disorder-not 
otherwise specified (PDD-NOS). 10 The distinction between these diagnoses hinge on 
subtle differences in age of onset, severity of symptoms, and association (or lack thereof) 
5 
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with language delay and intellectual disability. 15 Autistic disorder is defined by onset 
prior to three years of age and includes, but is not limited to, deficits in the three core 
symptom domains. I I The qualitative impairments in social interaction and RRBs in 
Asperger's disorder are identical to those for autistic disorder; however, language 
development and nonverbal intelligence are nearly normal.24 Asperger's disorder tends to 
be diagnosed later than autistic disorder. Io Because children with Asperger's disorder do 
not have delayed early language or problems with cognitive development, there are few 
early signs of abnormality. Difficulties in social interaction may become more apparent 
in the context of school when the child is seen with peers in a more structured social 
setting. As a result, a diagnosis for Asperger's disorder is most commonly made between 
the ages of four and eleven.24 Additionally, delays in motor development O! cl~siness 
may often be noted in children with Asperger's disorder. Io Rett syndrome is characterized 
by normal early growth and development followed by a deceleration of head growth 
between ages 5 and 48 months, loss of previously acquired purposeful hand skills, loss of 
social engagement, impaired expressive and receptive language development, 
psychomotor retardation, and stereotyped hand movements. Io Unlike the other autism 
conditions, Rett syndrome has a clear genetic cause (mutation of the MECP2 gene) and 
affects girls almost exclusively. PDD-NOS is a "sub-threshold" condition in which there 
is marked impairment of social interaction, communication, and/or RRBs, but when the 
full features for another explicitly defined PDD are not met. Typically, the symptoms of 
PDD-NOS should be recognized before a child is three years old. 10 In order to identify 
autism, several diagnostic instruments are available. Two commonly used diagnostic 
6 
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tools in autism research are the Autism Diagnostic Interview-Revised (ADI-R), a semi-
structured parent interview, and the Autism Diagnostic Observation Schedule (ADOS), 
which uses observation and interaction with the child.25 The Childhood Autism Rating 
Scale (CARS) is also widely use in clinical settings to assess: severity of autism based on 
observation of the child.26 
1.1.4. Genes and Autism 
Autism is a neurodevelopmental disorder that has strong genetic underpinnings. 
Despite this, finding the cause has been daunting for scientists because of the genetic 
complexity and wide phenotypic variation associated with this disorder. Initial evidence 
for a genetic etiology in autism came from twin and family studies. Bailey et al. found 
that 60% of monozygotic (MZ) twins were concordant for autism versus no dizygotic 
(DZ) twins; furthermore, 92% of MZ twins were concordant for a broader spectrum of 
related cognitive or social abnormalities compared to 10% of DZ twins.27 Additional 
evidence comes from the 2-6% recurrence rate in siblings of affected children, which is 
much higher than that approximate rate of 0.1-0.15% in the general population.28 Studies 
of parents and siblings have further shown that several characteristics are more prevalent 
in the family members of affected children than that of typically developing children. 
These characteristics, including social reticence, language and communication 
difficulties, preference for routines, and difficulty with change, are qualitatively similar to 
the traits comprising the criteria for autism, but are milder and have come to be known as 
the broad autism phenotype. 14'29 
7 
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The genetics of autism remains an extremely active area of research. Combined 
with rapidly advancing technology, an enormous amount of data attempting to explain 
the influence of genetics over autism has emerged. Patterns of inheritance in multiplex 
families (i.e., those families in which there are more than one child affected with the 
disorder), and the fact that some individuals demonstrate subtle related symptoms, 
suggest that autism is caused by multiple genetic abnormalities, with each abnormality 
contributing a small increment of risk to that individual. These observations have led to a 
theory that the liability to autism is due, in large part, to genetic inheritance in which 
combinations of susceptibility alleles contribute to the autism phenotype. 30 Those 
individuals who inherit many of the genetic abnormalities will exhibit more severe 
symptoms, whereas those individuals who inherit fewer genetic abnormalities will be 
only slightly affected for autism. However, in spite of the evidence supporting this 
theory, many cases of autism are the result of a de novo mutation (i.e., a genetic mutation 
that the parents neither possessed nor transmitted). Furthermore, autism is only attributed 
to a recognized genetic cause in less than 10% of cases, most commonly with tuberous 
sclerosis, fragile X syndrome, and other medical conditions.31 With regard to identifying 
genetic abnormalities associated with autism, there are three traditional approaches: 
genetic linkage studies, cytogenetic studies, and candidate gene studies. 
Given the neurobiological complexity of autism, genome-wide methods such as 
genetic linkage analysis have been utilized in an attempt to identify multiple interacting 
chromosome regions (loci), each of which may have a small effect on an individual's 
overall susceptibility to autism. Many researchers have focused on multiplex families to 
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perform linkage analysis. Genetic linkage analysis involves systematically testing 
markers in multiplex families to assess whether loci that seem to segregate with the 
disorder can be identified. Thus far, data from the analysis of genome scans have 
implicated as many as 20 genes in the causation of autism. 32 Consistent evidence for 
linkage has emerged for chromosome 7q (the long arm of chromosome 7). Other regions 
of interest, verified by several studies, include 2q (the long arm of chromosome 2), l 6p 
(short arm of chromosome 6), and l 7q (the long arm of chromosome 17).31 ,32 
Cytogenetic studies have also been very revealing by way of pinpointing relevant 
inherited or de novo chromosomal abnormalities in affected individuals. High-resolution 
cytogenetic scans in families with affected individuals have aided the location of specific 
I., .. 
genes or chromosomal loci potentially associated with autism. Chromosome aberrations, 
including breakpoints, translocations, deletions, duplications, and inversions, have been 
visualized with the use of various stains. With the exception of chromosomes 14 and 20, 
cytogenetic abnormalities of virtually all the chromosomes have been found to be 
associated with autism. 31 Cytogenetic abnormalities found at the l 5q 11-q 13 locus are 
reported most frequently, representing up to 1-4% of patients.33 Various case reports have 
described duplications at this locus, where maternal transmission of the defect is 
implicated.34'35 Chromosome translocations have also implicated the 7q22-33 locus.31 
Reports of cytogenetic abnormalities coinciding with genetic linkage findings have been 
rare; however, Ashley-Koch and colleagues have identified a multiplex family in which 
three siblings had inherited from their mother a paracentric inversion on chromosome 
7q.36 In this family, the two male siblings have autistic disorder, while the female sibling 
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has expressive language disorder. With regard to mode of inheritance, this suggests that 
the disorder is not inherited in a simple Mendelian fashion. Multiple interacting genes, as 
well as environmental factors, are likely to be involved. 
Candidate genes have been chosen on the basis of their position near known 
chromosomal aberrations, location near linkage signals, or knowledge about their 
biological function. The numerous reports of linkage findings and cytogenetic 
abnormalities on chromosomes 7 and 15 have indicated that these regions may harbour 
autism susceptibility genes.37'38 Several genes have been identified within these regions 
and are now considered potential candidate genes of autism. The candidate genes on 
chromosome 7 include WNT2 and FOXP2.39•40 WNT2 was investigated as a putative risk 
factor of autism because members of the WNT (Wingless) gene family influence the 
development of numerous organs and. systems, including the central nervous system 
(CNS).41 It has been reported that variations in the WNT2 gene are fowid more often in 
affected individuals, especially in a subset of people with severe language delays.39 One 
of the most interesting candidate genes of chromosome 7 is the FOXP 2 gene. Speech and 
language impairments have been documented in two different multigenerational families 
with point mutations of FOXP 2, as well as in several cases of chromosomal 
rearrangements that disturb the integrity of the FOXP2 locus.42•43 Thus far, the 
association of FOXP 2 with autism has been met with mixed results, although two studies 
have reported positive findings.40•44 Additionally, genes such as UBE3A and GABRB3 
have been identified as potential candidate genes because they map onto the common 
duplication site on chromosome l 5q 11-13. UBE3A is aiso linked to Angelman 
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Syndrome, a genetic disorder that shares 'many similar characteristics with autism. 
Individuals with Angelman syndrome have mental retardation, usually do not possess 
speech, may flap their arms and hands, and have poor muscle tone and inability to 
coordinate muscle movements. 32 GABRB3 codes for GABA ·receptor subunits. GABA is 
the principal inhibitory neurotransmitter in the CNS, controlling excitability in the adult 
brain. There is evidence to support a role for genetic variants within GABRB3 in autism.45 
Taken together, it is apparent that one prominent factor in the development of autism is a 
genetic predisposition. 
1.1.5. Environment and Autism 
The disparity among MZ twin pairs, who share 100% of their genes and are non-
concordant for diagnosis, indicates that there are other factors that contribute to the 
development of autism. Although autism is believed to be primarily genetic in origin, the 
role of environmental factors is an area of growing interest. The developing brain 
undergoes its most rapid development from the prenatal period through to early postnatal 
life. This critical period is most vulnerable to environmental insults because it depends on 
the temporal and regional status of developmental processes. Some aspects of neural 
development continue into adolescence, and even into early adulthood (approximately 25 
years of age).46 Neurodevelopment encompasses the process of neurogenesis, 
proliferation, migration, differentiation, synapse formation, and myelination. Synaptic 
pruning and reduction of excess neurons are also critical aspects of brain development. 
The sequential unfolding of form and function involves tightly regulated gene expression 
changes. Disruption of this sequence at any point during development can have long-
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lasting consequences for brain function later in life. Each of these developmental events 
represents a substrate for environmentally induced dysregulation, alone or in concert with 
genetic susceptibility, to influence the risk for autism. 
There is evidence to suggest that environmental exposure to chemical and 
biological age~ts during critical periods of gestation and/or early postnatal development 
can increase the likelihood of the development of autism.47 Figure I. I depicts the critical 
periods during prenatal human development that, following exposure to teratogens, can 
lead to developmental abnormalities.48 For instance, maternal use of alcohol during 
pregnancy can result in fetal alcohol syndrome, birth defects, and cognitive or 
behavioural problems.49 Several studies have described children with co-morbid 
diagnoses of both fetal alcohol syndrome and autism, suggesting that in some cases ' '· 
alcohol may be responsible for autism as a result of early gestational exposures.50•51 
Likewise, valproic acid, an anti-epileptic medication, has been linked with cases of 
autism, as well as developmental delays or neurological abnormalities in a number of 
exposed children. 52•53 Thalidomide is another notable association of autism with a 
pharmaceutical agent. Thalidomide, advertised in the 1950s as a safe drug for morning 
sickness, caused developmental disabilities and severe limb defects in the offspring of 
some women who took it while pregnant. The risk of autism was particularly increased 
when the exposure to the drug occurred early in pregnancy, specifically between the 20th 
and 24th day of gestation, lending support to the idea that autism reflects a disruption of 
neurological events early in the embryological period.47 More recently, a connection 
between misoprostol exposure during the first trimester of pregnancy and the 
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development of autism-related features in Mobius syndrome has been established.54 
Collectively, these findings suggest that the window of susceptibility for autism induction 
may be very early in gestation. Fortunately, there is a growing children's environmental 
health movement that emphasizes the unique vulnerabilities of fetuses and children to 
environmental exposures and points out the increasing body of evidence for adverse 
effects on biological growth and development. 55 
Maternal infection and prenatal viral exposure is considered yet another non-
genetic cause of autism. Many studies over the year have presented evidence for the 
association of autism with viral infections. The strongest association of a viral infection 
to autism is congenital rubella. 56 The prevalence rates were 412 children meeting full 
criteria of autism, with an additional 329 children displaying a significant number of 
autism-related symptoms, for a_ total of 741 affected children per 10,000 children having 
congenital rubella. Other viruses have also been reported to be associated with autism. 
Most of these reports are case studies linking viruses such as cytomegalovirus and herpes 
simplex to autism. 57•58 
A large body of evidence indicates that the immune system appears to play an 
important role in the development and progression of neurological disorders. 59 More 
specifically, disturbances of the blood-brain barrier system resulting from inflammation 
have been implicated as one of the leading causes. Infection-associated immunological 
events in early fetal life may play a role in the initiation of neurological disorders due to 
long-term alterations in the vasculature and function of the blood-brain barrier. A 
dysfunctional blood-brain barrier could lead to immediate cell death during susceptible 
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periods of brain development, thereby predisposing the developing nervous system to 
additional failures in ·subsequent cell migration and synapse maturation, or may increase 
the susceptibility of the brain to further exposures to toxins. 
Recent studies have shown that children diagnosed with autism display sustained 
inflammation, as evidenced by an increased expression of pro-inflammatory cytokines in 
the brain. 60 The transport or synthesis of cytokines in the brain facilitates 
neuroinflammation and possible neurotransmitter imbalances.61 This can have profound 
effects on many aspects of brain function including neurotransmitter metabolism, 
neuroendocrine function, synaptic plasticity, and neurocircuits that regulate mood, motor 
activity, motivation, anxiety, and alarm.62 In a mouse experimental system, it has been 
shown that the induction of prenatal inflammation using poly(I:C) during gestation led to 
disturbances of brain maturation associated with cognitive and behavioural defects, 
which were comparable to some of the symptoms observed in autism.63 Specifically, the 
relative expression of pro- and anti-inflammatory cytokines in the fetal brain in response 
to maternal immune challenge was deemed an important determinant for the precise 
pathological profile emerging in later life. The mechanisms of fetal neurotoxicity are 
complex and still not fully understood. 
Autism is also associated with some obstetric risk factors, including advanced 
parental age, low birth weight, gestation duration, and hypoxia during childbirth. 64•65 A 
variety of postnatal contributors to autism have been proposed as well, including 
allergies, drug exposure, vaccines, post-natal infections, certain foods, and heavy 
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metals.66 Thus far, the evidence for these risk factors is anecdotal and has not been 
confirmed by reliable studies. 
A primary area of interest that holds great importance for discerning the 
environmental contributions to autism is whether regressive autism reflects a distinct 
etiology from non-regressive autism. There has been significant public concern that 
exposure to harmful environmental agents during the early postnatal period triggers 
autism. The prospect that regressive autism is provoked by an environmental exposure 
suggests the need to carefully examine a range of postnatal exposures in addition to 
possible in utero exposures. On the other hand, it should be noted that the occurrence of 
developmental regression does not necessarily implicate environmental causation. There 
• 
are examples of disorders, s4ch as Rett syndrome, that are known to be linked to a single 
gene mutation that features a period of normal development followed by regression. 
Instead, regressive autism may reflect a latent effect of much earlier exposures. 
The rare instances of environmental agents acting alone to cause autism suggests 
the probable interaction of environmental influences with autism susceptibility genes. 
Interactions of genes and environment might occur at different levels. Genetic influences 
may act synergistically with environmental exposures as primary triggers of autism. 
Alternatively, a genetic predisposition may lead to the development of autism while 
environmental factors act to modify the phenotypic expression of the disorder. Research 
to date supports the theory that many different patterns of genetic and environmental 
influences act on a common set of neurodevelopmental processes to affect the risk of 
autism or its phenotypic expression. 67 
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Figure 1.1. Critical periods of human development. Prenatal development is divided into three stages: 
periconception (generally the 2 weeks following fertilization), embryonic (3 to 8 weeks), and fetal (9 to 38 
weeks). During the periconceptual period, hazardous environmental exposures usually cause fetal death. 
Disruption during the embryonic period can result in major physical malformations. Both the organ 
affected by exposure during this period and the resulting type of anomaly are highly dependent on both the 
agent and gestational age at which the exposure occurs. During the later stages of prenatal development, 
environmental exposures can result in impaired growth, physiological defects, or functional deficiencies. 
Figure adapted from Moore and Persaud. 1998.48 
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1.2. Early Detection of Autism 
1.2.1. Eluding Early Diagnosis: Diagnosis Based on Behaviour Alone 
As with any child with special needs, early identification is crucial in order for 
interventions to be implemented sooner. With regard to autism, there is an urgent need 
for early identification before deviation from the normal trajectory of development has 
progressed too far. As many as 50% of parents suspect a problem in the first year of life 
and most parents express concern to their paediatrician by the time their child is 18 
months of age. I2 Yet, autism is not commonly identified before two to three years of 
age. 68 Many clinicians hesitate to ascribe a diagnosis of autism even when some 
symptoms may be evident due to concerns about family distress, the possibility of being 
incorrect, or hope that the symptoms will reverse over time. In reality, the advantages of 
early diagnosis are numerous and include better preparation for educational planning and 
treatment, provisions for family support, reduction of family stress and anguish, and 
delivery of appropriate medical care to the child. I I The available evidence from a number 
of programs and studies suggest that early intervention leads to better outcomes. The fact 
that children demonstrate greater gains when they enter a program at a younger age 
further emphasizes the need for diagnostic instruments that are effective before two years 
of age.69 However, given the variability of symptoms, differences in age of onset, 
severity of symptoms, and possible regression of previously acquired skills for some 
children, autism may be especially difficult to diagnosis early and accurately based on 
clinically observed behavioural signs alone. 
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1.2.2. The Search for Biomarkers: Indicators of Risk for Autism 
The main impediment to early identification efforts resides m the fact that 
research on autism generally does not begin until a child has been identified with the 
disorder, which in the best scenario may not be until two years of age. Thus, knowledge 
about the infancy and toddler periods in autism is rare and exclusively based on 
retrospective sources of information gathered well after a diagnosis is made. Although 
parent reports and home videotapes have provided crucial information concerning the 
early behavioural phenotype of autism, this method has limited experimental control. One 
promising approach that is making headway in the field of autism is the supplementation 
of behavioural criteria with biological markers (or simply, biomarkers). Biomarkers have 
~· 
potential for improving diagnostic efficiency. The identification of a reliable biomarker 
for autism could overcome the limitations of the existing clinical behavioural methods. 
The ability to assess an infant's risk status based on a biomarker that is expressed before 
the onset of symptoms could eliminate the need to wait for behavioural criteria to be met 
before beginning treatment. This would likely improve the prognosis of affected 
individuals. A promising area of biomarker research focuses on genes and their encoded 
products. It is clear that genes play a large role in the causation of autism; thus, the 
pursuit of gene-based biomarkers seems to be a plausible approach to the research. 
1.2.3. Limitations of Traditional Methods of Studying Autism 
The identification of genetic linkages and chromosomal abnormalities, in 
combination with candidate gene studies, has aided in the elucidation of the 
neurobiological underpinnings of autism. Genetic linkage studies have even shown 
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progression by expanding to include environmentally responsive genes in traditional 
linkage searches.70 However, genetic studies to date have not yet uncovered any genes of 
strong effect. Given the multi-factorial nature of autism, studying a single candidate gene 
at a time is not likely to provide a comprehensive explanation of the phenotypic variation, 
which is believed to result from dysregulation of multiple genes. Furthermore, another 
aspect of studying genetic abnormalities that limits their utility as biomarkers is that they 
are static factors that do not change over the life course. In comparison, gene expression 
is highly flexible and can vary over time within the same individual. Gene expression can 
also reflect genetic or environmental influences, or both. These qualities afford gene 
expression greater potential to serve as useful biomarkers for various stages of autism, 
such as the asymptomatic at-risk period, early periods of subtle deficits, or 
. 71 
responsiveness to treatment. 
1.2.4. The New Frontier: Gene Expression Profiling 
The emergence of microarray technology has allowed many researchers to 
monitor the activity of a multitude of genes simultaneously to create a global picture of 
cellular function. DNA microarrays are ordered arrangements of nucleic acid fragments 
derived from individual genes located at defined positions on a solid support, enabling 
the investigation of thousands of genes in parallel by specific hybridization. 72 There are 
two types of DNA microarrays depending on the material arrayed: cDNA or 
oligonucleotide. Whether spotting cDNA or synthesized oligonucleotides, the nucleic 
acid fragments are deposited onto substrate-coated glass slides using highly precise 
robotic systems to produce dense arrays. This confers the advantage of smaller amounts 
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of sample for analysis because the arrays have small volumes for hybridization. The 
study of gene expression using microarrays is based on the competitive hybridization of 
differently labelled populations of cDNAs. This technique, called gene expression 
profiling, provides the opportunity to evaluate possible deviations in autism at the mRNA 
level. Since early development is largely dependent upon intrinsic gene expression 
patterns, altered mRNA levels during critical periods may significantly impact brain 
development. This method allows the evaluation of a wide range of candidate genes and 
how they fit into common molecular pathways. This approach may identify novel genes 
which are dysregulated in autism, as well as provide the basis for the development of 
more sensitive diagnostic tools for this disorder. The experimental strategy used in gene 
expression studies is to tease out differences in mRNA levels between affected and 
unaffected individuals. Beyond this working model, it may also address the phenotypic 
heterogeneity of autism, which may potentially map onto heterogeneity in biomarker 
profiles. Thus, as influential etiological factors and their associated biomarkers are 
identified, different phenotypic profiles of autism may be established based on similar 
gene expression profiles obtained between individuals that display overlapping symptoms 
(e.g., regressive versus early onset of symptoms). The subsequent detection of both 
environmental and biological influences on autism and biomarkers within these 
subgroups can then be used to begin appropriate, personalized interventions. 
1.2.5. Biological Materials for Gene Expression Profiling 
Several different types of biological materials have been used to differentiate gene 
expression patterns between affected individuals and healthy controls: post-mortem adult 
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or fetal brain tissues and white blood cells either in the form of perrpheral mononuclear 
blood cells or immortalized lymphoblastoid cell lines.73'74 Post-mortem brain tissue 
confers the advantage of exploring gene expression alterations in tissues most directly 
implicated in this disorder. Brain tissue is presumed to be the ideal study material for the 
mechanistic basis of autism but it is not without its limitations. The scarce availability of 
donated brain tissue samples for adequate sample sizes, difficulties in preserving the 
RNA, and potentially confounding factors related to the cause of death and tissue 
modifications during the post-mortem interval represent major drawbacks for this tissue 
source. More importantly, it is not an appropriate target for diagnostic assays. 
Researchers have turned instead to RNA extracted from white blood cells drawn from 
blood samples. It has been hypothesized that autism might arise through dysregulation of 
specific neuronal genes and that expression differences between affected and unaffected 
individuals might be present in tissues other than the brain. 75 While conceivably more 
distant from the pathophysiology of this disorder, it provides access to larger quantities of 
RNA and it is easier to obtain, which ensures larger sample sizes.76 However, the 
development of a non-invasive method of sample collection is of foremost importance 
considering that blood collection is a significant barrier to study participation, especially 
in studies involving young children. 
Buccal cells, also known as mouth epithelial cells, are easily collected with 
minimal discomfort and present an alternative sample material for biomarker testing. The 
rationale behind the use of buccal cells is that since epithelial and nervous tissue are 
derived from the same embryonic germ layer - the ectoderm - insults that occurred 
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during early development would be common to both cell types. Collection of buccal cells 
has proven to be an effective and painless procedure, and can be obtained using a variety 
of different methods, including cytobrushes, sterile swabs, mouthwash, and saliva. 77 The 
pursuit of epithelium-based biomarkers is still in its infancy but early successes provide 
the impetus for further investigation in this area. A few studi1es pertaining to oral cancer 
address the efficacy of using buccal cells for microarray gene expression analysis.78•79 An 
initial study comparing blood and buccal cells from the same individuals looked at the 
relative amounts of four genes and determined that the RNA isolated from buccal cells 
was of sufficient quality to be used to detect expression differences. 78 Buccal cell RNA 
has also been used for microarray-based differential gene expression studies by 
comparing gene expression between smokers and non-smokers. The results revealed 
several groups of genes that were either over- or under-expressed in smokers and which 
could be used to predict smoking exposure.79 To date, buccal cells have not been used in 
a transcriptomic approach to investigate gene expression differences in autism. A 
successful study of this type would support the notion that buccal cells have efficacy as 
· source material for biomarker discovery in autism. 
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1.3. FOXP Gene Studies 
1.3.1. Discovery of FOXP2 as a 'Language Gene' 
As mentioned previously, FOXP 2 was brought to the attention of the scientific 
community when it was identified as a gene that predisposes individuals to a rare speech 
and language disorder. In 1990, Hurst et al. reported a case of a three-generation 
pedigree, known as the KE family, half of whose members had developmental verbal 
dyspraxia (DVD) that is inherited in a pattern consistent with an autosomal dominant 
penetrance (Figure 1.2).42'80 DVD is a complex condition that has its onset early in 
childhood and includes elements of impairment in speech articulation and other linguistic 
skills, as well as broader intellectual and physical problems. Using data from the KE 
family, Fisher and colleagues performed a genome-wide search for the candidate gene 
and finally mapped the gene locus to chromosome 7q.81 In2001, analysis of patient CS, 
who had a translocation between chromosome 5 and 7 that caused almost identical 
language deficits, helped to identify FOXP2 as the gene responsible for this disorder.82 
These findings were further supported by the discovery of a FOXP 2 nonsense mutation at 
arginine 328 in another family, who affected members had orofaci~l dyspraxia.43 
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Figure 1.2. Inheritance pattern of the FOXP2 mutation in the KE family. The KE family consists of 
three generations, halfof whose members (15) are affected by developmental verbal dyspraxia (DVD). The 
16 unaffected family members and 6 spouses who married into the family are also displayed in the KE 
family pedigree. Squares represent males and circles show females. Dark blue colour shows affected 
members and light blue colour unaffected. Image adapted from Vergha-Kadehm et al. 2005.80 
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1.3.2. FOXP2 in Relation to Specific Language Impairment and Autism 
Specific language impairment (SLI) is defined as a failure to acquire normal 
expressive or receptive language despite adequate environmental influences and in the 
absence of other medical genetic conditions. Although autism has a clear diagnostic 
criterion from SLI, there is an interesting phenotypic overlap between these disorders. 
This idea is best demonstrated in instances where features of autism and SLI cannot be 
distinctly separated. There are reported cases of individuals who were diagnosed with 
language disorders during childhood whom nevertheless show significant social 
difficulties as adults.83 Given the report of linkage to 7q in the KE family and a positive 
association in another sample of children with SLI, the Collaborative Linkage Study of 
Autism carried out a genome screen on individuals with autism from multiplex families. 
An estimated 29% of the families were linked to a specific region on chromosome 7. 84 
This region is the same as the locus that Fisher et al. had previously implicated in SLI. 
Additional evidence comes from the prevalence rates of these disorders. Just as there is a 
higher prevalence of language difficulties in families of autistic individuals, there is also 
a higher prevalence of autism in the siblings of probands with SLI as compared to the 
general population. Furthermore, the prevalence of autism among the siblings of SLI 
probands is approximately the same as that seen in the siblings of autistic probands.85 
This suggests that the two conditions are pathogenetically linked and may have some 
causative genes in common, such as FOXP2. Chromosome 7q31, in which FOXP2 is 
located, has been considered to be a susceptibility locus for the language deficits in SLI 
and autism. Thus far, association and mutation screening analyses of FOXP2 have been 
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performed in these disease groups with mixed results. Researchers have yet to identify a 
mutation or association with FOXP 2 within SLI patients and, although two studies show 
a positive association between FOXP2 and autism, the majority of the literature indicates 
a negative association.40.44•86•87 However, the FOXP2 gene is exceptionally large in size 
and novel exons have recently been identified.43 Further studies will need to be conducted 
to determine the relationship between FOXP2, SLI, and autism. 
1.3.3. FOXP Sub-Family Genes 
The forkhead box (FOX) gene family encodes a large group of transcription 
factors that share a common DNA binding domain of sequences called the forkhead. 
Many members of the FOX family are involved in embryonic morphogenesis and 
mutations in the FOX genes have been linked to human developmental disorders 
including immune, skeletal, circulatory, and craniofacial defects. 88 
The FOXP sub-family of genes were recently recognized to be members of the 
FOX gene family. In addition to a forkhead domain, FOXP sub-family members contain 
a zinc finger domain and a leucine zipper motif.43 The FOXP sub-family comprises four 
members: FOXP 1-4 (Figure 1.3).89 The expression patterns of FOXP genes in fetal 
mouse, rat, nonhuman primate, and human brains show striking homology. Therefore, it 
stands to reason that findings from animal models would translate to humans. Here, the 
standard accepted nomenclature to refer to genes in different species has been adopted: 
FOXP for humans and Foxp for mice. Three of the FOXP subfamily members (FOXP 1, 
FOXP2, and FOXP4) are abundantly expressed throughout the developing brain. 
Conversely, FOXP3 is expressed predominantly in the immune system.43 FOXP11214 are 
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highly homologous and show more than 60% identity at the amino acid level and around 
80% identity at their forkhead domains at the amino acid level.43 Although FOXP 11214 
genes are expressed in the same anatomical regions, there is a distinct expression pattern 
for each of these genes in some neuronal cell types. 
FoxP 1, the member that was isolated first, is a regulator of mouse lung, heart, 
brain, testis, kidney, and gut development.9° Foxpl null embryos have severe defects in 
the cardiovascular system, including defects in ventricular sepatation, cardiac outflow 
tract, and myocyte maturation and proliferation.91 Foxpl null embryos have also shown 
abnormalities in motor neuronal identity in the spinal cord.92 Since Foxpl null embryos 
die at embryonic day 14.5, the role of Foxpl during the later stages of brain development 
has yet to be elucidated.91 Foxp2 is i.p.volved in lung, heart, gut, and brain development.93 
Within the brain, Foxp2 is expressed in several structures during development, including 
the cortical plate, basal ganglia, thalamus, inferior olives, and cerebellum.94 Functional 
analyses of FOXP2 in multiple species have revealed intriguing aspects of brain 
development and function. In humans, as discussed previously, FOXP2 is implicated in 
the biological mechanisms specifically involved in speech and language development. In 
mice, heterozygous mutations of Foxp2 display abnormal synaptic plasticity in striatal 
and cerebellar brain circuits, accompanied by significant deficits in motor skill learning.95 
Homozygous Foxp2 mutations yield more severe neural effects - altered ultrasonic 
vocalizations, cerebellar abnormalities, motor impairment, reduced postnatal weight gain, 
and early postnatal lethality.95-97 Additionally, selective knockdown of the avian FoxP2 
gene leads to incomplete and inaccurate imitation of tutor song, suggesting its 
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requirement in normal vocal learning in songbirds.98 Foxp4 is expressed in the 
developing heart, kidney, liver, spleen, and brain.99 It has been revealed that in Foxp4 
mutant mice, Foxp4 is essential for cardiac morphogenesis as these mice develop 
abnormally with two complete hearts and died in the embryonic stage. Ioo Moreover, 
Foxp4 is involved in the maintenance of Purkinje cells in the cerebellum.IOI 
Members of the FOX family of proteins bind to target DNA as monomers. 
FOXPl/2/4 proteins have the unique ability to dimerize for DNA binding and their 
transcriptional activity is regulated by homo- and heterodimerization, which is dependent 
on the zinc finger domain and leucine zipper motif. 102 The precise combination of homo-
and heterodimers of different FOXPl/2/4 proteins within the same neurons may modulate 
the transcription of downstream gene targets. With regard to brain development, changes 
in the expression ofFOXPl/2/4 transcriptional factors may result in premature or delayed 
activation of multiple downstream target genes and force morphogenetic processes out of 
step. 
28 
I I 
PxxP PxxP Tetromer Forkheod 
FOXP3 ...... 
--
43100 
PolyQ 71 105 207 268 336 421 
FOX Pl ... ..... ........ --11••11--------10600 
FOXP2 •• •••••••••• -···-•••t---------- 74000 
FOXP4 --l ... l-llHmmaHml---1 .. ID••HBH•••!IMil--t•••---- 68000 
• PolyQ; 41!t> Proline-rich; •LW Tetramerimtion domain; Forkheod 
Figure 1.3. Primary domain structure of FOXP subfamily members. The N-terminal amino acid sequence 
of FOXP3 is different from other FOXP subfamily members, including FOXPI, FOXP2, and FOXP4. 
Image adapted from Li and Greene. 2007. 89 
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1.3.4. Defining Downstream Pathways Regulated by FOXlP2 
Since FOXP2 encodes a transcription factor, functional genomics have been 
employed to investigate other key factors in the signa]ing pathways of which it 
participates. A signaling pathway involves mediators at multiple levels, including those 
that act upstream of FOXP 2 to regulate its expression, elements that modify the 
intracellular localization or activity of the FOXP2 protein, co-factors which interact with 
the FOXP2 protein, and downstream targets that it activates or represses. 103 Although 
mutations in the FOXP 2 gene are uncommon, it is reasonable to expect that the 
downstream targets in which it regulates in the brain are more broadly implicated in 
subtle defects of speech and language. High-throughput searches for genes regulated by 
FOXP2 have been carried out in hu'man fetal brain sariip.l~s and neuronal-like cell 
models. Two groups have identified several hundred putative gene targets; half of these 
recognized gene targets are overlapped between the two studies, thus strengthening the 
findings. 104,105 The expression of a majority of the target genes was repressed by FOXP2 
while the expression of a minority of the targets was activated by FOXP2. Thus, FOXP2 
can act as both a repressor and an activator under certain circumstances, possibly 
depending on co-factors such as FOXPl or FOXP4. The analyses of co-factors that 
interact with FOXP2 is a gap in the existing literature that needs to be addressed, 
especially since it might provide further clues to the involvement of FOXP2 in speech 
and language functions. Studies of FOXP2 will not only clarify fundamental questions 
regarding the origins of human speech and language, but also its contribution to the 
etiology of neurodevelopmental disorders such as autism. 
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CHAPTER 2: GENE EXPRESSION PROFILING IN INDIVIDUALS 
WITH AUTISM 
2.1. Introduction 
Autism is dramatically increasing in incidence. Yet, to date there are no definitive 
biomarkers that can be reliably used to diagnose autism. The majority of diagnoses are 
dependent on DSM-IV behavioural guidelines, using diagnostic tools such as the Autism 
Diagnostic Interview-Revised (ADI-R) or the Autism Diagnostic Observation Schedule 
(ADOS).25 Although the guidelines are well-defined, the rater's perception of the 
evaluated behaviour allows for ambiguity since the interpretation of the symptoms might 
vary among different individuals (e.g. parents, teachers, or clinicians). Furthermore, a 
diagnosis for Asperger' s Syndrome is usually not made until well after the child starts 
school and, even then, the child is often diagnosed with common learning disorders 
before Asperger's Syndrome is considered. 106 Therefore, there is a strong need for 
biomarkers that can be used consistently in a clinical settin~ to facilitate the diagnosis of 
autism, thereby allowing appropriate intervention and effective educational programs to 
commence at an earlier age. Moreover, it is important to identify genes that belong to the 
same molecular pathways and are associated with distinct autism phenotypes in order to 
design pharmaceutical treatments targeted to specific individuals. 
The advent of microarray technology, which allows for simultaneous comparison 
of thousands of transcripts, has provided the opportunity to investigate susceptibility 
genes and molecular pathways in psychiatric disorders. The advantage of gene expression 
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profiling using microarrays is the ability to study multiple genes in the context of gene 
regulatory networks within a living cell. Since autism is a multi-factorial disorder that is 
believed to be caused by a combination of genetic and environmental factors, using a 
global approach to study this complex disorder is well-suited. Thus far, the application of 
microarray technology to autism research has been limited to the use of post-mortem 
brain tissue, peripheral mononuclear blood cells, or lymphoblastoid cell lines.73'74 Given 
that autism has an early childhood onset, a less invasive method of sample collection 
would be of foremost importance. Exfoliated cytologic specimens from the buccal 
mucosa (mouth epithelium) have been shown to contain viable cells for gene expression 
assays, permitting non-invasive measurement of gene-environment interactions.78 Buccal 
cells are easily accessible and are derived from the same germ layer as neuronal cells 
(ectoderm) and thus may be used as a proxy to represent the neural transcriptome. 
Currently, there is no evidence that dysregulated gene expression or biomarkers exist in 
buccal cells of autism patients. However, it has been hypothesized that autism might arise 
through dysregulated expression of specific neuronal genes and that expression 
differences between affected and unaffected individuals might be present in tissues other 
than the brain. 
2.2. Hypotheses 
In this study, buccal samples were utilized for microarrays to investigate gene 
expression differences between typically developing children and children with autism. I 
hypothesize that: 
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1) RNA derived from buccal cells is a reliable genetic source for detection of gene 
expression profiles (mRNA levels); 
2) RNA derived from buccal cells can be used for detection of autism susceptibility 
genes that are neuronally expressed; 
3) Identified candidate susceptibility genes participate in common signaling pathways 
that are critical to the development and function of the central nervous system 
(CNS); 
4) Identified candidate susceptibility genes are expressed during early embryonic 
development; and 
5) There is a relationship between severity of autism symptoms exhibited by the 
pro bands and the expression level of the most differentially expressed genes. 
2.3. Methods 
2.3.1. Collection of Buccal Samples 
Buccal samples were obtained from individuals that were 25 years of age or under 
at the time of sample collection. The rationale behind the age range is that this study is 
focused on investigating the developmental changes in autism and some aspects of neural 
development continue on into early adulthood (approximately 25 years of age ).46 The 
collection protocol was reviewed and approved by the Research Ethics Board of York 
University, Toronto. All parents or legal guardians provided their written informed 
consent to participate. Human HT-12 v4.0 BeadChips, which require a minimum of three 
control samples for assays, was used for global gene expression analysis. There were 9 
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probands (8.7 ± 2.5 years old; 8 males and 1 female) and 4 healthy controls (9.3 ± 5.0 
years old; 3 males and 1 female) recruited to this study through participant recruitment 
advertisement at York University and collaboration with the Children's Treatment 
Network. All probands met the ADI-R, ADOS, or CARS criteria for autism as 
determined by an experienced child psychologist or a multidisciplinary team which 
included a paediatrician, occupational therapist, speech-language pathologist, and social 
worker. Participants were defined as healthy controls if the individual had no history of 
psychiatric disorders and met milestones for social, emotional, and communication 
development at appropriate ages. The number of male to female participants in this study 
reflects the skewed sex ratio indicative of a greater preponderance of males over females 
in autism. Full demographic details of the participants can be found in Table 2.1. The 
symptomatology (phenotype profile) of the affected participants will be discussed in 
section 2.4.5. 
Buccal samples were collected using sterile Cytobrush Plus® (Cooper Surgical). 
The subjects were instructed not to consume any foods or drinks other than water at least 
30 minutes prior to the sample collection. The brush was inserted into the subject's 
mouth while holding the chin firmly with one hand. The brush was pressed against the 
buccal mucosa and swiped in a single direction at least 15 times. The brush was then 
rotated and the procedure was repeated with the other side of the brush. Duplicate 
brushes were collected from each subject, one from each side of the inner cheek, at a 
single time point. There were no significant episodes of irritation or bleeding. The 
brushes were immediately stored in 2 mL microcentrifuge tubes containing 400 µL of 
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room temperature RNAlater solution (Clonetech) to prevent post-sampling degradation of 
the RNA. The brush ends were cut off with sterile surgical scissors so that the tubes could 
be capped. 
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Table 2.1. Demographic details of the participants with RNA Integrity Number (RIN). 
Participant Sex Age Ethnicity Status RIN ID 
C8 Male 10 CAU Healthy Control 6.5 
C9 Male 23 ASN Healthy Control 5.9 
D8 Male 1 ASN Healthy Control 6.9 
D3 Female 3 CAU Healthy Control 8.2 
A6 Male 3 CAU Pro band 7.2 
Bl Male 25 CAU Pro band 6.7 
B8 Male 2 CAU Pro band 6.6 
BIO Male 14 CAU Pro band 7.2 
C7 Male 4 HIS Pro band 6.6 
CIO Male 10 CAU Pro band 6 
Cll Male 5 ASN /HIS Pro band 9.4 
C12 Male 4 CAU Pro band 7.1 
D5 Female 11 CAU Pro band 7.5 
Shown is the demography of the study population used in the microarray study. CAU - Caucasian; ASN -
Asian; HIS - Hispanic. 
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2.3.2. Total RNA Isolation 
Total RNA was extracted from the buccal cells within 24 hours after sample 
collection. The duplicate brushes from each subject were processed together. Total RNA 
was isolated from buccal cells using the NucleoSpin RNA XS kit (Clontech). The 
extraction protocol was followed as outlined by manufacturer's instructions. RNA yield 
was determined on a NanoDrop ND-1000 Spectrophotometer. The RNA samples were 
subsequently sent to the University Health Network Microarray Center for quality control 
and microarray data analysis. 
2.3.3. Quality Control and Microarray Data Analysis 
Total RNA quality was assessed using the Agilent Bioanalyzer 2100. 
Electropherograms generated on the Agilent Bioanalyzer 2100 provide information about 
RNA concentration, allow visual inspection of RNA integrity, and automatically 
generates the ratio of 18S to 28S ribosomal subunits. RNA degradation is a gradual 
process where, as degradation proceeds, there is a decrease in the 18S to 28S ribosomal 
band ratio and an increase in the baseline signal between the two ribosomal peaks and the 
lower marker. The important elements of an electropherogram are depicted in Figure 2.1. 
The RNA Integrity Number (RIN) software algorithm allows for the classification of 
eukaryotic total RNA, based on a numbering system from 1 to 10, where 1 represents the 
most degraded profile and 10 being the most intact. 
Illumina gene expression protocols feature a first- and second-strand reverse 
transcription step, followed by in vitro transcription amplification that incorporates 
biotin-labelled nucleotides. For global gene expression studies, 50 ng of each RNA 
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sample was labelled using Illumina TotalPrep RNA Amplification kit Lot #1107026 
(Ambion) as per amplification protocol. 750 ng of cRNA generated from amplification 
and labelling were randomized and hybridized onto Human HT-12 v4.0 BeadChip arrays 
featuring 12 arrays per slide. Each Human HT-12 v4.0 BeadChip targets 47,231 probes 
derived from the National Center for Biotechnology Information Reference Sequence 
(NCBI) RefSeq Release 38 (November 7, 2009) and other sources. The BeadChip array 
was incubated at 58°C, with rotation speed 5 for 18 hours for hybridization. The 
BeadChip array was washed and stained as per Illumina protocol and scanned on the 
iScan (Illumina). The data files were quantified in GenomeStudio Version 2011.1 
(Illumina). Differential expression comparing probands to healthy controls was 
performed with Significance Analysis of Microarrays (SAM). P-values were corrected 
using Benjamini and Hochberg False Discovery Rate method. Gene Enrichment Analysis 
was used to test the array data for enrichment of differentially expressed genes. 
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Figure 2.1. Electropherogram detailing the regions that are indicative of RNA quality. The segment 
preceding the lower marker is designated the pre region. The marker region coincides with the area 
occupied by the marker peak. The 5S region covers the small ribosomal RNA fragments (5S and 5.8S 
ribosomal RNA, and transfer RNA). The fast region lies between the SS and the l 8S peak. The l 8S and 
28S peaks correspond to the 18S and 28S ribosomal RNA species, respectively. The inter region lies 
between the l 8S and 28S peaks. The precursor region covers the precursor RNA following the 28S peak 
and the post region lies beyond the precursor region. As RNA degradation proceeds, there is a decrease in 
the 18S to 28S ribosomal band ratio and an increase in the baseline siignal between the two ribosomal peaks 
and the lower marker. Image adapted from Agilent Application Note, Publication Number 5989-l 165EN. 
2004. 
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2.3.4. Function and Pathway Analysis 
The dataset of differentially regulated genes between probands and healthy 
controls were analyzed using The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) Bioinformatics Resources (http://david.abcc.ncifcrf.gov/) to identify 
molecular functions and biological processes, as well as signaling pathways. Statistically 
significant functions were determined usi~g the Fisher Exact test. To compare expression 
data at the transcriptomic level to protein-level expression, the Human Protein Atlas 
(http://www.proteinatlas.org/) was used to find out if the differentially regulated genes 
are expressed in the CNS. The Human Protein Atlas is a publicly available database 
cataloging the distribution of proteins in different normal human tissues, cancer types, 
and cell lines via validated antibody analysis. The data provided include 
immunohistochemistry and Western blot analysis. Establishing the protein expression 
profile of the differentially regulated genes helped to determine if genes expressed in 
peripheral buccal cells may also have a role in the CNS. 
2.3.5. Reverse Transcription Polymerase Chain Reaction and Gel Electrophoresis 
Based on the microarray results, differentially regulated genes with fold change 
(FC) above 1.5 were further characterized using mouse as an experimental model system. 
The mouse is often considered a good model system for investigating human 
development because the developmental sequences of the organ systems in the two 
species closely resemble one another. Human gestation lasts for approximately 40 weeks 
and corresponds to 19 days of gestation in mice. As well, a mouse model was used 
because 99% of mouse genes have analogues in humans. Three mouse developmental 
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stages were investigated - embryonic day 16 (E 16), embryonic day 19 (E 19), and 
postnatal day 8 (P8) - as well as the adult stage (Figure 2.2). The mouse brain samples 
for E16 and E19 comprise pooled RNA from 11 and 13 embryos, respectively. The P8 
sample consists of pooled RNA from 6 pups, and the adult sample is from 5 animals. 
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Figure 2.2. Chronology of neurogenesis in mouse brain structures. The developmental timeline of 
neurogenesis in mouse brain structures is shown. The x-axis depicts the days of gestation. The horizontal 
slopes correspond to the period of neurogenesis of different brain regions, with the peaks representing the 
time of maximum neuron production. The black vertical line on E 12 ~ell)bryonic day 12) represents the last 
day of gestation when gross external malformations can be caused by interference with cell proliferation. 
The red vertical line on E 16 represents a stage of prenatal development· when neurogenesis is occurring in 
many brain structures. The second red vertical line on E 19 represents 1the approximate day of birth. The 
third red vertical line on PS (postnatal day 8) corresponds to a stage of postnatal development when 
neurogenesis is over in most brain regions. Image adapted from Rodier. 1980. 107 
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Reverse transcription polymerase chain reaction (RT-PCR) was used to determine 
if the gene of interest was expressed in the wild-type mouse brain. Reverse transcription 
(RT) was performed with M-MuLV Reverse Transcriptase (New England Biolabs) in 
accordance with the manufacturer's instructions. 2 µg of RNA was used in a reaction 
with lOx RT Buffer, Oligo(dT) primer (0.25 µg/µL), dNTP mix (10 mM), and M-MuLV 
Reverse Transcriptase (200 U/µL). This mixture was incubated at 42°C for one hour and 
then at 90°C for 10 minutes to deactivate the enzyme. The success of the RT reaction was 
confirmed by PCR with Gapdh primers. The PCR reaction contained cDNA, 5X OneTaq 
Standard Reaction buffer, forward and reverse primers (10 µM), dNTP mix (10 mM), and 
OneTaq DNA Polymerase (0.025 U/µL) (New England Biolabs). The thermal cycler was 
programmed for 30 cycles of PCR amplification at 94°C for 30 seconds for denaturation; 
68°C for 2 minutes for annealing; and 68°C for 30 seconds for primer extension. The 
PCR products were then verified by gel electrophoresis. A gel concentration of 1.2% 
agarose in 1 X T AE buff er with 6% ethidium bromide was used. The samples were mixed 
with 6X nucleic acid loading buffer and loaded into the wells of the gel. Electrophoresis 
was conducted at 1 OOV on a PowerPac Basic Power Supply. A UV Transilluminator was 
used to visualize the size of the DNA bands. A 100 base pair DNA standard ladder was 
used to estimate the size of the DNA bands by comparison. Following the confirmation 
of cDNA synthesis, PCR was performed using primers specifically designed for the 
genes identified from the microarray analysis. All PCR primers were designed using the 
Primer3 program (http://frodo.wi.mit.edu/primer3/) and synthesized by Sigma-Aldrich. 
PCR primer sequences for microarray genes of interest are shown in Table 2.2. 
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Table 2.2. PCR primer sequences for microarray genes (FC > 1.5). 
Gene Primer Sequences (5' 7 3') Amplicon Size (base pair) 
Gapdh F:TTGTGATGGGTGTGAACCAC 169 R:GTCTTCTGGGTGGCAGTGAT 
Fl: GGAGCAGAGTGGAGAGTTTCA 
Rl:CCACGGGTAGCCTTGATTTA 220 
C4orj7 F2:CGATAGCAGTATCAGCTAG 404 R2:CTCTCTTAACAGGAATATTGATC 
F3:GTCCGCGATAGCAGTATCAG 312 R3:CAGTTAAGGATCTGCAGTTGGA 
Csf3r F:TGTGCCCCAACCTCCAAACCA 236 R:GCTAGGGGCCAGAGACAGAGACAC 
Cdl4 F:GCTCAACTTTTCCTGCGAAC 542 R:GCAAAGCCAGAGTTCCTGAC 
Krt80 F:AGCTCTCGAAGCCTCACAAG 459 R:AGCATCCAGGTCCTTCTTCA 
Arhge/51 F:CGAAAGGCACTGGTCTCTTC 686 R:ACATTGCTGTTGCAGTCTCG 
Klf4 F:CCACCAGGACTACCCCTACA 330 R:CTGTGTGAGTTCGCAGGTGT 
Sh3dl9 F:TCCTGCATCCAAATCATCAA 885 R:GTCTTTGGTGGCACCTTTGT 
Cdknlb F:CAGAATCATAAGCCCCTGGA 224 R:TCTGACGAGTCAGGCATTTG 
Erbb3 F:GCGAGAAGGCAAACAAAGTC 642 R:AGGTCATCAACTCCCAAACG 
Arid5b F:GTTGTGGGAAGAAAGGACCA 916 R:TCCCAGTTTTTGAGCAGCTT 
Rbm47 F:GAGGGCGTACTCAACGTGAT 815 R:GCCACTGTGCCAGGTTTAAT 
Clpx F:GCGCAGAGCTCCTCTTAGAA 505 R:CTTCTCAGCCTCTGCTTGCT 
Ma/2 F:TACTCCGGAGCTTTCGTCTG 405 R:CAGACCCAAACTGCAACCAT 
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2.3.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
The expression level of a select few microarray genes of interest, chosen based on 
functional relevance in the CNS, was quantified using the 7500 Fast Real-Time PCR 
System with SYBR Green reagent (Applied Biosystems). The comparative Ct method 
was used to analyze the data. Raw Ct values were normalized using the housekeeping 
genes Hprt (hypoxanthine phosphoribosyl transferase) and Sdha (succinate 
dehydrogenase) to obtain the L\Ct values. The L\Ct values of the samples were compared 
to a calibrator (adult stage sample). The relative quantity (RQ) value represents the fold 
change expression of each target sample compared to the reference. Reported RQ ratios 
are the mean of comparisons between three qRT-PCR experiments. QRT-PCR primers 
were designed using Primer Express 3.0 (Applied Biosystems) and synthesized by 
Sigma-Aldrich. QRT-PCR primer sequences for microarray genes of interest are shown 
in Table 2.3. Statistical significance was determined by performing a one-way analysis of 
variance (ANOV A) followed by Student's t-test. 
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Table 2.3. QRT-PCR primer sequences for microarray genes of interest. 
Gene Primer Sequences (5' ~ 3') Amplicon Size (base pair) 
Gapdh F:CGGCCGCATCTTCTTGTG 62 R:ACACCGACCTTCACCATTTTG 
Pgkl 
F:CAGTTGCTGCTGAACTCAAATCTC 65 R:GCCCACACAATCCTTCAAGAA 
Csj3r F:GACCCCATGGATGTTGTGAAA 83 R:GAGACTACATCAGGGCCAATGTC 
Cdl4 F:GGAAGCCAGAGAACACCA 130 R:CTTGTTGCTGTTGCTTCTGG 
Klf4 F:ACTATGCAGGCTGTGGCAAAA 100 R:CCGTCCCAGTCACAGTGGTA 
Cdknlb F:GGTGCCTTTAATTGGGTCTCA 80 R:CCGGATTGTCTGACGAGTCA 
Erbb3 F:GAGGATGGCAATGGTTATGTCA 61 R:CCCGGGAAGAGGATGTACCT 
Clpx F:CCAAGATGCCAATTACAATGTAGAG 80 R:GCACACTGCCAATCTTATCTACTT 
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2.4. Results 
2.4.1. Quality Assessment of RNA Samples 
In order to use buccal mucosa samples for microarray studies, total RNA was 
isolated from buccal cells and purified. Total RNA yield was initially assessed on the 
NanoDrop ND-1000 Spectrophotometer. RNA quality was then measured on the Agilent 
Bioanalyzer 2100 at the University Health Network Microarray Center to generate an 
estimate of the quality of RNA samples. The RNA Integrity Number (RIN) is a quality 
metric used to aid in assessment of RNA samples independent of the relative 
concentration. The RIN system evaluates the ribosomal RNA (rRNA) species, due to the 
abundance and high stability of rRNA transcripts in the cells, which is assumed to be a 
good indication of the mRNA species (the RNA species of interest). Even though it is a 
reasonable assumption, it is not yet possible to determine ahead of time whether a 
microarray experiment will work or not. Rather, the RIN offers repeatability and quality 
control to determine whether to use a sample or to discard it. Conventionally, a RIN of 7 
or greater is required for a sample to be used for microarray studies. 108 However, 
previous studies have used samples with RIN values as low as 5.2 in generating 
microarray data of reasonable quality. 109 
The RIN for each buccal mucosa sample is shown in Table 2.1. The mean RIN for 
all experiments is 7.1 (range, 5.9 to 9.4). The results indicate that the quality of RNA 
derived from buccal cells varies between different samples (see example in Figure 2.3). 
Some samples (from participants C8, C9, D8, Bl, B8, C7, and ClO) did not meet the 
threshold (RIN value of 7) and were deemed of "borderline quality", but were considered 
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to be of sufficient quality to be included in microarray experiments. The samples were 
fluorescently labelled and hybridized onto the Bead Chip array. A list of genes showing 
differential expression in probands compared to healthy controls resulted from statistical 
analysis of the array. In this sense, microarray experiments were successfully performed 
with the buccal RNA from all participants listed in Table 2.1. 
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Figure 2.3. Quality assessment of buccal RNA samples. The integrity of buccal cell-derived RNA from 
the study participants was found to be highly variable. Three RNA samples at varying stages of intactness 
are shown in this figure. The top electropherogram indicates that buccal :RNA can be of high quality (RIN 
9.4), or as the middle electropherogram shows, of acceptable quality (RIN 7.1). Conversely, the bottom 
electropherogram reveals that buccal RNA from a different sample was strongly degraded (RIN 5.9) since 
there is a series of peaks shown at low retention times, while the two ribosomal RNA peaks are of lower 
intensity. RIN - RNA Integrity Number. 
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2.4.2. Expression of Differentially Regulated Genes in the Central Nervous System 
Learning of the expression of the differentially regulated genes in the central 
nervous system (CNS) is of importance because autism is a neurodevelopmental disorder 
- a dysregulation of these genes in peripheral tissues would imply a similar deviation in 
the brain. The dataset of differentially regulated genes (see Table 2.4) between probands 
and healthy controls was examined to determine the percentage of genes that are 
expressed in the CNS. In addition to reviewing the existing literature pertaining to the 
differentially regulated genes, the Human Protein Atlas was used to establish protein 
expression profiles as well. Of the entire list of differentially regulated genes, 66.3% are 
expressed in the CNS and only 6.2% are expressed exclusively in peripheral tissues 
(Figure 2.4). There is no information about the remaining 27.5% of the differentially 
regulated genes either because they have yet to be characterized or have not been studied 
in the CNS. The fact that the majority of these genes are exp~essed in the CNS indicates 
that RNA derived from buccal cells may be used to study the CNS. 
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Table 2.4. Differentially regulated genes between probands and healthy controls. 
Probe ID Gene Symbol P-value Corrected Average P-value Fold Change 
ILMN 1725276 C4ort7 4.42 x 10-5 2.85 x 10-2 25.28 
ILMN 2371280 CSF3R 2.62 x 10-4 4.37 x 10-2 6.18 
ILMN 2396444 CD14 1.25 x 10-4 3.43 x 10-2 5.14 
ILMN 1705814 KRT80 4.7 x 10-5 2.89 x 10-2 -2.6 
ILMN 2214473 ARHGEF5L 1.55 x 10-4 3.82 x 10-2 -1.85 
ILMN 2137789 KLF4 8.01 x 10-5 3.2 x 10-2 -1.76 
ILMN 1653133 SH3Dl9 5.58 x 10-5 2.99 x 10-2 
-1.75 
ILMN 2196347 CDKNIB 1.76x 10-4 4.01x10-2 
-1.74 
ILMN 1751346 ERBB3 2.05 x 10-4 4.2 x 10-2 -1.72 
ILMN 1721626 ARID5B 1.93 x 10-4 4.09 x 10-2 
-1.64 
ILMN 3224926 RBM47 1.13 x 10-4 3.43 x 10-2 
-1.63 
ILMN 1709894 CLPX 8.04 x 10-5 3.2 x 10-2 -1.6 
ILMN 1770653 MAL2 6.61x10-5 2.99 x 10-2 
-1.52 
ILMN 1768867 AP3Bl 1.87 x 1004 4.01 x 10-2 -1.49 
ILMN 1741176 CHMP2B 6.15 x 10-5 2.99 x 10-2 
-1.48 
ILMN 1790549 TSPAN3 1.62 x 10-5 1.98 x 10-2 -1.46 
ILMN 2043109 TOPIP2 1.94 x 10-5 1.98 x 10-2 -1.42 
ILMN 1760593 CRYI 1.35 x 10-6 6.48 x 10-2 
-1.41 
ILMN 1849013 t 1.13 x 10-4 3.43 x 10-2 -1.39 
ILMN 2319913 DGKA 3.35 x 10-5 2.62 x 10-2 
-1.38 
ILMN 1688295 ZNF219 2.17 x 10-4 4.2 x 10-2 
-1.36 
ILMN 1714364 PTK2 7.76 x 10-5 3.2 x 10-2 
-1.36 
ILMN 2045911 FBX028 2.2 x 10-5 1.98 x 10-2 
-1.36 
ILMN 1718070 CASP9 1.65 x 10-4 4 x 10-2 
-1.35 
ILMN 2100689 MAP2K4 9.99 x 10-6 1.69 x 10-2 
-1.34 
ILMN 1701413 PIGQ 2.56 x 10-4 4.37 x 10-2 
-1.34 
ILMN 3225300 LOC728532 1.67 x 10-5 1.98 x 10-2 
-1.33 
ILMN 1702837 PSMDl 8.85 x 10-6 1.69 x 10-2 
-1.33 
ILMN 1679322 SH2D4A 8.11x10-7 6.48 x 10-2 -1.33 
ILMN 1767747 HDAC2 2.02 x 10-4 4.2 x 10-2 
-1.31 
ILMN 1696028 ETNKI 2.32 x 10-4 4.3 x 10-2 
-1.31 
ILMN 1774427 CALCOCOl 2.37 x 10-4 4.3 x 10-2 
-1.29 
ILMN 2073289 MTSSI 1.23 x 10-4 3.43 x 10-2 
-1.28 
ILMN 2404917 AFAP1L2 1.25 x 10-4 3.43 x 10-2 
-1.27 
ILMN 2413615 LLGL2 6.22 x 10-5 2.99 x 10-2 
-1.27 
ILMN 1678957 WDR55 1.19 x 10-4 3.43 x 10-2 
-1.26 
ILMN 1722276 PAFAHlBl 1.07 x 10-4 3.43 x 10-2 
-1.26 
ILMN 2341548 MY05B 6.85 x 10-5 2.99 x 10-2 
-1.26 
ILMN 1778236 PTPNl 1 1.44 x 10-6 6.48 x 10-3 -1.26 
ILMN 1657470 YTHDF3 6.74 x 10-5 2.99 x 10-2 -1.25 
ILMN 1789283 PPP2R5C 1.8 x 10-4 4.01x10-2 
-1.24 
ILMN 1812776 FBX028 2.24 x 10-4 4.27 x 10-2 
-1.24 
ILMN 3245452 FAM149Bl 9.66 x 10-5 3.43 x 10-2 
-1.24 
ILMN 2336186 LCMTI 1.86 x 10-4 4.01 x 10-2 
-1.24 
ILMN 2090123 DHX29 2.76 x 10-6 9.32 x 10-3 
-1.24 
ILMN 2246510 TSCI 1.44 x 10-4 3.69 x 10-2 
-1.24 
ILMN 1717154 AQR 1.29 x 10-4 3.43 x 10-2 
-1.23 
ILMN 1730995 AFAP1L2 8.04 x 10-6 1.69 x 10-2 
-1.23 
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ILMN 3283592 
ILMN 1718813 
ILMN 1805999 
ILMN 1729019 
ILMN 1788778 
ILMN 1676241 
ILMN 1765558 
ILMN 2052717 
ILMN 2399877 
ILMN 1651278 
ILMN 3251550 
ILMN 2113362 
ILMN 2149766 
ILMN 1660270 
ILMN 1724410 
ILMN 1656293 
ILMN 2186137 
ILMN 1758337 
ILMN 2258774 
ILMN 1697460 
ILMN 2362346 
ILMN 1720476 
ILMN 1652407 
ILMN 1795704 
ILMN 2294784 
ILMN 2192032 
ILMN 3211488 
ILMN 1658759 
ILMN 1750482 
ILMN 2395204 
ILMN 1740213 
ILMN 1731268 
ILMN 1754772 
ILMN 1720438 
ILMN 1779356 
LOC442609 
CNKSRl 
MYOlD 
SEPT7 
SEPTl 1 
BCOR 
NPAS2 
GRAMDlC 
COGS 
SNIPl 
PHLDAl 
ARL61Pl 
APPBP2 
C7orf28A 
USP46 
GOSR2 
RRAD 
ZNF213 
MRPL43 
REEP6 
TRPV4 
PHF2 
ZMYND8 
KIAA0232 
PRDMl 
SRP19 
LOC400061 
PEX19 
LOC285307 
SLTM 
ELOVL7 
GAK 
LOC650698 
LOC653147 
TP53 
8.53 x 10·5 
1.04 x 10-4 
2.39 x 10-4 
2.16x 10-4 
1.87 x 10-4 
1.36 x 10-4 
2.66 x 10-4 
6.65 x 10-5 
4.69 x 10"6 
2.64 x 10-4 
2.1x10·5 
2.13x10-4 
3.57 X 10"5 
1.16 x 10-4 
5.87 x 10·5 
2.58 x 10-4 
2.42 x 10-4 
1.95 x 10·5 
8.76 X 10"5 
2.17 x 10-4 
2.68 x 10-4 
3.64 x 10·5 
1.51 x 10-4 
4.13 x 10·5 
1.4 x 10·5 
2.41x10-4 
2.67 x 10-4 
1.29 x 10-4 
1.8 x 10-4 
1.1x10-4 
1.1 x 10-4 
1.28 x 10-4 
1.72 x 10-4 
3.68 x 10·5 
6.07 x 10·5 
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3.29 x 10·2 
3.43 x 10·2 
4.3 x 10·2 
4.2 x 10·2 
4.01x10·2 
3.53 x 10·2 
4.37 x 10·2 
2.99 x 10·2 
1.27 x 10·2 
4.37 x 10·2 
1.98 x 10·2 
4.2 x 10·2 
2.62 x 10-2 
3.43 x 10·2 
2.99 x 10-2 
4.37 x 10·2 
4.3 x 10·2 
1.98 x 10·2 
3.29 x 10·2 
4.2 x 10·2 
4.37 x 10·2 
2.62 x 10·2 
3.79 x 10·2 
2.8 x 10·2 
1.98 x 10·2 
4.3 x 10·2 
4.37 x 10·2 
3.43 x 10·2 
4.01x10·2 
3.43 x 10·2 
3.43 x 10·2 
3.43 x 10·2 
4.01x10·2 
2.62 x 10-2 
2.99 x 10·2 
-1.22 
-1.22 
-1.22 
-1.22 
-1.22 
-1.21 
-1.21 
-1.2 
-1.2 
-1.19 
-1.19 
-1.19 
-1.19 
-1.18 
-1.18 
-1.18 
-1.17 
-1.17 
-1.17 
-1.16 
-1.16 
-1.16 
-1.16 
-1.14 
-1.14 
-1.14 
-1.14 
-1.13 
-1.13 
-1.13 
-1.13 
-1.11 
-1.1 
-1.1 
-1.08 
Differentially regulated genes (adjusted p-values < 0.05) with fold changes are displayed in this table. The 
table is sorted by descending average fold change values. The genes that show at least 1.5-fold change 
(listed above the double line shown) were examined in further detail as potential autism susceptibility 
genes. t One differentially regulated gene does not have an official gene symbol and is recognized by 
probe ID (ILMN_1849013). 
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6.2°/o 
Expressed Exclusively in 
Peripheral Tissues 
C4orf7, FAM149B1, GRAMD1C, ELOVL7, TP53 
66.3°/o 
Expressed in the CNS 
I l 
27.5°/o 
No !Information 
TOP~P2, DGKA, ZNF219, FBX028, 
ETNK1, MTSS11 WDRSS, YTHDF3, 
LCMT1, AQR, MY01D, BCOR, 
APPBP2, C7orf2.8A, RRAD, 
MRPt.43, LOC728532, LOC442609, 
LOC4,00061, LOC285307, 
LOC6506981 LOC653147 
CD14, CSF3R, KRTBO, ARHGEFSL, KLF4, SH3D19, CDKN1B, ERBe3, AR/058, RBM47, CLPX, 
MAL2, AP3811 CHMP2B, TSPAN3, CRY1, PTK2, CASP9, MAP2K4, PIGQ, PSMD1, SH204A, 
HDAC2, CALCOC01, AFAP1L2, LLGL2, PAFAH1B1, MYOSB, PTPNrf 1, PPP2R5C, DHX29, 
TSC1, CNKSR1, SEPT?, SEPT11, NPAS2, COGS, SNIP1, PHLDA11 ARLG/P1, USP46, GOSR2, 
ZNF213, REEP6, TRPV4, PHF2, ZMYNDB, KIAA0232, PRDM1, SRP19, PEX19, SLTM, GAK 
Figure 2.4. Tissue distribution of the differentially regulated genes. The entire list of differentially 
regulated genes is shown to be categorized into three groups: genes that are expressed in the CNS, genes 
that are expressed exclusively in peripheral tissues, and genes in which thei;e is not sufficient information to 
determine its localization. A large majority of the identified genes has expression in the CNS, which 
indicates a role for these genes outside of peripheral tissues. CNS - Central Nervous System. 
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2.4.3. Differentially Upregulated Genes in Autism 
The list of differentially regulated genes revealed three genes that were 
upregulated among the probands as compared to the healthy controls. These three genes 
are C4orf7 (chromosome 4 open reading frame 7), CSF3R (colony stimulating factor 3 
receptor), and CDJ4 (CD14 molecule) with approximately 25-, 6-, and 5-average fold 
change upregulation, respectively. Surprisingly, the three upregulated genes had the 
highest average fold changes. 
Individual Fold Changes of Differentially Upregulated Genes 
Gene expression is the most fundamental level at which the genotype gives rise to 
the phenotype. Although these genes are uniformly upregulated among the probands, the 
mRNA levels were found to vary considerably from individual to individual (Figure 2.5). 
For instance, even though C4orj7 had a 25-fold change average, participant A6 
demonstrated extremely high expression of C4orj7 (approximately 73-fold change) 
where as participant ClO showed only a slight upregulation (approximately 5-fold 
change) (Figure 2.5A). For CSF3R, the probands showed a 6-fold change average. 
Participant B8 demonstrated the greatest expression of this gene (17-fold change) 
whereas participant Cl 1 only showed a 3-fold change difference (Figure 2.5B). CD14 has 
a 5-fold change average; participant B8 once again showed the greatest expression of this 
gene (13-fold change) and participant Cll showed the lowest (almost 2-fold change) 
(Figure 2.5C). This suggests that the differences in gene expression could potentially be 
represented in behavioural outcomes (see section 2.4.5 for further discussion). 
54 
A) 
B) 
C) 
Q) 
C> 80 
c 
cu 
~ 
0 
'C 
0 
LL 
s 
60 + 
I I 
C4orf7 
:I 
0 (/) 
.c 
c( 
40 l ·1 
20 ~ 1· -- - 1 · . ~jtl~. 
0 L T ·r···· ~ ·r ··- • • · AVG A6 81 810 88 C10 C11 C12 C7 05 
Aff 
g 20 r -
c 
CU I 
c3 15 +- - - - - -- - --
1 
"C I 
CSF3R 
0 r ~1~--1-=-1···1-- ·1 ·· . I. --1,-1-
"' 0 i· ·~ ~ ·r ·-· ·r· ····~·~ ~ -, 
AVG A6 B1 910 BS C10 C111 'C12 C7 05 
Aff 
CD14 
g 15 r --- ----- -- -
fii I ~ +· -···· . --
; · r,- -1----- --1-
.a o I .,.. ~·~· ~­c(
AVG A6 81 810 88 C10 C11 C12 C7 05 
Aff 
Figure 2.5. Differentially upregulated genes in autism. The relative gene expression levels of the three 
upregulated genes A) C4orj7, B) CSF3R, and C) CD 14 are shown. The red bars represent the average 
absolute fold change and the black bars represent the individual fold change for each proband relative to 
healthy controls. The participants involved in this study are identified as A6, Bl, BIO, BS, CIO, CJ I, Cl2, 
C7, and D5. A VG Aff-Average of affected participants. 
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Molecular Functions and Biological Processes Associated with Differentially 
Upregulated Genes 
DAVID Bioinformatics Resources revealed molecular functions and biological 
processes that are associated with these differentially upregulated genes (Table 2.5). The 
molecular function and biological process of C4orj7, renamed FDC-SP (follicular 
dendritic cell secreted protein), has yet to be clearly defined. However, C4orf7 is known 
to be expressed by follicular dendritic cells and activates leukocytes during an ongoing 
immune response. 110 The activated leukocytes then bind onto the surface of B-lymphoma 
cells, spurring speculation that C4orf7 is a modulator of B cell activity. CSF3R encodes a 
protein that is the receptor for colony stimulating factor 3, a cytokine that regulates the 
production, differentiation, and function of granulocytes. 111 CD 14 is a surface antigen 
that is expressed on monocytes and macrophages. It coordinates with other proteins to 
mediate the innate immune response to bacterial lipopolysaccharide and also upregulates 
adhesion molecules at the cell surface. 112 The fact that these upregulated genes all play a 
role in some aspect of the immune response supports the notion of immune system 
irregularities in individuals with autism. 
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Table 2.5. Molecular functions and biological processes associated with 
differentially upregulated genes~ 
Gene Symbol Fold Molecular Function Biological Change Process 
C4orj7 25.3 None found None found Chromosome 4 open reading frame 7 
CSF3R Defense response 6.2 Receptor activity Signal transduction Colony stimulating factor 3 receptor Cell adhesion 
Signal transduction 
CD14 5.1 Receptor activity Response to heat CD 14 molecule Lipopolysaccharicle binding Immune response 
Cytokine secretion 
DA YID Bioinformatics Resources analysis revealed molecular functions and biological processes 
associated with the differentially expressed genes. 
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2.4.4. Differentially Downregulated Genes in Autism 
The differentially downregulated genes which showed at least 1.5-fold change 
were investigated further to establish functional significance,. There were 10 genes that 
exceeded the 1.5-fold change cut-off: KRT80 (keratin 80), ARHGEF5L (rho guanine 
nucleotide exchange factor 5-like), KLF4 (Kruppel-like factor 4), SH3D19 (SH3 domain 
containing 19), CDKNJB (cyclin-dependent kinase inhibitor lB), ERBB3 (v-erb-b2 
erythroblastic leukemia viral oncogene homologue 3), ARID5B (AT rich interactive 
domain 5B), RBM47 (RNA binding motif protein 47), CLPX (ClpX caseinolytic 
peptidase X homolog), and MAL2 (Mal, T-cell differentiation protein 2). 
Individual Fold Changes of Differentially Downregulated Genes 
For the downregulated genes, the average fold change among the affected group 
and individual fold change for each proband are graphed in Figure 2.6. Although the 
downregulated genes did not demonstrate fold change values as large as that seen for the 
upregulated genes, the mRNA levels were still found to fluctuate among probands. 
KRT80 had a -2.6-fold change average among affected participants; participant B8 
showed the greatest downregulation of this gene (approximately -3.6-fold change) while 
participant BIO had the least (approximately -1.8-fold change) (Figure 2.6A). 
ARHGEF5L had a -1.9-fold change average; participant B8 showed the greatest 
downregulation of this gene (-2.3-fold change) whereas participant Bl had the least (-1.3-
fold change) (Figure 2.6B). For KLF4, the affected participants had a -1.8-fold change 
average; participant A6 had -2.4-fold change and participant C7 had -1.5-fold change of 
this gene, representing the highest and lowest downregulation of this gene, respectively 
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(Figure 2.6C). SH3D19 had -1.8-fold change; participant B8 had the greatest 
downregulation and participant C7 showed the least downregulation of this gene, with -
2.3- and -1.5-fold change, respectively (Figure 2.6D). CDKNJB had a -1.7-fold change 
average; participant B8 showed the greatest downregulation of this gene (-2.3-fold 
change) and participant Bl showed the least downregulation (-1.4-fold change) (Figure 
2.6E). ERBB3 had a -1.7-fold change; participant A6 showed the greatest downregulation 
(-1.9-fold change) and participant ClO showed the least downregulation (-1.4-fold 
change) (Figure 2.6F). ARID5B had a -1.6-fold change average; participant B8 had the 
greatest downregulation (-2.2-fold change) and participant D5 had the least (-1.3-fold 
change) (Figure 2.6G). RBM47 had a -1.6-fold change average; participant Bl showed 
the greatest downregulation of this gene (-2.2-fold change) whereas participant D5 
demonstrated the least downregulation (-1.3-fold change) (Figure 2.6H). CLPX had a -
1.6-fold change average; participant B8 showed the greatest downregulation of this gene 
(-1.9-fold change) and participant D5 showed the least downregulation (-1.2-fold change) 
(Figure 2.61). MAL2 had a -1.5-fold change average; participant Cl l demonstrated the 
greatest downregulation (-1. 7-fold change) and participant B 10 showed the least (-1.2-
fold change) (Figure 2.6J). As with the upregulated genes, the differences in gene 
expression among probands could be represented in behavioural outcomes, such as the 
severity of autism symptoms (see section 2.4.5 for further discussion). 
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Figure 2.6. Differentially downregulated genes in autism. The relative gene expression levels of the 
downregulated genes that also show at least 1.5-absolute fold change. The down regulated genes are A) 
KRT80, B) ARHGEF5L, C) KLF4, D) SH3Dl9, E) CDKNJB, F) ERJ1B3, G) ARJD5B, H) RBM47, I) 
CLPX, and J) MAL2. The green bars represent the average absolute fold change and the black bars 
represent the individual fold change for each proband relative to healthy controls. The participants involved 
in this study are identified as A6, Bl, BIO, B8, CIO, Cl 1, Cl2, C7, and D5. AVG Aff - Average of 
affected participants. 
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Molecular Functions and Biological Processes Associated with Differentially 
Downregulated Genes 
DAVID Bioinformatics Resources was used to identify molecular functions and 
biological processes that are associated with the differentially downregulated genes 
meeting expression cut-off of 1.5-fold change (Table 2.6). KRT80 encodes intermediate 
filament proteins that are responsible for the structural integrity of epithelial cells. 113 The 
molecular function and biological process of ARHGEF5L, renamed ARHGEF35 (rho 
guanine nucleotide exchange factor 3 5), is not known yet though it is structurally similar 
to ARHGEF5. By structural similarity, the encoded protein may form a complex with G 
proteins and stimulate Rho-dependent signals. Rho GTPases play a role in numerous 
cellular processes initiated by extracellular stimuli that work though G protein coupled 
receptors. KLF4 acts as a transcriptional activator or repressor depending on the promoter 
context and cooperation with other transcription factors. KLF4 regulates the expression 
of key transcriptional factors during embryonic development and also plays a role in 
preventing the differentiation of embryonic stem cells. 114 SH3DJ9 plays a role in the 
regulation of cell morphology. 115 CDK.Nl B is an important regulator of cell cycle 
progression.116 ERBB3 encodes a member of the ERBB family of receptor tyrosine 
kinases. Four members of the ERBB family have been identified: ERBB 1, ERBB2, 
ERBB3, and ERBB4. These receptor proteins, through homo- and heterodimerization, 
convey extracellular signals into the cell through protein phosphorylation. 117 Following 
activation, a signaling cascade is initiated that drives many cellular responses, including 
cell proliferation, differentiation, migration, and survival or apoptosis. ARID5B is a 
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transcriptional regulator that plays a role in adipogenesis and organ development. 118 
RBM47 is known to bind to RNA but the biological process remains unknown. CLPX 
encodes an ATP-dependent specificity component of the Clp protease that directs the 
protease to specific substrates for proteolysis.119 MAL2 is gene that encodes a multispan 
transmembrane protein that is required for transcytosis, an intracellular transport pathway 
used to deliver membrane-bound proteins and exogenous cargos from the basolateral to 
apical surface. 120 
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Table 2.6. Molecular functions and biological processes associated with differentially 
downregulated genes meeting expression cut-off of 1.5-fold change. 
Gene Symbol Fold Molecular Biological Process Change Function 
KRT80 
-2.6 Structural molecule None found 
Keratin 80 
ARHGEF5L 
Rho guanine nucleotide -1.9 None found None found 
exchange factor 5 
Regulation of: 
KLF4 
-1.8 DNA and ion binding Transcription 
Kruppel-like factor 4 Transcription activity Cell proliferation 
Inflammatory response 
SH3Dl9 Cell morphogenesis 
-1.8 Protein binding Membrane organization SH3 domain containing 19 Intracellular transport 
Regulation of: 
CDKNJB Protein binding Cell proliferation 
cyclin-dependent kinase -1.7 Kinase activity Signal transduction 
inhibitor I B Receptor activity Microtubule polymerization 
DNA damage response 
ERBB3 Protein binding Signal transduction 
v-erb-b2 erythroblastic 
Kinase activity Organ morphogenesis 
-1.7 Receptor activity Schwann cell differentiation leukemia viral oncogene Protein dimerization Neuron apoptosis 
homologue 3 
activity Axonogenesis 
ARID5B Protein binding Regulation of transcription 
AT rich interactive domain 5B -1.6 DNA binding Organ morphogenesis Transcription activity Signal transduction 
RBM47 
-1.6 RNA and nucleotide None found RNA binding motif protein 47 binding 
CLPX Protein binding Protein folding ClpX caseinolytic peptidase X -1.6 
homolog 
Peptidase activity Proteolysis 
MAL2 
Mal, T-cell differentiation 
-1.6 Protein binding None found 
protein 2 
DA YID Bioinformatics Resources analysis revealed molecular functioms and biological processes 
associated with the differentially expressed genes. 
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2.4.5. Genotype-Phenotype Profiles of Probands 
Although clinical assessments of the probands were performed by different 
professionals, thereby adding variability to the available behavioural data, an attempt to 
establish the genotype-phenotype profiles of the probands was made. The goal was to 
determine if there are any correlations between the level of mRNA of dysregulated genes 
and severity of autism symptoms on an individual basis. The genotype information was 
obtained from the microarray results. The expression level:s of the three upregulated 
genes (C4orj7, CSF3R, and CDJ 4) and 10 downregulated genes (KRT80, ARHGEF5L, 
KLF4, SH3D19, CDKNJB, ERBB3, ARID5B, RBM47, CLPX, and MAL2) comprise the 
genotype profile of probands. The pro bands that had an above-average expression of the 
upregulated and downregulated genes were denoted with red and green markings, 
respectively (Figure 2. 7). The phenotype profile of the pro bands was established based on 
the obtained clinical assessment reports (with the exception of participant D5). Reported 
symptoms were organized into the three main domains of autism: speech impairments, 
social interaction deficits, and restricted and repetitive behaviours (RRBs ). Other 
characteristics that are commonly associated with autism were also taken note of, such as 
motor impairment, developmental regression, resistance to change, and anxiety. The 
combined genotype-phenotype profile is shown in Figure 2.6. Based on observations, the 
data suggest a possible relationship between the number of symptoms in the speech and 
social interaction domains and the mRNA levels of the upregulated genes, especially with 
C4orj7. For instance, participants A6, B8, Cl 1, and Cl2 demonstrated an above-average 
expression of C4orj7 and displayed at least five symptoms of deficits in social 
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interaction. Additionally, participant A6 revealed an approximately 73-fold change 
upregulation of C4orj7 and demonstrated the most speech impairments in comparison to 
all the pro bands. In contrast, participants B 1 and B 10 have a sub-average expression of 
C4orf7 and showed less than five symptoms of deficits in social interaction. However, 
due to the variability between clinical assessment reporting formats and type of reported 
symptoms, as well as lack of assessment report from participant D5, this observation 
remains tentative and preliminary. 
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Repetitive Behaviours. t Clinical assessment report was not obtained from this participant. 
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2.4.6. Signaling Pathways Dysregulated in Autism 
The dataset of differentially regulated genes between probands and healthy 
controls was analyzed using DAVID Bioinformatics Resources to identify statistically 
enriched signaling pathways. The significance of the association between the dataset and 
the signaling pathway was measured in two ways: i) a ratio of the number of molecules 
from the dataset that map to the signaling pathway divided by the total number of 
molecules that map to the signaling pathway and ii) Fisher's exact test was used to 
calculate a p-value determining the probability that the association between the genes in 
the dataset and the signaling pathway is explained by chance alone. 121 A p-value of less 
than 0.05 was considered significant. Two signaling pathways of interest were revealed: 
the ERBB signaling pathway and circadian rhythm. The downregulated genes ERBB3, 
PTK2, MAP2K4, and CDKNJB were found to participate in the ERBB signaling pathway 
(Figure 2.8). The downregulated genes CRYJ and NPAS2 are involved in circadian 
rhythm (Figure 2.9). 
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Figure 2.8. Dysregulation of the ERBB signaling pathway in autism. The ERBB receptor tyrosine 
kinase family (ERBB 1-4) are activated following ligand binding and receptor dimerization. Ligands can 
display receptor specificity or bind to one or more receptors. ERBB2 lacks a known ligand. ERBB3 lacks 
several key conserved amino acid residues but has been shown to possess catalytic activity through 
transautophosphorylation. ERBB proteins are also present in the nucleus as transcription regulators. For 
instance, ERBB2 interacts with Nup358 and importin Pl and translocates to the nucleus where it modulates 
the transcription of multiple downstream genes including cyclooxygenase 2 (COX2). The differentially 
downregulated genes CDKNJB, ERBB3, PTK2, and MAP2K4 participant in this pathway (denoted in 
green). Red stars denote previously described neuropsychiatric susceptibility genes. 
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Figure 2.9. Dysregulation of circadian rhythm in autism. Circadian rhythm involves a molecular 
network of genes and proteins that control biological timing. CLOCK and NP AS2 heterodimerize to 
BMALI to activate the transcription of genes, including PERJ-3, CRYJ-2, REV-ERBa, and RORa. The 
gene products of PER, CRY, and REV-ERBa operate via a PER/CRY heterodimer that inhibits the effects of 
the CLOCK/BMALI or NPAS2/BMALI heterodimer while REV-ERBa represses the expression of 
BMAL 1. Protein turnover eventually releases the genes from repression and the cycle starts over. The 
differentially downregulated genes CRYI and NPAS2 participate in this pathway (denoted in green). Red 
stars denote previously described autism susceptibility gene candidates. 
69 
I l' 
2.4.7. Temporal Expression of Potential Susceptibility Genes for Autism 
The temporal expression level of identified potential susceptibility genes for 
autism was evaluated in the wild-type mouse. The differentially regulated genes meeting 
the 1.5-absolute fold change threshold were initially evaluated as potential susceptibility 
genes for autism. Polymerase chain reaction (PCR) was used to assess the expression of 
C4orj7, Csj3r, Cdl 4, Krt80, Arhgef5l, Klf4, Sh3dl 9, Cdknl b, Erbb3, Arid5b, Rbm47, 
Clpx, and Mal2 in the mouse brain during embryonic day 16 (El6), embryonic day 19 
(E 19), postnatal day 8 (P8), and adult stage. With the exception of C4orj7, all of the 
genes were found to have positive expression in the mouse brain (Figure 2.10). The 
absence of C4orf7 expression in the brain is supported by the existing literature. 110 Six 
genes (Csj3r, Cd14, Klf4, Cdknl b, Erbb3, and Clpx) were then chosen as potential 
susceptibility genes for autism because of their functional relevance in the nervous 
system. As previously discussed, Csf3r is a cytokine that regulates the production, 
differentiation, and function of granulocytes. Cdl 4 is a surface marker present on 
monocytes and plays a role in triggering cytokine secretion. Klf4 is a regulator of key 
transcription factors during embryonic development. Cdknl b is a cell cycle regulator. 
Erbb3 is involved in biological processes such as Schwann cell differentiation and 
axonogensis. Clpx directs the Clp protease to specific substrates for proteolysis and is 
also a putative target of Foxp2, an autism susceptibility gene. 
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Figure 2.10. Positive expression of twelve differentially regulated genes (~1.5-fold change) in the 
wild-type mouse brain. Polymerase chain reaction followed by agarose gel electrophoresis was used to 
assess expression. Csf3r (236 bp), Cd14 (542 bp), Krt80 (459 bp), Arhgef5/ (686 bp), Klf4 (330 bp), 
Sh3dl9 (885 bp), Cdknlb (224 bp), Erbb3 (642 bp), Arid5b (916 bp), Rbm47 (815 bp), Clpx (505 bp), and 
Ma/2 ( 405 bp) demonstrate positive expression in the mouse brain during embryonic day 16 (E 16), 
embryonic day 19 (E19), postnatal day 8 (P8), and (A) adult stage. 
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Quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify 
the expression of Csj3r, Cdl 4, Klf4, Cdknl b, Erbb3, and Clpx to determine whether they 
are more highly expressed during early or late development. The adult sample was used 
as a reference to compare expression levels. As seen in Figure 2.11, Csj3r had the highest 
expression during the adult stage, followed by P8, and then .E19 and El6. The level of 
gene expression was found to be statistically significant between all stages except E 19 
and P8. Cd14 had the highest expression during E16 which gradually decreased through 
E19 to the adult stage. The expression levels of Cdl4 were found to be significantly 
different between E 16 and P8, as well as E 16 and adult. Klf4 had the highest expression 
during E16 and E19, which were not significantly different from each other. The 
expression of Klf4 declined as development progressed. The expression of Klf4 at E 16 
and El 9 was found to be significantly different from that at P8 and adult. Cdknl b is most 
highly expressed at E16 with declining expression through E19 and P8. The expression 
levels of Cdknl b were significantly different from each other except between E 19 or P8 
and adult. Erbb3 was found to be most highly expressed during adulthood, which was 
significantly different from E16, E19, and P8. Clpx had the highest expression during 
E 16 which gradually declined from E 16 through adulthood. All stages were found to be 
statistically significant except P8 and adult. In summary, it appears that Cd14, Klf4, 
Cdknl b, and Clpx have clear roles during prenatal development, as illustrated by the 
higher levels of expression during E 16 and E 19 relative to the postnatal stages. Although 
Erbb3 seems to be more highly expressed in the adult stage, the E 16 stage has the second 
highest level of expression, which might indicate some functional significance for brain 
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development at E16. Csf3r has the lowest expression during E16 and demonstrates 
gradual increase in expression after this stage, which suggests a greater need for this gene 
as maturation of the progeny proceeds. 
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Figure 2.11. Expression of identified potential susceptibility genes for autism during prenatal and 
postnatal development in mouse brain. Quantitative real-time polymerase chain reaction was used to 
assess expression. A) Csf3r and E) Erbb3 expression is highest in the adult stage. B) Cdl 4, D) Cdknl b, and 
F) Clpx demonstrate the highest expression at El6. C) Klf4 shows equally high expression during El6 and 
El9. *p<0.05; Error Bars: ±SEM. 
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2.5. Discussion 
2.5.1. Quality Assessment of RNA Samples 
The results presented here are an evaluation of buccal RNA samples as an 
efficient and non-invasive means of sample collection for evaluating relative gene 
expression changes. The quality of RNA from buccal cells was found to vary between 
samples even though swabbing pressure and technique was perceived to be consistent. In 
some cases, the RNA was more prone to degradation although the same procedure was 
precisely followed during each sample collection. By way of explanation, perhaps it is 
because the cells recovered from the mouth are superficial ones that are in the process of 
apoptosis, which may cause damage to the genetic material. The existing literature 
indicates that approximately 25% of buccal cells collected from healthy subjects with 
non-inflammatory mucosa are apoptotic. 122 Another retrospective consideration is that 
lifestyle habits can cause differences in exfoliation of oral mucosa. The oral flora is 
extremely diverse and subject-specific based on individual habits, including diet, eating 
mannerisms, and brushing habits. 123 All of these factors can lead to unequal rates of 
DNA/RNA damage. Nevertheless, despite the inconsistency in RNA quality, total RNA 
from buccal cells was found to be of sufficient quality to be used in successful microarray 
experiments and a list of genes showing differential expression between probands and 
healthy controls was produced (Table 2.4). 
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2.5.2. Expression of Differentially Regulated Genes in the :Central Nervous System 
Further analysis of the dataset of differentially regulated genes in autism revealed 
that the majority of these genes (66.3%) are expressed in the CNS (Figure 2.4). This is a 
strong indication that RNA from buccal cells can be used to study the human brain and 
also strengthens the idea that autism can be studied using ,easily accessible peripheral 
tissues, which may reflect abnormalities that are also present in the brain. A few 
differentially regulated genes have restricted expression in peripheral tissues, including 
C4orj7, a 25-fold upregulated gene in the autism group. Yet, despite the absence of 
C4orj7 expression in the CNS, there is increasing evidence for the involvement of other 
body systems in autism, such as the gastrointestinal and immune systems, which suggests 
that peripheral tissues may also be affected. Identification of consistent autism 
susceptibility genes from buccal cells could aid in the efforts of learning more about the 
related physiological symptoms associated with autism, such as gastrointestinal 
irregularities and immune system abnormalities. 
2.5.3. Differentially Upregulated Genes in Autism: Evidence of Altered Immune 
Response and Possible Genotype-Phenotype Correlations 
Emergence of a common biological theme among the differentially upregulated 
genes affirms reports of immune response abnormalities in autism and lends insight into 
possible genotype-phenotype relationships. 
The dataset of differentially regulated genes revealed three upregulated genes 
(C4orj7, CSF3R, and CD14) that were all found to play a role in the immune system. 
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Dysregulated immune function is a recurrent finding in autism. Results from numerous 
studies include evidence of brain reactive antibodies; skewed T cells numbers; altered 
cytokine levels in the brain, cerebrospinal fluid, and periphery; and altered function of 
innate immune cells such as monocytes and NK cells. 124-128 Here, the results of the 
present study also support the notion of immune system irregularities in autism. 
C4or0 (Chromosome 4 open reading frame 7) 
Elevated C4orf7 mRNA levels may be triggered by the greater quantities of 
activated B cells in autism and provides further evidence that the activation status of 
immune cells is altered in autism. 
Recent findings on C4orf7 (renamed FDC-SP, but hence forward still referred to 
as C4orf7), a secreted protein expressed by follicular dendritic cells (FDCs ), reveal a 
distinctive expression pattern within the immune system and the ability to bind 
specifically to activated B cells.11° FDCs are the stromal cells located in the germinal 
centre, a dynamic site within lymph nodes where antigen-activated B cells rapidly 
proliferate and differentiate, generating plasma cells (which produce antibodies) and 
memory B cells. A prior study examining the characteristics of whole blood immune cell 
subpopulations found that B cells were 20 - 25% higher in children with autism 
compared with typically developing children. 129 Notably, there were significant 
differences in activated B cell subsets in autism, while the number of immature B cells 
was not different. These data suggest that B cells are increased in autism, and 
furthermore, it is preferentially the activated and mature B cells which differ from 
controls. To put the findings of the present study into perspective with the existing 
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literature, it would be reasonable to expect an increase in expression of C4orf7 in 
response to greater quantities of activated B cells, which would be consistent with its 
function as a modulator of B cell activity.130 
A connection exists between tumour necrosis factor alpha (TNF-a), C4orf7 mRNA 
levels, and behavioural outcomes in autism. 
As stated in the results section, participants A6, B8, C 11, and C 12 had an above-
average expression of C4orf7 and also demonstrated at least five symptoms indicative of 
social interaction deficits. Notably, participant A6 showed a 73-fold change upregulation 
of C4orj7 and displayed the most number of symptoms in the speech and social 
interaction domains, in addition to developmental regression. 
Brief exposure of FDC-like cell lines to tumour necrosis factor alpha (TNF-a) has 
been shown to induce high-level expression of C4orf7. 110 Elevation of CSF levels of 
TNF-a have been significantly higher in patients with autism demonstrating regression of 
previously acquired language skills, in comparison to typically developing or 
neurological disease controls. 126' 131 Among the probands of this study, participants A6, 
Bl, Cl I, C12, and C7 exhibited developmental regression and of which, participants A6, 
Cl I, and C12 had an above-average upregulation of C4orj7 (Figure 2.7). It is an 
intriguing observation that participants A6, Cll, and C12 also showed the highest fold 
changes in. C4orf7 expression, which were approximately 73-, 54-, and 56-fold change, 
respectively (Figure 2.5A). The results are suggestive of a connection between C4orf7 
mRNA levels and developmental regression in autism. 
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The findings of this study suggest that elevated levels of TNF-a, which are 
associated with developmental regression of linguistic skills in autism, could trigger high-
level expression of C4orj7. In turn, C4orj7 upregulation could be correlated with more 
general aberrant behaviours relating to autism, in addition to developmental regression. 
Admittedly, conclusions cannot be reached based on this study alone, due to a lack of 
unified reporting format for the clinical assessments. The connection between C4orj7 
expression and behavioural outcomes in autism warrants further investigation; however, 
if such a relationship exists, C4orj7 may be potentially used a biomarker for autism 
symptoms. 
CSF3R (Colony stimulating factor 3 receptor) 
Higher levels of colony stimulating factor 3 (CSF) production is associated with 
better cognitive and adaptive function in children with autism but higher expression of its 
receptor, CSF3R, is not correlated with more favourable developmental outcomes. 
The current study demonstrated that CSF3R expression is greatly increased in 
children with autism compared to healthy counterparts. CSF3R is the receptor for colony 
stimulating factor 3 (CSF3), a hematopoietic growth factor and an inflammatory cytokine 
that stimulates growth and differentiation of myeloid progenitor cells into monocytes and 
dendritic cells (DCs ). 132 In addition to playing a role in increasing innate immune cell 
numbers during infections, CSF3 has been shown to cross the blood-brain barrier to 
stimulate neurite outgrowth and promote axonal regeneration. 133,134 
CSF3 has been shown to be greatly increased in individuals with autism. 60,135 
Ashwood and colleagues found that the increased production of CSF3 was associated 
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with improved developmental outcomes and less aberrant behaviour in autism, and 
suggested a role of CSF3 in the improvement of cognition and adaptive function in 
autism. 135 In the present study, an upregulation was seen not with CSF3, but with its 
receptor CSF3R. An above-average over-expression of CSF3R exhibited by the probands 
of the current study did not seem to correlate with better socialization skills or fewer 
behavioural abnormalities and, in fact, seem to suggest the opposite. 
Mechanisms of chronic inflammation in the brain may be mediated by 
upregulation of CSF3R. 
The observation that CSF3R expression by the probands did not correlate with 
better developmental outcomes may be explained by the fact that CSF3 activation is also 
responsible for the production of reactive glial cells, astrocytes, and microglia. An 
activated profile of these cells is considered to be a barrier to neuroprotection. 136 For 
instance, in CNS diseases such as Alzheimer's disease and multiple sclerosis, increased 
production of astrocytes and microglia contribute to inoreased inflammation, and 
subsequent neuronal damage and neuronal loss. 137 In autism, the presence of activated 
microglia has been described in post-mortem brain specimens.60•138 
The findings of this study suggest that the mechanisms of chronic inflammation 
could be mediated by upregulation of CSF3R, which would provide more receptor 
bindings sites for CSF3 to exert its actions as a pro-inflammatory cytokine. For example, 
CSF3 is a potent enhancer of TNF-a production. 139 The production of cytokines from 
microglia could influence neuronal survival, function, and synaptic plasticity. 140 
Although CSF3 activation is involved in several beneficial effects, including neurite 
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outgrowth and axonal regeneration, which could lead to better developmental outcomes 
as explained by Ashwood and colleagues; hyperstimulation of CSF3-CSF3R signaling is 
likely to have deleterious effects on neurons. 135 
The blockade of CSF3R has been shown to suppress microglia activity. 141 Since 
microglia cell activation is a prominent feature of autism, blocking CSF3R, and thus 
microglia activity, may have important anti-inflammatory effects and implications for 
therapy. Further investigation of the role of CSF3R in immune responses and 
neurodevelopment in autism is warranted. 
CD14 (CD14 molecule) 
Dysregulated CD 14 expression in children with autism may render them more 
susceptible to bacterial dysbiosis, and possibly result in gastrointestinal irregularities 
and worsen disease prognosis. 
CD 14 is essential for the recognition of bacterial lipopolysaccharide (LPS) 
present in Gram-negative bacteria. 112 It acts as a pattern recognition protein which 
accepts LPS from LPS-binding protein to elicit the endotoxin cellular response by 
reacting with various Toll-like receptors (TLRs). 
The present study found an upregulation of CD 14 in autism compared to controls. 
This finding conflicts with the existing literature seeing that the association between 
autism and CD 14 has been previously refuted. CD 14 was investigated for its possible role 
in autism after reports of intestinal bacterial dysbiosis in affected children. 142 Emanuele 
and colleagues investigated whether adult patients with severe autism have differences in 
circulating endotoxin, its soluble receptor CD14, and markers of immune-inflammatory 
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activation (IL-1 ~, IL-6, and IL-10) compared with healthy controls and found no 
significant elevation of CD 14.143 
However, CD14 exists in two forms - either in a soluble form or anchored to the 
membrane of monocytes by a glycosylphosphatidylinositol tail. 144 Monocytes, precursors 
of macrophages and microglia, are robust cytokine producers that profoundly influence 
the activity of neighbouring immune cells. A prior investigation indicated significantly 
increased monocyte counts in children with autism compared with typically developing 
children.145 It should be noted that there are three types of monocytes in human blood: the 
classical monocytes are characterized by high-level expression of the CD14 cell surface 
receptor (CD14++CD16); the non-classical monocytes show low-level expression of 
CD14 and with additional co-expression of the CD16 receptor (CD14+CD16++); and the 
intermediate monocytes with high-level expression of CD14 and low-level of CD16 
(CD14++CD16+).146 These monocyte subsets are physiologically different and changes in 
their numbers have been observed in various disease conditions. In stroke patients, the 
number of circulating monocyte subsets is associated with disease prognosis: 
CD14++CD16- monocyte numbers are positively associated with poor outcome, early 
clinical worsening, and higher mortality. 147 It has been suggested that in the presence of 
CNS inflammation, peripheral blood monocyte numbers and functions may be associated 
with the degree of disease severity. 18 
Furthermore, CD14++CD16- monocytes express high levels of chemokine 
receptors CCRl, CCR2, CXCR2, and respond to the chemokine ligands CCL2 and 
CCL 7. 148 In a study of transcript profiles of peripheral blood monocytes in children with 
82 
autism who exhibit aberrant behavioural symptoms following infection and other immune 
insults, those with persistent gastrointestinal symptoms revealed altered regulation of 
CCL2 and CCL 7 .18 The data indicate that in a subset of affected children with 
gastrointestinal irregularities, dysregulated immune responses may render them more 
vulnerable to common bacterial infection or dysbiosis. 
Unfortunately, the clinical assessment reports obtained from the probands of the 
present study did not place emphasis on gastrointestinal irregularities in affected 
individuals. Based on the results of the present study, however, a resultant hypothesis is 
formed: pro bands exhibiting an above-average expression of CD 14 (participants A6, 
B 10, and B8) have gastrointestinal symptoms. Whether increased CD 14 may contribute 
to the pathophysiology of inflammation and autism symptoms should be further explored 
in future studies. 
The relationship between CSF3R and CDJ4 in neutrophil maintenance support 
previous reports of dysregulated immune responses and enhanced immune activity in 
autism. 
Mobley and colleagues investigated the differences between the monocytes 
subsets to provide clues for possible distinctive functions and also revealed a relationship 
between CD14 and CSF3R. 149 At the earliest stage of the innate immune response, 
CD14++CD16+ monocytes respond directly to invading microorganisms by releasing a 
multifunctional cytokine that initiates the acute phase immune response and directs the 
production of CSF3. CSF3 then promotes the production of neutrophils and instigates 
CD14++CD16- monocytes that remove them once their job is finished. Differential 
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expression of CSF3R by the CD14++CD16- monocytes suggests that the induction of this 
subset could be correlated with the CSF3-dependent production of neutrophils. This 
safety mechanism would ensure that whenever neutrophils are released, the cells required 
to dispose of those neutrophils are also produced. Neutrophils are capable of producing 
potent bactericidal agents, including reactive oxygen species, nitric oxide, and proteases 
that not only kill the invading pathogen, but can also inflict severe collateral damage on 
nearby host tissues. In the present study, all the probands (A6, BIO, and B8) but one (D5) 
that demonstrated an above-average upregulation of CSF3R also had an above-average 
up-regulation of CD 14 (Figure 2. 7). Thus, it seems that the expression of CSF3R and 
CD 14 might be related. The current findings are consistent with previous reports of 
enhanced immune activity in autism and further indicate that a dysfunctional innate 
immune response may occur in a number of individuals with autism. 
The data indicate that altered immune function in children with autism may be 
linked to disturbances in behaviour and developmental functioning. 
Taken together, the data present compelling evidence for immune dysfunction in 
autism and may indicate that the dysregulation of genes involved in the immune 
response, such as C4orj7, CSF3R, and CDJ 4, can modulate behaviours relating to autism. 
Although the data should be treated with caution until further validation can be 
performed, it should be noted that a number of other studies have also shown an 
association between altered immune profiles and autism symptoms. 128•135•150•151 More 
extensive longitudinal studies will be required to characterize the immunological changes 
associated with autism and the severity of behavioural symptoms. 
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2.5.4. Differentially Downregulated Genes in Autism: Evidence of Dysregulated 
Signaling Pathways in Autism 
The differentially downregulated genes meeting expression cut-off of 1.5-fold 
change (KRT80, ARHGEF5L, KLF4, SH3DJ9, CDKNJB, ERBB3, ARID5B, RBM47, 
CLP X, and MAL2) demonstrated common molecular functions including DNA binding, 
protein binding, and transcriptional activity, and also shared common biological 
processes such as signal transduction and regulation of cell proliferation and 
transcription. However, these genes did not reveal a unifying biological theme, unlike the 
differentially upregulated genes which were all found to be involved in the immune 
response. Nevertheless, pathway analysis revealed two signaling pathways of interest 
from the entire list of differentially regulated genes (Table 2.4). Furthermore, it was 
several of these downregulated genes, and not the upregulated genes, that were found to 
be involved in dysregulated signaling pathways associated with autism. 
The importance of identifying dysregulated signaling pathways in autism. 
Many genetic linkage, cytogenetic, and candidate gene studies have implicated a 
multitude of loci, chromosomal hot spots, and genetic variants in autism. Despite 
substantial efforts to unravel the genetic basis of autism, a detectable genetic aberration is 
recognized in less than 10% of cases.31 The remaining 90% of idiopathic cases represent 
a broad clinical spectrum that has proven exceedingly difficult to define. Yet, regardless 
of the wide genetic heterogeneity, there are core phenotypic features common to all cases 
of autism and it is conceivable to think that there are common biological pathways that 
are dysregulated in autism. A proposed theory posits that distinct genetic variants, each of 
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which occurs rarely among autism cases, disrupt the function of a core group of genes, of 
which perturbation to these genes is necessary to cause autism. Such a functional 
disruption may explain how multiple genetic factors could result in a single disorder with 
central neural network dysfunction. 152 The ascription of differentially regulated genes to 
gene regulatory networks may provide further insights into potential mechanisms 
contributing to autism, whereas individual gene studies are unlikely to provide a 
comprehensive explanation of the phenotypic variation that is characteristic of autism. 
ERBE Signaling Pathway 
The results from the pathway analysis show that the differentially downregulated 
genes ERBB3, CDKNJB, PTK2, and MAP2K4 belong to the ERBB signaling pathway 
(Figure 2.8). 
The ERBB family of receptor tyrosine kinases includes four members: ERBB 1 to 
ERBB4.117 These receptor proteins, through homodimerization and heterodimerization, 
convey extracellular signals into the cell through protein phosphorylation. Following 
activation, a signaling cascade is initiated that drives many cellular responses, including 
cell proliferation, differentiation, migration, and survival or apoptosis. The signaling 
diversity originating from the ERBB family of receptor tyrosine kinases is generated by 
the repertoire of ERBB ligands and the combinatorial properties of receptor dimers. As 
well, ERBB proteins may also act as transcriptional regulators. For instance, ERBB2 can 
interact with Nup358 and importin ~1 to translocate to the nucleus where it modulates the 
transcription of multiple genes including cyclooxygenase 2 (COX2), which has been 
previously associated with autism. 153•154 
86 
I I 
Alterations in ERBB signaling have been implicated in the underlying pathology 
of neuropsychiatric disorders. 
Neregulins (NRGs) are growth factors that signal through ERBB receptors. 
NRG 1-ERBB signaling is known to play crucial roles in tile development and patterning 
of the cerebral cortex and cerebellum.155-157 Moreover, NRG 1-ERBB4 interactions can 
modulate gamma oscillations in the brain, which is perceived to be critical for normal 
cognitive functions. 158 Collectively, these studies imply that NRG 1-ERBB signaling 
defects may alter the generation or function of neurons in the developing and adult brain. 
Several genes in the NRG-ERBB signaling pathway, including NRG 1, NRG3, and 
ERBB4, have been implicated in the genetic predisposition to schizophrenia. 159-161 The 
symptoms of schizophrenia include altered social behaviours, which is an area of 
phenotypic overlap with autism. Resultant changes in neural circuitry and 
electrophysiology in the cerebral cortex may lead to neuropsychiatric disorders such as 
schizophrenia, as well as autism. 
The present study revealed that ERBB3 was downregulated among the probands. 
ERBB3 has an inactive kinase domain but has been shown to possess catalytic activity 
through transautophosphorylation, thus indicating it acts as a co-receptor. 117 Given that 
ERBB3 and ERBB4 interact to form receptors together, it would be important to further 
investigate the function of ERBB3 in neurodevelopmental events. 
Major signaling pathways activated by ERBB receptors. 
Activated ERBB tyrosine kinase domains generate intracellular docking sites for 
adaptor proteins, such as Grb2 and N ck; and kinases, such as Src and 
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phosphatidylinositol 3-kinase (PI3K), which in turn activates the Ras/ERK, PI3K/AKT, 
Src/PTK2, and Nck/PAK signaling pathways. 117 
The Ras/ERK signaling pathway is initiated through ERBB receptor activation via 
Grb2. There are genetic mutations that have been found to increase the risk of autism and 
that have potentially strong links to the Ras/ERK pathway. The Ras/ERK signaling 
pathway has been shown to play dual roles by promoting both cell development and cell 
death. Zou and colleagues detected significantly enhanced Ras/ERK signaling activities 
in the frontal cortex of people with autism, as well as in the brain of BTBR mice that 
model autism. 162 
Dysregulation of the PI3K/AKT signaling is currently thought to be a contributing 
factor of autism. The PI3K/AKT signaling pathway (via the p85 regulatory subunit) is 
known to be involved in cellular functions such as cell growth, proliferation, 
differentiation, motility, and survival. 163 Although there is a great deal of overlap in the 
signaling pathways activated by the four ERBB receptors, there are also examples of 
preferential activation of specific pathways. For example, ERBB3 is thought to be the 
most efficient activator of PBK due to the presence Qf multiple binding sites for p85. 164 
Another component of the PI3K/ AKT signaling pathway is PTEN (phosphatase and 
tensin homologue on chromosome 10). PTEN functions primarily as a phosphatase to 
antagonize PI3K signaling. Removal of PTEN results in the upregulation of P13K 
signaling, through the increased phosphorylation of P13K effectors such as AKT. PTEN 
is a tumour suppressor gene mutated in many human cancers, and has also been 
associated with autism. 165•166 A recent study found that within a small subset of subjects 
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with autism and macrocephaly (larger head circumference), 17% had mutations in the 
PTEN gene. 167 In this context, it is interesting to note that CDK.NlB is a downstream 
target of AKT. CDK.NlB was found to be downregulated among the probands of this 
study. In reinforcing the view that autism involves abnormal regulation of brain growth 
during development, Courchesne and colleagues have hypothesized that CDK.NlB may 
be associated with early brain overgrowth, which could disrupt the organization and 
connectivity of the cortex and alter the balance of excitatory and inhibitory signals in the 
brain. 168 Furthermore, other related neurological disorders, which also harbour mutations 
in the PBK pathway, are associated with autism. For instance, individuals with mutations 
in the tuberous sclerosis complex 112 (TSC 1/2) - a direct substrate of AKT activity -
develop tuberous sclerosis and, with a high incidence of 25-50%, also exhibit autism. 166 
Recent studies suggest that reduced cell migration may be involved in the 
pathogenesis of autism.169 PTK2 has a vital functional role in neural migration, dendritic 
morphology, axonal branching, and synapse formation. Protein expression levels of Src 
and PTK2 have been shown to be significantly decreased in lymphoblasts from subjects 
with autism. 170 In addition, these lymphoblasts exhibit decreased migration, have 
increased adhesion properties, and impaired IgG production. These results suggest that 
Src-PTK2 signaling activity is reduced in autism; a finding that validates the current 
study results, as PTK2 mRNA levels were found to be significantly reduced among 
affected subjects. 
Lastly, MAP2K4 (mitogen-activated protein kinase 4) is another differentially 
downregulated gene belonging to the ERBB signaling pathway. MAP2K4 mediates 
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responses to various cellular stresses and inflammatory cytokines. Downstream of 
Nck/PAK signaling, MAP2K4 phosphorylates and activates JNK. An in silico study of 
the gene expression profile from autism implicated genes found that JNK signaling was a 
central hub for immune signaling in autism. 152 This work provides integrated evidence 
that autism susceptibility genes and other neuropsychiatric-implicated genes may 
converge onto central signaling pathways. 
Circadian Rhythm 
Another significantly enriched pathway identified from the microarray data 
analysis was circadian rhythm. Circadian rhythm involves a molecular network of genes 
and proteins that control biological timing. The identified differentially downregulated 
genes CRYJ and NPAS2 participate in this pathway (Figure 2.9). 
In the generation of circadian rhythm, the positive elements of the system, 
CLOCK and NP AS2, heterodimerize to BMAL I and activate the transcription of P ERJ-
3, CRYJ-2, REV-ERBa, and RORa. The encoded gene products of PER, CRY, and REV-
ERB a, the negative elements of the system, operate via a PER/CRY heterodimer that 
inhibits the effects of the CLOCK/BMAL 1 or NP AS2/BMAL 1 heterodimer while REV-
ERBa represses the expression of BMAL 1. Protein turnover eventually releases the genes 
from repression and the cycle starts over. The time taken for the migration of proteins and 
mRNA to and from the nucleus broadly defines the,...., 24 hour period of this oscillatory 
system. 
Circadian rhythm has been proposed to have multiple effects on neurological, 
hormonal, and gastrointestinal functions commonly dysregulated in autism. Atypical 
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sleep architecture has been reported in many individuals with autism.1 71 Circadian 
hormone (melatonin) abnormalities have been found as well. 172 Dysregulation of genes 
involved in the circadian rhythm mechanism could have a systemic impact on individuals 
with autism, causing many of the related symptons that are commonly found in autism. 
Genetic variations in the circadian genes have been previously investigated in individuals 
with autism and showed a positive association with NP AS2 and P ERJ. 173 As well, both 
CRYJ and NPAS2 have been found to be differentially regulated in severe cases of autism 
in a microarray study using lymphoblastoid cell lines. 174 In a different study employing 
lymphoblastoid cells, DNA methylation differences in RORa between subjects with 
autism and controls were demonstrated. 175 In addition to its role in circadian rhythm, 
RORa transcriptionally regulates aromatase, an enzyme that converts testosterone to 
estrogen. The aromatase protein is significantly reduced in the frontal cortex of autism 
subjects relative to controls, and is strongly correlated with RORa protein levels in the 
brain.176 The results indicate that RORa, through its transcriptional target aromatase, 
could provide insight into the sex bias in autism. Collectively, these studies pertaining to 
dysregulation of circadian rhythm in autism further validate the results of the current 
study. 
2.5.5. Temporal Expression of Potential Susceptibility Genes for Autism 
Evaluation of the temporal expression level of the differentially upregulated genes 
Csf3r and Cdl 4 in wild-type mouse and speculated roles in brain development. 
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In this study, the expression of Csf3r and Cdl 4 was further examined in the 
mouse brain throughout three stages of development (E 16, E 19, and P8) and the adult 
stage to elucidate its role in the developing CNS. 
Csj3r was found to be most highly expressed in the adult stage and had lowest 
expression at E16 (Figure 2.1 lA). Similarly, Kirsch and colleagues studied the 
expression pattern of Csj3r in the mouse embryo to determine whether its expression in 
the adult nervous system had any correlation to the embryonic expression. 177 The authors 
found that in adults, Csf3r is expressed in neurons of many brain areas, including 
neurogenic regions such as the subventricular zone and the subgranular layer of the 
dentate gyms. However, the expression of Csf3r in the developing CNS is most 
prominent in radial glial cells. Radial glial cells are multifunctional cells involved in 
many aspects of brain and spinal cord development. 178 Most intriguingly, radial glial cells 
have been recently perceived as the neuronal progenitors that generate neurons in the 
cerebral cortex. 179' 180 These findings implicate the importance of Csj3r embryonic 
expression and a likely significance in the early development of the nervous system, 
despite the low levels of expression at El 6. 
On the contrary, Cdl 4 was found to be most highly expressed in the mouse brain 
at E16 with expression gradually decreasing throughout development (Figure 2.1 lB). The 
CD14/TLR4 complex has been identified as a pathogen recognition receptor that 
responds to LPS, a cell wall component of gram-negative bacteria. 112 Binding of LPS to 
its receptor complex activates the transcription factor nuclear factor kappa B (NFKB), 
leading to robust increases in production and release of pro-inflammatory cytokines, 
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including IL-IP and TNF-a.1 81 In turn, increases in pro-inflammatory cytokines activate 
inducible cyclooxygenases (COX) to convert arachidonic acid into prostaglandins that 
influence the inflammatory response and physiological outcomes. 182,183 There are an 
increasing number of hypotheses that try to explain the immune abnormalities in autism, 
including maternal infections during pregnancy, congenital viral infections, or 
xenobiotic-induced abnormalities. 184' 185 A previous report imdicated that in the first month 
of life, children that later develop autism have more infections than their counterparts. 186 
These findings, in conjunction with the observation that children with autism are more 
responsive to signaling via TLRs, suggest that aberrant signaling through CD 14/TLRs 
may participate in this disorder. 187 Inappropriate stimulation of immune responses during 
critical neurodevelopmental periods could contribute to alterations that are characteristic 
of autism. 
Evaluation of the temporal expression level of the differentially downregulated 
genes Klf4, Cdknl b, Erbb3, and Clpx in wild-type mouse and speculated roles in brain 
development 
The 10 differentially downregulated genes that met the expression cut-off 1.5-fold 
change were found to have positive expression in the brain. Based on functional 
relevance in the CNS, four genes were further studied in the mouse brain throughout 
development: Klf4, Cdknlb, Erbb3, and Clpx. 
Klf4 was most highly expressed during prenatal development, which includes the 
neurogenesis period (Figure 2.11 C). Embryonic neurogenesis is regulated by the 
activation of specific genetic programs. In the hypothalamus, a brain region that has been 
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previously implicated in autism, discrete populations of neurons play essential roles in 
homeostasis by regulating hormone secretion from the pituitary. Among these, neuronal 
thyrotropin-releasing hormone (TRH) populations control essential physiological roles, 
including energy homeostasis, autonomi~ function, and coordinating the hypothalamus-
pituitary-thyroid axis function. The transcription factor Kif 4 has been shown to be 
enriched in TRH neurons during hypothalamic development. 188 In murine hypothalamic 
cells, it has been demonstrated that Klf4 regulates Trh activity through motifs present on 
the Trh gene promoter.189 Accordingly in Klf4 null mice, hypothalamic Trh expression 
was downregulated at E15; resulting in diminished bioactive peptide levels. The present 
study examined the expression of Kif 4 within a similar period of embryonic development 
(E 16), and is able to confirm that Kif 4 is a critical factor in brain development during this 
stage, given the high-level expression exhibited (Figure 2. lOC). At the neonatal stage, 
although the Trh transcript levels of the Klf4 null mice were observed to be normal, 
reduced peptide levels persisted.189 TRH simulates the release of thyroid-stimulating 
hormone (TSH) and prolactin. TSH and prolactin responses to TRH have been compared 
among individuals with autism, neurological control groups, and healthy controls. 
Interestingly, mean TSH basal and peak levels were significantly lower in individuals 
with autism, suggesting hypothalamic dysfunction in autism. 190 A previous report 
describing the characterization of deficiencies in the TRH receptor (TRH-Rl) in mice 
found that TRH-Rl knockout mice displayed increased anxiety-like behaviours. 191 The 
behavioural changes in TRH-Rl knockout mice provide evidence for the involvement of 
the TRH/THR-Rl system in regulating mood and shed insight into the participation of 
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particular circuits in autism related phenotypes. Thus, the results indicate that Klf 4 is part 
of the differentiation program for maturation of TRH expression within the 
hypothalamus. Further, dysregulation of Klf4 during critical periods of prenatal 
development may contribute to hypothalamic dysfunction, possibly leading to altered 
behavioural outcomes. 
Cdknl b was found to be most highly expressed during prenatal development as 
well, particularly at E16 (Figure 2.1 lD). Some studies have reported that children with 
autism have larger brains than controls, but only up to approximately four years of 
age. 168,192 The findings provide evidence that increased brain volume results from an 
increased rate of brain growth occurring prior to four years of age. In cross-sectional 
analysis of two year olds, it was reported that children with autism had significantly 
enlarged gray and white matter volumes compared to the deve[opmentally delayed group, 
but only white matter volumes were enlarged compared to the typically developing 
group. 193 Because genetic factors are most likely to underlie the abnormal regulation of 
brain growth during early life, Courchesne and colleagues have suggested that the linkage 
between autism and genes that are known to alter white matter development be further 
explored.168 CDKNJ B was proposed as a candidate gene because it controls proliferation 
of glial and neural cells and affects myelin formation by oligodendrocytes. A remarkable 
increase of glial cells in the cerebellum and neuronal cells in the hippocampus has been 
shown in mice knock out studies of CDKNJB. 194 Dysregulation of the CDKNlB gene 
could lead to additional glial and neuronal cell divisions before withdrawal from cell 
proliferative cycles and subsequently contribute to brain overgrowth. It has been 
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hypothesized that increased head brain size in autism has its onset around 12 months of 
age. 193 Longitudinal behavioural studies of infants at high genetic risk for autism, who 
are later diagnosed with autism at 36 months, report marked deficits in reciprocal social 
interaction observed by 12 months of age. 195 The temporal relationship between the onset 
of both autism symptoms and brain overgrowth at approximately 12 months suggest a 
relationship between these two events. Although evidence of brain .overgrowth does not 
become apparent until postnatal life, brain development begins prenatally and is achieved 
through a delicate balance between cell proliferation and subsequent cell cycle 
withdrawals. Abnormalities in early brain development may set the stage for additional 
failures in postnatal life. It is plausible that brain overgrowth, through dysregulation of 
CDKNJ B, results in the development of autism phenotypes through physical disruption of 
neural circuitry. 
The developmental expression of Erbb3 was studied and the highest expression of 
this gene was found during the adult stage (Figure 2.1 lE). This gene encodes a member 
of the Erbb family of receptor tyrosine kinases. The importance of Erbb receptors in 
development has been demonstrated from analyses of genetically modified mice. Loss of 
Erbbl leads to perinatal lethality in mice showing abnormalities in multiple organs, 
including the brain, skin, lung, and gastrointestinal tract. 196 Erbb2 null mice die before 
Ell due to cardiac malformations and affected neural development. 197 Sharing a similar 
phenotype, Ebb4 null mice die during mid-embryogenesis from cardiac malformations 
and alterations in innervation of the hindbrain in the CNS. 198 In the case of Erbb3, it is 
also expressed throughout development; however, a detailed analysis of its function has 
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yet to be reported. The present study found that Erbb3 has predominant expression in the 
adult stage; nevertheless, its expression during embryonic development appears to be 
critical. Erbb3 knockout mice die by E13.5 and display cardiac defects. Additionally, 
these animals lack Schwann-cell precursors and Schwann cells that accompany peripheral 
axons of sensory and motor neurons. 199 From these data, it is clear the ERBB3 plays a 
critical role in modulating specific aspects of embryogenesis,: although its exact function 
in CNS development remains to be elucidated. 
Finally, Clpx revealed the highest expression at E16, which gradually decreased 
throughout development (Figure 2.1 lF). Clpx recognizes peptide sequences in protein 
substrates, unfolds stable tertiary structures in the protein, and translocates the unfolded 
polypeptide chain into a sequestered proteolytic compartment in Clpp for degradation 
into small peptide fragments. 119 Clpx was investigated as a gene of interest because 
according to a study conducted by Vemes and colleagues, it may be a putative 
downstream target of FOXP2.105 In humans, mutations of the FOXP2 gene are the only 
known cause of developmental speech and language disorders.81 Studying the 
downstream targets of FOXP2 can provide the opportunity to investigate the language 
deficits in autism (discussed further in Chapter 3). However, in spite of the high-level 
expression at El6, evidence showing the CLPX contributes to neuronal physiology 
within the CNS is scarce. 
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2.6. Conclusions 
An overview of autism research emphasizes the genetic endeavours in this area as 
well as the diversity of the methods used. Whereas cytogenetic studies search for 
inherited or de novo genetic abnormalities on an individual basis, genetic linkage studies 
are performed to examine if the inheritance of a particular allele occurs more frequently 
in affected members of multiplex families than would be expected by chance. Additional 
investigations, such as candidate gene studies, are chosen a priori based on a plausible 
pathogenetic model of autism. The purpose of these techniques is to identify genetic 
mutations that predispose an individual to autism. However, it is becoming evident that 
autism may result from the disrupted function of a core group of genes that cause neural 
network dysfunction, which could occur at the level of mRNA transcriptional regulation. 
In this case, transcriptomic data are required to bridge together distinct genetic variants. 
Microarray studies are beginning to provide important insights into gene expression 
alterations and dysregulated signaling pathways in autism. In addition, this method 
presents a valuable framework for accounting for environmental influences on gene 
express10n. 
The current work demonstrating the efficacy of buccal samples in gene expression 
assays provides further impetus for using peripheral tissues to identify potential autism 
susceptibility genes that are also dysregulated in the brain. The results of this study 
revealed an upregulation of genes participating in the immune response - a fit:iding that 
was initially described in brain transcriptome studies. Thus, the present findings illustrate 
the reproducibility of gene expression changes associated with immune system 
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dysfunctions in autism when using samples outside of disease-relevant tissues. 
Collectively, these data support the notion that an increased immune response is involved 
in the pathogenesis of autism. Circadian rhythm, an identified dysregulated signaling 
pathway in this study, represents another finding that is in line with previous autism 
candidate gene studies as well as gene expression studies usiQg lymphoblastoid cell lines. 
Other key study findings include evidence for CDKNJB and CD14 dysregulation in 
autism. Indication of CDKNJB downregulation supports a previously formulated 
hypothesis regarding brain overgrowth in the first few years of autism and proof of CD 14 
dysregulation may re-open debate over the involvement of the CD 14 molecule in autism, 
as it has been refuted. 
At the same time, true to the discovery purposes of microarray experiments, this 
study also revealed new genes and molecular mechanisms underlying gene expression 
patterns in autism. Analysis of the differentially regulated genes identified several novel 
dysregulated genes, including CSF3R, KLF4, ERBB3, and CLPX. As evidenced by the 
positive expression during brain development in a mouse model system, all of these 
genes are likely to be involved in some aspect of nervous system development and 
function. Accordingly, focused investigations on the promising role of these genes in 
autism development can be particularly helpful in this regard. Another novel dysregulated 
gene identified by this study that did not show positive expression in the brain is C4orj7. 
However, the fact that autism seems to affect multiple organs, and not exclusively the 
brain, suggests that peripheral tissues may also be affected. Studying C4orj7, a 25-fold 
change upregulated gene in autism, affords the opportunity to learn more about the 
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physiological symptoms associated with autism. Another identified dysregulated 
pathway, ERBB signaling, appears to play an important role in the migration and 
differentiation of neuronal and glial precursors early in brain development. Further, 
ERBB signaling is speculated to play a significant role in social behaviours and has been 
implicated in the pathogenesis of schizophrenia. Perturbations of the ERBB signaling 
pathway could lead to a variety of abnormal neurodevelopmental events, which could 
have implications for neurodevelopmental disorders characterized by social deficits, 
including schizophrenia and autism. These results support the notion that various genetic 
factors underlie the development of autism, and that these factors can be converging at or 
diverging from central networks. Lastly, the findings of this study enabled the 
identification of potential susceptibility genes that may underlie brain development and 
other physiological symptoms connected to autism. Ultimately, identified biomarkers can 
facilitate the process of early diagnosis and aid in the development of effective and 
personalized intervention programs and treatments. Moreover, buccal cell collection is a 
non-invasive method that would be ideal for screening initiatives as part of medical 
diagnoses. 
2. 7. Limitations and Future Areas of Study 
The results suggest that buccal RNA is a genetic source that could be used to 
detect differential gene expression between affected and unaffected individuals. 
However, the inter-individual variation of buccal RNA quality and reduced RNA yield 
(in comparison to lymphoblastoid cell lines) are limiting factors for use as a source 
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material in expression studies. One method to overcome these limitations is to amplify 
cell numbers from buccal swabs by growth in tissue culture. This experimental system 
would offer high quality RNA yields above the minimal threshold required for genome-
wide expression assays and additional DNA/RNA recoveries for future studies. 
Therefore, the aim of future experiments would be to generate immortalized cell cultures 
for propagation of human buccal epithelium. 
A review of the literature indicates that it is possible to grow buccal cells in tissue 
culture. Transfection with the SV 40T (simian virus 40 T) antigen has been commonly 
used to transform cells in vitro. Stable integration of SV40T into human buccal cells has 
been successfully used to produce an immortalized cell line, which retained non-
malignant properties upon extended culture.200 Recently, Ramirez and colleagues found a 
technique that reproducibly generates immortalized cells from human bronchial 
epithelium without the use of viral oncoproteins.201 By expressing two genes, hTERT 
(human telomerase reverse transcriptase) and Cdk4 (cyclin-dependent kinase 4), it was 
demonstrated that the resulting immortal human bronchial epithelial cell lines do not have 
a malignant phenotype and have few genetic alterations. Using the methods described by 
Ramirez and colleagues, another research group has accomplished the establishment of 
immortalized buccal cell lines. 202 This method could be used in future gene expression 
profiling studies of children with autism. 
Another study limitation was the inconsistency between different professionals in 
the evaluation of autism symptoms. This represented a major drawback in making 
genotype-phenotype correlations. Future research collaborations with organizations 
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committed to the treatment and education of children with autism, such as New Haven 
Leaming Centre, may help in establishing a more consistent approach. The application 
process of New Haven Leaming Centre involves a specific behavioural assessment that 
confirms the primary diagnosis of autism in a strict, uniform manner. Systematic clinical 
assessments with identical reporting formats would lead to more accurate investigations 
of the relationship between genetic information and behavioural symptoms. 
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CHAPTER 3: TRANSCRIPTIONAL REGULAT[[ON BY FOXPl/2/4 
DIMERIZATION: IMPLICATIONS FOR SPEECH AND 
LANGUAGE DEFICITS IN AUTISM 
3.1. Introduction 
The existing literature draws a connection between autism and the neural 
mechanisms behind the development of speech and language. Genome-wide screens 
using multiplex families to identify autism susceptibility loci revealed that chromosome 
7q31-33 harboured the most consistent results.203•204 Mutations of the FOXP2 gene, 
located on chromosome 7q31, are responsible for a severe developmental disorder of 
verbal communication, suggesting that it may be related to the speech and language 
abnormalities of autism. It has been proposed than an insufficient dosage of FOXP2 at a 
key stage of embryogenesis may result in pathology of neural structures that are 
important for speech development.82 FOXP2, which encodes a transcription factor, has 
been implicated not only in speech and language disorders, but also as a regulator of 
genes with a role in autism.205 Therefore, genetic association studies with FOXP2 and 
autism have been conducted. Although a few studies found negative results, two studies 
have shown a positive association.40•44•87•206 Moreover, another member of the FOXP 
gene subfamily, FOXP 1, has been recently linked to autism as well.207•208 Amongst the 
probands that participated in the "Gene Expression Profiling in Individuals with Autism" 
study (see Chapter 2), there was a patient with a 5.3 Mbp deletion of the 3p14.l-p13 
region, where FOXP 1 is located; hence, further interest in the FOXP genes was fostered. 
Studies in mice have demonstrated that the neural expression pattern of Foxp2 and its 
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closest homologues, Foxpl and Foxp4, are partly overlapping and abundantly expressed 
in the developing brain.209 Given that the transcriptional activity of FOXP2 requires 
dimerization, either with itself or with FOXPl and FOXP4, the specific combination of 
FOXPl/2/4 homodimers and heterodimers may regulate the transcription of downstream 
target genes that may be involved in language acquisition. Studies of FOXPl/2/4 will not 
only clarify the origins of human speech and language, but also its contributions to the 
etiology of neurodevelopmental disorders such as autism. 
3.2. Hypothesis 
It has been previously shown that various FOXP transcription factors can form 
homodimers (i.e., FOXPl/Pl, FOXP2/P2, and FOXP4/P4) or heterodimers (i.e., 
FOXP1/P2, FOXP1/P4, and FOXP2/P4). 102 Although the gene targets of various 
FOXPl/2/4 heterodimers are unknown, high-throughput searches for the direct neural 
targets of FOXP 2 have revealed hundreds of genes with roles in the nervous system, such 
as modulation of synaptic plasticity, neurodevelopment, and neural transmission. 104' 105 
The objective of this study was to determine whether different combinations of 
FOXPl/2/4 proteins will lead to altered gene dosages of downstream targets of FOXP2. 
Ten known neural targets of FOXP2 were chosen for further examination in this study, 
including CERJ, NCOR2, NEUROD2, PAX3, SNWJ, SFRP4, WISP2, PRICKLEJ, 
EFNB3, and SLIT 1. These genes were selected based on their function during embryonic 
development. CERJ, SFRP4, WISP2, and PRICKLEJ participate in the WNT (Wingless) 
signaling pathway and NCOR2 and SNWJ belong to the Notch signaling pathway.210-215 
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Both WNT and Notch signaling pathways are essential for regulation of embryonic 
development.216 Moreover, NEUROD2, P AX3, EFNB3, and SLIT are involved in the 
development of the nervous system.211-220 
It was hypothesize that the formation of different FOXPl/2/4 homodimers or 
heterodimers will lead to differential expression of targets genes that may contribute to 
altered neurodevelopment. To test this hypothesis, quantitative real-time polymerase 
chain reaction (qRT-PCR) was used to quantify the expression level of target genes in 
HEK293 cells that were transfected with various FOXPl/2/4 constructs (i.e., FOXPl/Pl, 
FOXP2/P2, and FOXP4/P4 homodimers or FOXP1/P2, FOXP1/P4, and FOXP2/P4 
heterodimers ). 
3.3. Methods 
3.3.1. Molecular Cloning of Homo sapiens FOXPJ, FOXP2, and FOXP4 cDNA 
The FOXPJ (GenBank: BC152752), FOXP2 (GenBank: BC126104), and FOXP4 
(GenBank: BC052803) cDNA was obtained from the DNASU Plasmid Repository or the 
Mammalian Gene Collection (MGC). The open reading frames (ORFs) were amplified 
by polymerase chain reaction (PCR) using forward and reverse primers incorporating 
Kpnl and Xhol restriction sites. Following PCR amplification and restriction digest with 
Kpnl and Xhol, the digested fragments were subject to gel purification and clean-up with 
the EZ-10 Spin Column DNA Gel Extraction Kit (Bio Basic Inc.). The 2.0 kb FOXPl 
fragment was ligated into the Kpnl!Xhol cloning sites of mammalian expression vector 
pcDNA3-Flag with T4 DNA ligase. The 2.2 kb FOXP2 fragment was ligated into the 
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KpnIJXhol cloning sites of the mammalian expression vector pcDNA3/myc-His(-A) with 
T4 DNA ligase. The 2.0 kb FOXP4 fragment was ligated into~ the KpnIJXhol cloning sites 
of both pcDNA3-Flag and pcDNA3/myc-His A expression vectors. The resulting 
FOXP1/pcDNA3-Flag, FOXP2/pcDNA3. l-myc-His, FOXP4/pcDNA3-Flag, and 
FOXP4/pcDNA3.1-myc-His constructs were transformed into NEB 5-alpha Competent E. 
coli cells to be amplified and then digested with the restriction enzymes Kpnl and Xhol to 
confirm the appropriate length of the insert. The FOXP 112/4 gene inserts were sequenced 
with forward and reverse primers, as well as an internal primer, at the York University 
Core Molecular Facility. The sequences were confirmed using the multiple sequence 
alignment tool NCBI BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). All primers were 
designed using the Primer3 program (http://frodo.wi.mit.edu/primer3/) and produced by 
Sigma-Aldrich. Primer sequences are shown in Table 3.1. 
106 
! l 
Table 3.1. Primer sequences for FOXPJ, FOXP2, and F<JXP'4 cDNA for PCR and 
sequencing. 
Gene Designation Primer Sequences (5' 7 3') Amplicon size Vector ~base }!air~ 
pcDNA3- F:AGCTTGGTACCGATGATGCAAGAATCTGGGACT FOXPJ R:TGCCGCTCGAGCCTCCATGTCCTCGTTTACTGG 2036 Flag I: AACCACAGGCAACAATCACA 
pcDNA3.1/ F:GCTTGGTACCATGATGACTCCCCAGGTGATCA 
FOXP2 R:CCGCTCG~GTTCCAGATCTTCAGATAAAGGCTC 2205 
myc-His A I: TTCCTCCTCGACTACCTCCT 
pcDNA3.1/ F:GCTTGGTACCGAATGATGGTGGAATCTGCCTCG FOXP4 R:CCGCTCGAGGGACAGTTCTTCTCCCGGCA 2061 
myc-His A I: CACCGCTACCTCGTTTGC 
pcDNA3- F:AGCTTGGTACCGATGATGGTGGAATCTGCCTCG FOXP4 R:CGTACTCGAGCGGACAGTTCTTCTCCCGGCA 2064 Flag I: CACCGCTACCTCGTTTGC 
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3.3.2. Polymerase Chain Reaction (PCR) 
PCR was used to amplify FOXPJ, FOXP2, and FOXP4 ORFs for the purpose of 
molecular cloning into mammalian expression vectors. The 50 µL PCR reaction mixture 
contained a cDNA template, the forward and reverse primer at 0.2 µM, 200 µM dNTPs, 
5x OneTaq Hot Start Standard Reaction buffer, and 0.025 U/µL of the OneTaq Hot Start 
DNA Polymerase (New England Biolabs). The thermal cycler was programmed for 30 
cycles of PCR amplification at 94°C, 30 seconds for denaturation; 68°C, 2 minutes for 
annealing; and 68°C, 30 seconds for primer extension. The presence of a PCR product of 
the appropriate size was verified by agarose gel electrophoresis. 
3.3.3. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was performed to verify the size of PCR products and 
restriction digest fragments. A gel concentration of 1 % agarose in 1 X T AE buff er with 
10% GelGreen (VWR International) was used. The samples were mixed with 6X nucleic 
acid loading buff er and loaded into the wells of the agarose gel. Electrophoresis was 
conducted at 1 OOV on a PowerPac Basic Power Supply. A UV Transilluminator was used 
to visualize the size of the DNA bands. A 1 kb DNA standard ladder (Sigma) was used to 
estimate the sizes of the DNA bands by comparison. 
3.3.4. Restriction Digests 
Restriction digests were performed to produce DNA fragments for directional 
insertion into mammalian expression vectors and to confirm whether plasmid 
construction was successful. Restriction digests were performed for 1-2 hours at 37°C 
using 20 U/µL of restriction enzyme (New England Biolabs). The appropriate buffer 
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(NEBuffer 1-4) and bovine serum albumin (BSA) were added to the reaction mixture at 
10-fold dilution. For sequential restriction digests, the digested DNA fragments were 
purified using the EZ-10 Spin Column PCR Products Purification Kit (Bio Basic Inc.) 
prior to performing another digest on the same fragments. Subsequently, the resulting 
restriction fragments were separated according to their lengths by agarose gel 
electrophoresis. A UV Transilluminator was used to visualize the DNA. Gel slices 
containing the desired DNA fragments were excised and purified using the EZ-10 Spin 
Column DNA Gel Extraction Kit (Bio Basic Inc.). 
3.3.5. Ligation of DNA Inserts into a Plasmid 
DNA fragments with cohesive ends were ligated into complimentary cohesive end 
vectors of choice using T4 DNA Ligase (New England Biolabs). The ligation mixture 
included 400 U/µL T4 DNA Ligase, 1 OX T4 DNA Ligase Reaction Buffer (New England 
Bio labs), vector DNA, and DNA insert. A molar ratio of 1 :3 vector to insert was used for 
the ligation reaction. This mixture was incubated at 16°C overnight prior to use in E. coli 
transformation. 
3.3.6. Transformation Using Chemically Competent E.coli Cells 
NEB 5-alpha Competent E. coli cells (New England Biolabs) or One Shot TOPlO 
Chemically Competent E. coli cells (Invitrogen) were used to generate large quantities of 
the desired plasmid. After thawing a tube of NEB 5-alpha Competent E. coli cells on ice 
for 10 minutes, 5 µL of plasmid DNA was added to the competent cell mixture, and 
placed on ice for 30 minutes. After this incubation period, the mixture was then heat 
shock at 42°C for exactly 30 seconds and placed back on ice for 5 minutes. Room 
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temperature SOC Outgrowth Medium (New England Biolabs) was pipetted into this 
mixture, which was shaken vigorously at 250 rpm at 37°C for 1 hour. For One Shot 
TOPI 0 Chemically Competent E. coli cells, 5 µL of plasmid DNA was added to the 
thawed competent cell mixture, and incubated on ice for 30 minutes. The mixture was 
then heat shocked for 30 seconds at 42°C and quickly placed back in ice for 2 minutes. 
Pre-warmed S.O.C. Medium (Invitrogen) was added to each vial, which was shaken at 
225 rpm at 37°C for 1 hour. The cells were plated onto warmed selection plates and 
incubated overnight at 37°C. Single bacterial colonies were inoculated into 5 ml of Luria-
Bertani (LB) broth supplemented with the appropriate antibiotic in 15 mL snap-cap tubes 
and shaken (200 rpm) at 37°C. Incubation of the cultures did not exceed 24 hours to 
ensure that the plasmids are produced in healthy cells. The plasmids were purified using 
the EZ-10 Spin Column Plasmid DNA Minipreps Kit (Bio Basic Inc.). The results of a 
diagnostic restriction digest were analyzed by agarose gel electrophoresis to ensure that 
the DNA fragments were of the expected lengths. A glycerol stock solution containing 
800 µL of E. coli solution in 50% glycerol was created and stored at -80°C for future 
purposes. 
3.3.7. Luria-Bertani Plates and Medium 
Luria-Bertani (LB) plat_es and media were used to grow clone plasmids and 
transformed competent E. coli cells. The LB media (1 % tryptone, 0.5% yeast extract, and 
1 % NaCl in deionized H20) was autoclaved for 20 minutes and left to cool at room 
temperature. The appropriate selection antibiotic (50 µg/mL of ampicillin, kanamycin, or 
streptomycin) was added prior to use. For LB plates, agar was added to LB media (1 % 
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. tryptone, 0.5% yeast extract, 1 % NaCl, and 1.5% agar in deionized H20) before 
autoclaving. After the addition of the antibiotic, the LB media was poured into 10 cm 
plates and left to solidify at room temperature before storage at 4°C. 
3.3.8. Plasmid Preparation of pcDNA3.l/myc-His(-A) and pcDNA3-Flag 
The mammalian expression vectors pcDNA3.l/myc-His(-A) (Invitrogen) and 
pcDNA3-Flag (Invitrogen) were streaked onto ampicillan plates and left to incubate 
overnight at 3 7°C. The single colonies that formed on the ampicillan plates were then 
inoculated into 5mL cultures of LB ampicillan broth. The culture was incubated at 3 7°C 
with shaking (200 rpm) overnight. Incubation of the cultures did not exceed 24. hours. 
Plasmid DNA was generated from this culture using a miniprep DNA isolation kit (EZ-
10 Spin Column Plasmid DNA Minipreps Kit, Bio Basic Inc.). Restriction digest with 
KpnI and XhoI was performed in preparation for directional insertion of a desired gene of 
interest. A 5.5 kb digestion product was produced. 
3.3.9. HEK293 Cell Culture and Lipfectamine Transfection 
HEK293 cells, obtained from the American Tissue Culture Collection (ATCC), 
were maintained in a 37°C incubator containing 5% C02. HEK293 cells were grown in 
Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS). Lipofectamine 2000 (lnvitrogen) was used for transfection of 
HEK293 cells. One day prior to transfection, cells were plated in 6-well plates (10 
cm2/well) or 12-well plates ( 4 cm2/well) in 2.5 mL or 1.5 mL of growth medium without 
antibiotics, respectively. Cells were allowed to reach 90-95% confluency at the time of 
transfection. DNA was diluted in Opti-MEM Reduced Serum Medium without serum and 
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mixed gently. Opti-MEM Reduced Serum Medium was also used to dilute Lipofectamine 
2000 prior to complexing with DNA. The diluted DNA and Lipofectamine 2000 were 
combined and incubated at room temperature for 20 minutes to promote DNA-
Lipofectamine 2000 complex formation. The ratio of LiopfectAMINE 2000 to DNA used 
was 3: 1. This mixture was subsequently added to each well containing cells and media. 
The cells where incubated at 5% C02 in a 3 7°C incubator for 6 hours before changing to 
2 mL complete growth medium with antibiotics. The cells were incubated for another 18 
hours to allow protein expression. 1000 µg/mL Geneticin (G418) was used for selecting 
cells transfected with appropriate FOXPl/2/4 constructs. 
3.3.10. Immunocytochemistry 
Immunocytochemistry was performed to assess the presence of a particular protein 
by use of a specific antibody, thereby allowing visualization and examination under a 
microscope. HEK.293 cells were seeded in 35 mm dishes with cover slips previously 
treated with poly-D-lysine hydrobromide for 18-24 hours. For fixation, the cells were 
incubated for 20 minutes at 4°C with phosphate buffered saline (PBS) containing 4% 
paraformaldehyde. For immunocytochemistry, the cells were first incubated for 10 
minutes at room temperature with 0.5% Triton X-100 in PBS. The primary antibodies 
used were mouse monoclonal anti-Myc (1 :200; #sc-40, Santa Cruz Biotechnology) or 
rabbit polyclonal anti-His tag (1 :400; #ab78159, Abeam) or both for double staining. The 
incubation period was for one hour at room temperature. The cells were rinsed and then 
repeatedly washed with PBS-T for 15 minute intervals before an hour-long incubation 
with secondary antibodies. The secondary antibodies used were fluorescein isothiocynate 
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(FITC)-conjugated anti-rabbit lgG (1:300; #111-095-144, Jackson ImmunoResearch 
Laboratories) and Texas Red (TR) dye-conjugated anti-mouse lgG (1:300; #115-
0750146, Jackson ImmunoResearch Laboratories). The cells were rinsed, washed four 
times with PBS-T for 5 minute intervals, incubated with 4'-6-diamidino-2-phenylindole 
(DAPI) (0.05% DAPI in PBS-T) for 20 minutes, then washed three times with PBS-T for 
5 minute intervals. The coverslips were mounted onto microscope slides with Vectashield 
Mounting Medium (Vector Laboratories) and visualized using a Nikon Eclipse 80i 
microscope. 
3.3.11. Western Blot Analysis 
Western blot analysis was used in order to determine whether HEK293 cells 
expressed FOXPI/2/4 proteins. Protein samples were mixed with Ix Laemmli sample 
buffer (BioRad), heated for 5 minutes in boiling water, cooled on ice and loaded on the 
gel alongside the molecular marker, Precision Plus Protein Dual Colour Standards 
(BioRad). The samples were run at 90 V for approximately 10 minutes until samples 
reached the bottom of the stacking gel and then at 100 V through the separating gel in 1 X 
running buffer until the samples had migrated to the bottom of the separating gel. After 
transferring the gel onto a 0.2 µM nitrocellulose membrane, proteins were blocked in 5% 
milk in TBS-T for two hours. The membranes were incubated overnight at 4 °C with 
mouse monoclonal anti-Myc (1 :200; #sc-40, Santa Cruz Biotechnology) or rabbit 
polyclonal anti-His tag (1 :300; #ab78159, Abeam), and then incubated with anti-mouse 
horseradish peroxidase-conjugated secondary antibody (1: 10,000; #sc-2060 Santa Cruz 
Biotechnology) or anti-rabbit horseradish peroxidase-conjugated secondary antibody 
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(1: I 0,000; #sc-2054 Santa Cruz Biotechnology) for one hour at room temperature. The 
membranes were washed four times in five minute intervals with TBS-T and incubated 
with Amersham ECL Prime Western Blotting Detection Reagent (#RPN2232sk, GE 
Healthcare). The bound antibodies were detected by Geliance 600 Imaging System 
(PerkinElmer). 
3.3.12. Reverse Transcription 
RNA from transfected HEK.293 cells was isolated using the NucleoSpin 
RNA/Protein kit (Machery-Nagel). Reverse transcription was performed with M-MuL V 
Reverse Transcriptase (New England Biolabs) in accordance with the manufacturer's 
instructions. I µg of RNA was used in a reaction with lOx RT Buffer, OligodT primer, 
dNTP mix (2.5 mM each), and M-MuL V Reverse Transcriptase (200 U/µL). This 
mixture was incubated at 42°C for one hour and then at 90°C for 10 minutes to inactivate 
the enzyme. The success of the reaction was confirmed by polymerase chain reaction 
with GAP DH primers. The subsequent PCR products were then verified by agarose gel 
electrophoresis. 
3.3.13. Quantitative Real-Time Polymerase Chain Reaction ( qRT-PCR) 
Primers specific for candidate genes were designed using Primer Express 3.0 
(Applied Biosystems) and synthesized by Sigma-Aldrich (Table 3.2). QRT-PCR was 
performed using the 7500 Fast Real-Time PCR System. The qRT-PCR reaction mixture 
included SYBR Green reagent, 2 µM each of forward and reverse primers, and cDNA 
template. The comparative Ct method was used to analyze the data. Raw Ct values were 
normalized to the geometric mean of the housekeeping genes HP RT (hypoxanthine 
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phosphoribosyl transferase) and GAP DH (glyceraldehyde 3-phosphate dehydrogenase) to 
obtain the .~Ct values. The ~Ct values of the samples were compared to a calibrator 
(empty vector control). The FOXPl-Flag sample, derived from HEK.293 cells transfected 
with FOXP1/pcDNA3-Flag, was compared to a control derived from HEK.293 cells 
transfected with the pcDNA3-Flag vector only. The FOXP2-Myc and FOXP4-Myc 
samples, derived from HEK.293 cells transfected with FOXP2/pcDNA3.1-myc-His or 
FOXP4/pcDNA3.1-myc-His, were compared with HEK.293 cells transfected with the 
pcDNA3.1/myc-His vector. The double transfection samples were compared to the 
average of both empty vector controls. Reported relative quantification (RQ) ratios are 
the mean of comparisons of three biological replicates. Three separate passages of each 
cell line were used as biological replicates. Statistical significance was determined by 
performing a one-way analysis of variance (ANOVA) followed by Student's t-test. 
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Table 3.2. Primer sequences for downstream genes of FOXP2 for qRT-PCR. 
Gene Primer Sequences (5' 7 3') Amplicon size ~base J;!air} 
CERJ F: CAGAGTTCTCTTTCCCCCGTACT 82 R:TTCTCCTCAGCTTCCTCATGGT 
NCOR2 F:TCAGCGGAGTGAAGCAGGAG 493 R:TCGATGCTGGCTGAGGAGAT 
NEUROD2 F:CAAGCGGCCAGACCTAGTGT 55 R:CTGCGACAGACCCTTGCA 
PAX3 F:GAGAGAACCCGGGCATGTT 57 R:CCGCGTCCTTGAGTAATTTGTC 
SNWJ F:GGCAGAAGCCCTCTACATTGC 63 R:ACTTGGGCACGCATTTCC 
SFRP4 F:CCCGGAGGATGTTAAGTGGAT 70 R:GTCAACATCAAGAGGCCTTTCC 
WJSP2 F:GGTCGCAGTCCACAAAACAG 57 R:CACCGTGTCCCCATTCC 
PRICKLEJ F:TCACTGTGGCAGGCACCAT 91 R:CTCAGCTTCTGTGCACTCATCAG 
EFNB3 F:TCGGCGAATAAGAGGTTCCA 60 R:GTCCCCGATCTGAGGGTACA 
SLITJ F:GGAGGCCACTGGGATGTTTA 84 R:CCATCTTCAATTTCTGACACCTTGT 
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3.4. Results 
3.4.1. Development of FOXPl/2/4 Constructs 
Homo sapiens FOXPJ, FOXP2, and FOXP4 ORFs were amplified by PCR using 
forward and reverse primers incorporating Kpnl and Xhol restrictions sites. After 
restriction digest with the restriction enzymes Kpnl and .Xho[, the resulting FOXP 1 and 
FOXP2 fragments were ligated into the Kpnl!Xhol cloning sites of the pcDNA3-Flag and 
pcDNA3. llmyc-His vector, respectively. Homo sapiens FOXP4 ORF was inserted into 
both mammalian expression vectors (pcDNA3-Flag and pcDNA3.llmyc-His) at the 
Kpnl!Xhol cloning sites, for the purpose of co-transfections. Following transformation 
into NEB 5-alpha Competent E. coli cells for amplification, FOXP1/pcDNA3-Flag, 
FOXP2/pcDNA3.1-myc-His, FOXP4/pcDNA3-Flag, and FOXP4/pcDNA3.1-myc-His 
were digested with the restriction enzymes Kpnl and Xhol to ensure the integrity of the 
constructs. It was verified that the FOXPl/2/4 gene inserts that dropped out from the 
vector were of appropriate size (Figure 3.1). The FOXPl/2/4 gene inserts were also 
sequenced with forward, internal, and reverse primers for further confirmation. 
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A) FOXP1/pcDNA3-Flag 
* 
C) FOXP4/pcDNA3-Flag 
* 
i I 
B) FOXP2/pcDNA3.l-myc-Bis 
* 
D) FOXP4/pcDNA3.1-myc-His 
* 
Figure 3.1. Restriction digest of FOXPl/2/4 constructs with Kpnl and X/wl to confirm insert drop-
out. (A) FOXPl/pcDNA3-Flag, (B) FOXP2/pcDNA3.1-myc-His, (C) FOXP4/pcDNA3-Flag, and (D) 
FOXP4/pcDNA3.l-myc-His were digested with Kpnl and Xhol to determine whether plasmid construction 
was successful. The DNA band sizes for FOXPJ, FOXP2, and FOXP4 are approximately 2 kb, as indicated 
by the arrowheads. The asterisk(*) represents the corresponding undigested FOXPl/2/4 construct. 
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3.4.2. Subcellular Localization of FOXPl/2/4 Proteins 
In order to determine the protein expression and the subcellular localization of 
FOXP 1, FOXP2, and FOXP4, immunocytochemistry was performed on HEK293 cells 
over-expressing 3'-Flag-tagged FOXPl (FOXPl-Flag), 3'-myc-His-tagged FOXP2 
(FOXP2-Myc), 3'-Flag-tagged FOXP4 (FOXP4-Flag), or 3'- myc-His-tagged FOXP4 
(FOXP4-Myc) alone or in combination. The subcellular localiization of FOXPl-Flag and 
FOXP4-Flag were determined using anti-Flag antibodies and detected with FITC-
conjugated secondary antibodies (Figure 3.2A and Figure 3.2C, respectively). FOXP2-
Myc and FOXP4-Myc localization were determined using anti-Myc antibodies and 
detected with TR-conjugated secondary antibodies (Figure 3.2B and Figure 3.2D, 
respectively). FOXPl-Flag and FOXP2-Myc co-localization in HEK293 cells that were 
transfected with both FOXP1/pcDNA3-Flag and FOXP2/pcDNA3.l-myc-His was 
determined using anti-Flag and anti-Myc antibodies and dete·cted with FITC-conjugated 
and TR-conjugated secondary antibodies (Figure 3.3A). Similarly, the co-localization of 
FOXPl-Flag and FOXP4-Myc, as well as FOXP2-Myc and FOXP4-Flag, were 
determined using both anti-Flag and anti-Myc antibodies, and detected with FITC-
conjugated and TR-conjugated secondary antibodies (Figure 3.3B and Figure 3.3C). The 
results show that the over-expressed FOXPl/2/4 proteins were localized predominantly in 
the nucleus to various levels in different cells, which was confirmed through its co-
localization with DAPI. DAPI is known to form fluorescent complexes with double-
stranded DNA in the nucleus. 
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C) 
D) 
Figure 3.2. Immunocytochemical localization of FOXPl/2/4 homodimeirs. In HEK293 cells, subcellular 
localization of A) FOXPI-Flag was determined using anti-Flag antibodies and detected with FITC-
conjugated secondary antibodies. B) Localization of FOXP2-Myc was determined using anti-Myc 
antibodies and TR-conjugated secondary antibodies. C) Localization of FOXP4-Flag was determined using 
anti-Flag antibodies and FITC-conjugated secondary antibodies. D) FOXP4-Myc was detected using anti-
Myc antibodies and TR-conjugated secondary antibodies. The FOXPI/2/4 proteins are localized 
predominantly in the nucleus, which is confirmed with its co-localization with DAPL 
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A) 
B) 
C) 
Figure 3.3. Immunocytochemical localization of FOXPl/2/4 'heterodimers. The subcellular co-
localization of A) FOXPI-Flag and FOXP2-Myc, B) FOXPI-Flag and FOXP4-Myc, and C) FOXP2-Myc 
and FOXP4-Flag in HEK293 cells was determined using anti-Flag andi anti-Myc antibodies and detected 
with FITC-conjugated and TR-conjugated secondary antibodies. The FOXPI/2/4 proteins are localized 
predominantly in the nucleus, as determined by co-staining with DAPt 
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3.4.3. Western Blot Analysis of FOXPl/2/4 Protein Expression 
The expression of FOXPI-Flag and was confirmed by western blot analysis using 
anti-Flag antibody. An 82 kDa band corresponding to the size of Homo sapiens FOXPI 
was detected in HEK293 cells transfected with 3'-Flag-tagged FOXPI but not in 
untransfected HEK293 cells or cells that were transfected with the pcDNA3-Flag empty 
vector (Figure 3.4A). The expression of FOXP2-Myc and FOXP4-Myc was verified 
using anti-Myc antibody, where an 82 kDa band was seen to represent the Homo sapiens 
FOXP2 and FOXP4 protein but not in untransfected HEK293 cells or cells transfected 
with the pcDNA3.Ilmyc-His empty vector (Figure 3.4B). The co-expression of FOXPI-
Flag and FOXP2-Myc, FOXPI-Flag and FOXP4-Myc, and FOXP2-Myc and FOXP4-
Flag in HEK293 was confirmed as well (Figure 3.4A-B). The confirmation of protein 
expression in the transfected cells means that the RNA from these cell lines may be used 
for quantitative real-time polymerase chain reaction. 
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B) 
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~-actin 37kD 
Figure 3.4. Expression of FOXPl/2/4 protein in HEK293 cells using western blot analysis. Antibodies 
against the A) 3'-Flag or B) 3'-Myc tag revealed protein band sizes for FOXPI/2/4 proteins to be 82 kDa. 
The membranes were re-probed with antibody against ~-actin to ensure equal loading. 
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3.4.4. Quantification of the Expression of Downstream FOXP2 Targets 
Quantitative real-time polymerase chain reaction (qR.T-PCR) was used to assess 
gene expression differences due to the combinatorial actions of FOXPl/2/4 proteins on 
the downstream targets of FOXP2. The downstream targets of FOXP2 (CERJ, NCOR2, 
NEUROD2, PAX3, SNWJ, SFRP4, WISP2, PRICKLEJ, EFNB3, and SLITJ) were chosen 
based on their role during embryonic development. Using mRNA from transfected 
HEK293 cell lines, the expression level of the target genes was quantified relative to the 
geometric means of the housekeeping genes HPRT and GAPDH and compared to cells 
transfected with the respective pcDNA3-Flag and pcDNA3.1-myc-His empty vectors. 
Statistically significant differences of expression changes were found amongst the 
various combinations of FOXPl/2/4 homodimers and heterodimers for eight of the target 
genes (CERJ, NCOR2, NEUROD2, SNWJ, SFRP4, WISP2, PRICK.LEI, and EFNB3). 
The various dimeric combinations of FOXPl/2/4 proteins had no effect on PAX3 and 
SLITJ expression. Figure 3.5 depicts the relative quantification (RQ) of downstream 
FOXP2 target genes activated by FOXPl and FOXP2 homodimers and heterodimers. 
Expression changes caused by FOXPl and FOXP4 homodimers and heterodimers are 
shown in Figure 3.6. The effects of FOXP2 and FOXP4 homodimers and heterodimers 
on downstream target genes are shown in Figure 3.7. A direct comparison of the 
differential expression induced by FOXPl/2/4 heterodimers is shown in Figure 3.8. The 
effect of transcriptional regulation by FOXPl/2/4 dimerization on each target gene is 
described in the following sections. 
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CERJ (Cerberus 1) 
The expression of CERJ was repressed by all FOXPl/2/4 combinations. A one-
way analysis of variance (ANOV A) was conducted to compare the effects of FOXPl/2/4 
dimerization on target gene expression. There was a significant main effect of 
FOXPl/2/4 dimerization on CERJ gene expression (F(5, 12) = 9.87, p = 0.0006). Post 
hoc comparisons indicated that the RQ ratio for FOXP2 homodimers (-2.28 ± 0.35; mean 
± SEM) was not significantly different than FOXPl homodimers (-1.12 ± 0.01) (Figure 
3.5). The RQ ratio for FOXPl homodimers was found to be significantly (p = 0.0004) 
different from FOXP1/P2 heterodimers (-2.59 ± 0.11) (Figure 3.5). However, differenti~l 
expression was not seen between FOXP2 homodimers and FOXP1/P2 heterodimers; 
thus, indicating that FOXPl does not seem to influence the expression of CERJ via a 
FOXP1/P2 heterodimeric combination. The RQ ratio for FOXP4 homodimers (-2.73 ± 
0.14) was found to be significantly (p = 0.0002) different from FOXPl homodimers 
(Figure 3.6). The expression level of CERJ brought about by FOXP1/P4 heterodimers (-
2.18 ± 0.35) appeared to be intermediary of that by the FOXPl and FOXP4 homodimers, 
although this was not statistically significant (Figure 3.6). The RQ ratio for FOXP2/P4 
heterodimers (-1.28 ± 0.02) was smaller than its corresponding FOXP2 and FOXP4 
homodimeric counterparts (p = 0.0064 and p = 0.0005, respectively), suggesting that 
FOXP2/P4 heterodimers are weaker transcriptional repressors than FOXP2 and FOXP4 
homodimers (Figure 3.7). Moreover, the FOXP2/P4 heterodimer was determined to be a 
significantly weaker transcriptional repressor than the FOXP1/P2 and FOXP1/FOXP4 
heterodimers (p = 0.001 andp = 0.012, respectively) (Figure 3.8). 
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NCOR2 (Nuclear receptor co-repressor 2) 
The results show that the transcriptional outcomes of NCOR2 differed 
significantly across the six FOXPI/2/4 protein combinations (F(5, 12) = 32.17, p < 
0.0001). Post hoc analyses indicated that while the RQ ratios ofFOXPl (1.31±0.18) and 
FOXP2 homodimers (1.44 ± 0.11) were not different, FOXP1/P2 heterodimers (3.79 ± 
0.41) produced a significantly higher upregulation of NCOR2 than its homodimeric 
counterparts (p = 0.0018 and p = 0.0026, respectively) (Figure 3.5). FOXPl and FOXP4 
homodimers (0.54 ± 0.78) were not statistically significant (Figure 3.6). FOXP1/P4 
heterodimers (-1.24 ± 0.16), which caused transcriptional repression, had a significantly 
different effect on NCOR2 expression than FOXPl and FOXP4 homodimers (p = 0.0014 
and p = 0.0143, respectively), which resulted in transcriptional activation (Figure 3.6). 
FOXP2 and FOXP4 homodimers led to NCOR2 upregulation with no significant 
difference; although comparisons with FOXP2/P4 heterodimefs (5.79 ± 0.55) revealed a 
significantly larger RQ ratio by the heterodimeric combination (p < 0.0001 and p < 
0.0001, respectively) (Figure 3.7). The expression levels of NCOR2 were significantly 
different between FOXP1/P2 and FOXP1/P4 (p < 0.0001), FOXP1/P2 and FOXP2/P4 (p 
= 0.0072), and FOXP1/P4 and FOXP2/P4 (p < 0.0001) heterodimeric combinations 
(Figure 3.8). 
NEUROD2 (Neurogenic differentiation factor 2) 
Statistical analysis showed significant differences (F(5, 12) = 26.25, p < 0.0001) 
across FOXPI/2/4 protein combinations on NEUROD2 expression. Post hoc tests 
revealed that the RQ ratios of FOXPl (-2.43 ± 0.37) and FOXP2 homodimers (1.40 ± 
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0.10) were significantly (p < 0.0001) different; whereas FOXPl homodimers caused 
downregulation, FOXP2 homodimers led to upregulation of NEUROD2 (Figure 3.5). The 
RQ ratio of FOXP1/P2 heterodimers (-2.10 ± 0.53) was significantly (p < 0.0001) 
different from FOXP2 homodimers but was nearly equivalent to that of FOXP 1 
homodimers (Figure 3.5). Hence, it does not seem likely that the regulation of NEUROD2 
involves FOXP1/P2 heterodimers. The RQ ratio of FOXP4 homodimers (1.13 ± 0.06) 
was significantly different from FOXPl homodimers and FOXP1/P4 heterodimers (-1.39 
± 0.23) (p < 0.0001 and p = 0.0001, respectively) (Figure 3.6). While FOXP4 
homodimers led to NEUROD2 upregulation, FOXPl homodimers and FOXP1/P4 
heterodimers caused NEUROD2 downregulation (Figure 3.6). In addition, the RQ ratio of 
FOXPl homodimers was not significantly different from that of FOXP1/P4 heterodimers 
(Figure 3.6). This demonstrates that FOXP4 is not likely to influence NEUROD2 
expression through interactions with FOXP 1. The RQ ratio of FOXP2/P4 heterodimers (-
1.51 ± 0.38) was significantly different from that of both FOXP2 and FOXP4 
homodimers at the p < 0.0001 level (Figure 3.7). Even though FOXP2 and FOXP4 
homodimers caused transcriptional activation, the heterodimeric combination of FOXP2 
and FOXP4 brought about the transcriptional repression of NEUROD2. All FOXPl/2/4 
heterodimeric combinations caused transcriptional repression of NEUROD2 although 
they were not found to be significantly different from one another (Figure 3.8). 
PAX3 (Paired box 3) 
The expression of PAX3 was uniformly upregulated by FOXPl/2/4 homodimers 
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and heterodimers (Figure 3.5-3.8). No significant difference was found between 
FOXPl/2/4 dimeric combinations inPAX3 expression (F(5, 12) = 1.14,p = 0.39). 
SNWJ (SNW domain containing 1) 
One-way ANOVA revealed significant differences in SNWJ expression between 
FOXPl/2/4 protein combinations (F(5, 12) = 190.85, p < 0.0001). Post hoc analyses 
revealed that the RQ !atio of FOXPl homodimers (1.22 ± 0.08) was significantly 
different from FOXP2 homodimers (-1.33 ± 0.13, p < 0.0001) and FOXP1/P2 
heterodimers (-1.55 ± 0.04, p < 0.0001) (Figure 3.5). FOXPl homodimers caused the 
transcriptional activation of SNWJ but FOXP2 homodimers and FOXP1/P2 heterodimers 
led to transcriptional repression. Since FOXP2 homodimers and FOXP1/P2 heterodimers 
did not have a significantly different effect on SNWJ expression, it seems unlikely that 
FOXPl regulates the expression of SNWJ in concert with FOXP2 (Figure 3.5). The RQ 
ratios of FOXPl and FOXP4 homodimers (1.27 ± 0.06) were not significantly different 
(Figure 3.6). On the other hand, SNWJ expression as influenced by FOXP1/P4 
heterodimers (-1.20 ± 0.16) was significantly different from both FOXPl and FOXP4 
homodimers at the p < 0.0001 level and caused downregulation instead (Figure 3.6). The 
expression level of SNWJ mediated by FOXP4 homodimers was found to be significantly 
different from that of FOXP2 homodimers and FOXP2/P4 heterodimers (-1.18 ± 0.02) at 
the p < 0.0001 level, although the latter two combinations were not significantly different 
from one another (Figure 3. 7). The data indicates that FOXP4 is also unlikely to 
heterodimerize with FOXP2 to modulate the expression of SNWJ. The FOXPl/2/4 
heterodimers were observed to cause downregulation of SNWJ expression (Figure 3.8). 
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SFRP4 (Secreted frizzled-related protein 4) 
One-way ANOV A showed a significant main effect of FOXPl/2/4 dimerization 
on SFRP4 gene expression (F(5, 12) = 24.00, p < 0.0001). Post hoc tests did not indicate 
a significant difference between FOXPl homodimers (-il.64 ± 0.57) and FOXP2 
homodimers (-1.55 ± 0.15) (Figure 3.5). Although FOXPl and FOXP2 homodimers 
demonstrated nearly equal ability to repress SFRP4 expression, FOXP1/P2 heterodimers 
(-2.60 ± 0.06) produced significantly greater transcriptional repression than its 
homodimeric counterparts (p = 0.0205 and p = 0.0131, respectively) (Figure 3.5). FOXP4 
homodimers (1.07 ± 0.02) had an opposite effect on SFRP4 expression and caused 
transcriptional activation; this was found to be significantly (p < 0.0001) different from 
FOXPl homodimers (Figure 3.6). However, the RQ ratio of FOXP1/P4 heterodimers (-
1.62 ± 0.10) was not significantly different from FOXPl homodimers, suggesting that 
FOXP4 does not regulate SFRP4 expression via FOXP1/P4 heterodimers (Figure 3.6). 
The RQ ratio of FOXP4 homodimers was significantly different from FOXP2 
homodimers, as well as FOXP2/P4 heterodimers (-1.80 ± 0.18) at the p < 0.001 level 
(Figure 3.7). The RQ ratio of FOXP2 homodimers differed significantly (p < 0.001) from 
FOXP2/P4 heterodimers (Figure 3.7). A comparison of the effects of FOXP heterodimers 
on SFRP4 expression revealed that these dimer combinations cause transcriptional 
repression (Figure 3.8). In particular, the FOXP1/P2 heterodimers caused the strongest 
repression, which was significantly different from FOXPl/4 and FOXP2/4 (p = 0.0187 
and p = 0.0475, respectively). 
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WISP2 (WNTJ inducible signalingpathway protein 2) 
One-way ANOV A showed significant differences in WISP 2 expression across 
FOXPl/2/4 protein combination (F(5, 12) = 9.49, p = 0.0007). Post hoc tests indicated 
that the RQ ratios of FOXPl homodimers (-1.49 ± 0.08) and FOXP2 homodimers (-2.00 
± 0.27) were not significantly different (Figure 3.5). FOXPl and FOXP2 homodimers 
were responsible for the transcriptional repression of WISP2. The RQ ratio of FOXP1/P2 
heterodimers (-3.76 ± 0.47) was significantly greater fuan FOXPl and FOXP2 
homodimers and caused even further transcriptional repression (p = 0.0029 and p = 
0.0127, respectively) (Figure 3.5). The RQ ratios of FOXPl and FOXP4 homodimers (-
1.39 ± 0.19) were not significantly different from one another; however, FOXP1/P4 
heterodimers (0.32 ± 0.87) caused a significantly different effect than FOXPl and 
FOXP4 homodimers (p = 0.0116 and p = 0.0160, respectively) (Figure 3.6). It is 
interesting to note that although FOXPl and FOXP4 homodimers were comparable 
transcriptional repressors of WISP2, FOXP1/P4 heterodimers seem to nullify the 
transcriptional activity of its respective homodimers. There were no significant 
differences between FOXP2 homodimers, FOXP4 homodimers, and FOXP2/P4 
heterodimers (-1.11 ± 0.05) in WISP2 expression (Figure 3.7). Each of the FOXP 
heterodimeric combinations had a distinct influence over WISP 2 expression (Figure 3 .8). 
FOXP1/P2 heterodimers are significantly (p = 0.0009) greater transcriptional repressors 
of WISP2 than FOXP2/P4 heterodimers. In contrast, the FOXP1/P4 heterodimers are 
transcriptional activators. 
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P RICKLEJ (Prickle homolog 1) 
The effect of FOXPl/2/4 dimerization on PRICKLEJ expression was significant 
(F(5, 12) = 7.65, p = 0.0019). Post hoc analyses indicated that the RQ ratio of FOXPl 
homodimers (-1.46 ± 0.23) was significantly (p = 0.0003) different from FOXP2 
homodimers (1.68 ± 0.34) (Figure 3.5). FOXPl and FOXP2 homodimers had opposing 
effects on PRICKLE 1 expression: FOXP 1 homodimers caused transcriptional repression 
but FOXP2 homodimers caused transcriptional activation. FOXP1/P2 heterodimers (0.23 
± 1.00) exhibited a slight upregulation of P RICKLEJ that was at an intermediary level 
between the respective homodimers, but was not found to be statistically significant 
(Figure 3.5). Comparisons of RQ ratios between FOXPl homodimers, FOXP4 
homodimers, and FOXP1/P4 heterodimers did not reveal any significant differences 
(Figure 3 .6). Although the expression level of P RICKLEJ by FOXP2 homodimers was 
significantly different from FOXP4 homodimers and FOXP2/P4 heterodimers (-1.22 ± 
0.10) at the p = 0.0006 level, the latter two dimer combinations demonstrated identical 
expression levels of PRICKLE] (Figure 3.7). Therefore, it does not appear that FOXP2 
regulates PRICKLEJ through heterodimeric interactions with FOXP4. The RQ ratios of 
FOXP1/P4 and FOXP2/P4 heterodimers were not significantly different (Figure 3.8). The 
RQ ratio of FOXP1/P2 heterodimers differed significantly (p = 0.0405) from FOXP2/P4 
heterodimers. 
EFNB3 (Ephrin-B3) 
Statistical analysis revealed significant differences in EFNB3 expression across 
FOXPl/2/4 protein combinations (F(5, 12) = 7.32, p = 0.0023). Post hoc tests showed 
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that the RQ ratio of FOXPl homodimers (1.31 ± 0.05) was significantly different from 
FOXP2 homodimers (-1.74 ± 0.4,p = 0.0028) and FOXP1/P2 heterodimers (-2.04 ± 0.37, 
p = 0.0014), although the latter two protein combinations were not significantly different 
(Figure 3.5). The RQ ratio of FOXP1/P4 heterodimers (-2.39 ± 0.46) had a significantly 
different effect than FOXPl and FOXP4 homodimers (0.30 ± 0.92) (p = 0.0007 and p = 
0.0064, respectively) (Figure 3.6). EFNB3 expression is differentially regulated between 
FOXP2 and FOXP4 homodimers (p = 0.0275) (Figure 3.7). The RQ ratio of FOXP2/P4 
heterodimers (0.47 ± 0.79) was found to be significantly (p = 0.185) different from 
FOXP2 homodimers, but not FOXP4 homodimers (Figure 3.7). The expression of 
EFNB3 activated by FOXP2/P4 heterodimers was found to be significantly different from 
FOXP1/P2 or FOXP1/P4 heterodimers (p = 0.0094 and p = 0.0043, respectively) (Figure 
3.8). FOXP2/P4 heterodimers caused EFNB3 upregulation while FOXP1/P2 and 
FOXP1/P4 heterodimers caused downregulation. 
SL/Tl (Slit homolog 1) 
The expression of SLITl was unanimously downregulated by FOXPl/2/4 
homodimers and heterodimers (Figure 3.5-3.8). There was no significant main effect of 
FOXPl/2/4 dimeric combinations on SL/Tl expression (F(5, 12) = 1.82,p = 0.18). 
In summary, this study was able to confirm the functional regulation of 
downstream FOXP2 targets in a cell-based model system and found that FOXPl/2/4 
transcription factors can act both as a repressor and an activator. The findings from the 
current study suggest that the relative levels of FOXP2 and its interacting co-factors, such 
as FOXPl and FOXP4, affect its ability to act as a transcriptional activator or repressor. 
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Furthermore, this study provides evidence of the complexity of regulatory mechanisms 
mediated by the FOXP subgroup. 
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Figure 3.5. Differential expression of FOXP2 downstream genes mediated by FOXP1/P2 homodimers 
and heterodimers. FOXPl (Pl), FOXP2 (P2), or FOXP1/P2 (Pl/P2) over-expression revealing functional 
regulation of downstream targets (CERJ, NCOR2, NEUROD2, PAX3, SNWJ, SFRP4, WJSP2, PRJCKLEJ, 
EFNB3, and SLITJ) by Pl and P2 homodimers and Pl/P2 heterodimers. Quantitative real-time polymerase 
chain reaction was performed using cDNA prepared from transfected HEK293 cell lines. Expression 
changes (Y-axis) are given as the mean of three cell passages from cells transfected with FOXP 1 and/or 
FOXP2 compared with cells transfected with an empty vector control and are normalized for equal 
expression of the internal control, HPRT and SDHA. Genes with significant difference in expression 
between control and FOXP over-expressing cells are indicated with an asterisk (*). *p<0.05; Error Bars: 
±SEM. 
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Figure 3.6. Differential expression of FOXP2 downstream genes mediated by FOXP1/P4 homodimers 
and heterodimers. FOXPl (Pl), FOXP4 (P4), or FOXP1/P4 (Pl/P4) over-expression revealing functional 
regulation of downstream targets (CERJ, NCOR2, NEUROD2, PAX3, SNWJ, SFRP4, WISP2, PRICKLEJ, 
EFNB3, and SLITJ) by Pl and P4 homodimers and Pl/P4 heterodimers. Quantitative real-time polymerase 
chain reaction was performed using cDNA prepared from transfected $EK293 cell lines. Expression 
changes (Y-axis) are given as the mean of three cell passages from cells transfected with FOXP 1 and/or 
FOXP4 compared with cells transfected with an empty vector control .and are normalized for equal 
expression of the internal control, HPRT and SDHA. Genes with significant difference in expression 
between control and FOXP over-expressing cells are indicated with an asterisk(*). *p<0.05; Error Bars: 
±SEM. 
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Figure 3.7. Differential expression ofFOXP2 downstream genes media~ed by FOXP2/P4 homodimers 
and heterodimers. FOXPI (P2), FOXP4 (P4), or FOXP2/P4 (P2/P4) over,.expression revealing functional 
regulation of downstream targets (CERJ, NCOR2, NEUROD2, PAX3, SNWJ, SFRP4, WISP2, PRICKLEJ, 
EFNB3, and SL/Tl) by P2 and P4 homodimers and P2/P4 heterodimers. Quantitative real-time polymerase 
chain reaction was performed using cDNA prepared from transfected HEK293 cell lines. Expression 
changes (Y-axis) are given as the mean of three cell passages from cells transfected with FOXP2 and/or 
FOXP4 compared with cells transfected with an empty vector contFol and are normalized for equal 
expression of the internal control, HPRT and SDHA. Genes with significant difference in expression 
between control and FOXP over-expressing cells are indicated with an asterisk (*). *p<0.05; Error Bars: 
±SEM. 
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Figure 3.8. Differential expression of FOXP2 downstream genes mediated by FOXPl/2/4 
heterodimers. FOXP1/P2 (Pl/P2), FOXP1/P4 (Pl/P4), or FOXP2/P4 (P2JP4) over-expression in HEK293 
cell lines confirm that the combinatorial actions of FOXPI/2/4 transcripti~n factors coordinately regulate 
the expression of downstream targets (CERJ, NCOR2, NEUROD2, PAX3, SNWJ, SFRP4, WISP2, 
PRICKLEJ, EFNB3, and SL/Tl). This graph shows the FOXPI/2/4 heterodimers together without the 
corresponding homodimeric combinations. Genes with significant differenc~ in expression between control 
and FOXP over-expressing cells are indicated with an asterisk(*). *p<0.05; !Error Bars: ±SEM. 
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3.5. Discussion 
It is well-recognized that genetic mutations of FOXP2 are associated with 
abnormalities in speech development and linguistic skills. Although FOXP 2 mutations 
are rare, it has been speculated that the downstream pathways it regulates could hold 
relevance for common language impairments.221 However, since its discovery as a 
'language gene', its precise functions from molecular and cellular perspectives have 
remained largely elusive. Previous studies have utilized a functional genomics approach 
to identify other elements of the pathways in which it participates, including targets that it 
regulates. 104' 105 The identified putative targets of FOXP2 represent a molecular entry 
point into the neural mechanisms underlying human speech and language. 
The current study was undertaken to address the need for additional studies to 
determine which targets are most relevant for mediating the effects of FOXP 2 on speech 
and language. This study helped to elucidate the contributions of FOXP 1 and FOXP4 in 
FOXP2-mediated regulation and the influence that FOXPl/2/4 dimerization has over the 
putative targets of FOXP2. In addition, this study investigated the downstream neural 
targets of FOXP 2 that are important for embryonic development, in order to examine the 
broader impact on language deficits and bridge together clinically distinct disorders on a 
molecular level, such as autism and 9p deletion syndrome. 
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3.5.1. Several Selected Gene Targets are Differentially Regulated by FOXPl/2/4 
Homodimers and Heterodimers 
The present study used HEK293 cell lines for stable transfections with FOXP 1, 
FOXP2, and FOXP4 in all combinations or an empty vector control, and involved 
quantitative assessments of mRNA expression on a gene-by-gene basis with use of qRT-
PCR. In line with previous studies suggesting that FOXP2 proteins act as repressors, six 
of the targets tested (CERJ, SNWJ, SFRP4, WISP2, EFNB3, and SLITJ) demonstrated 
reduced expression in the presence of FOXP2. Four genes (NCOR2, NEUROD2, PAX3, 
and P RICKLEJ) displayed increases in transcription in response to FOXP2 over-
expression in HEK293 cell lines, suggesting that the protein may also act as an activator 
for a subset of direct targets. The results indicating that FOXP2 has dual functionality, 
acting to either repress or activate gene expression, are parallel to that reported by Spiteri 
and Vernes and their colleagues. 104•105 Although activation of transcription has long been 
recognized as an essential component of gene regulation during development, the role of 
transcriptional repression programs is equally as crucial. Of the ten downstream targets 
investigated, eight genes (CERJ, NCOR2, NEUROD2, SNWJ, SFRP4, WISP2, 
P RICKLEJ, and EFNB3) displayed significant effects of altered gene expression due to 
FOXPl/2/4 interaction. The ability of FOXPl/2/4 proteins to dimerize in many different 
combinations could be a way in which transcriptional regulat~on is fine tuned in a cell-
specific manner. The results of this study did not demonstrate a clear synergistic pattern 
of FOXPl/2/4 dimerization preference across gene targets but rather, revealed that the 
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target genes have a preferred protein combination for transcriptional activation and/or 
repression that differed on a gene-to-gene basis. 
3.5.2. WNT Signaling Modulation by FOXPl/2/4 Dimeruation May Have 
Implications for Human Speech and Language 
The WNT family of signaling proteins participate in multiple developmental 
events during embryo genesis and has also been implicated in adult tissue homeostasis. 222 
WNT signaling is initiated by the binding of WNT ligands to a transmembrane FZD/LRP 
(frizzled/lipoprotein receptor-related protein) receptor complex, causing the activation of 
the cytoplasmic protein DVL (dishevelled). DVL inactivates GSK3 ~ (glycogen synthase 
kinase-3~), which results in the accumulation and subsequent nuclear translocation of 
CTNNB 1 (~-catenin). In the presence of appropriate co-activators, CTNNB 1 binds to the 
TCF/LEF (T-cell factor/lymphoid enhancer factor) family of DNA-binding proteins and 
upregulates the transcription of various target genes that drive proliferation and cell fate 
determination. In the absence of WNT signaling, the activated GSK3~ forms an 
intracellular complex that targets CTNNB 1 for degradation via the ubiquitin-proteosome 
pathway. 
CERJ (Cerberus 1) 
The present study showed that the expression of CERJ is repressed not just by 
FOXP2, but by other members of the FOXP subfamily as well. The results show that 
FOXP 1 does not seem to influence CERJ expression in a heterodimeric combination with 
FOXP2 or FOXP4. The data indicate that FOXP2 and FOXP4 homodimers were strong 
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transcriptional repressors of CERJ (Figure 3.7). Conversely, FOXP2/P4 heterodimers are 
significantly weaker transcriptional repressor than its corresponding FOXP2 and FOXP4 
homodimeric counterparts. Moreover, the FOXP2/P4 heterodimer was determined to be a 
significantly weaker transcriptional repressor than the FOXP1/P2 and FOXP1/FOXP4 
heterodimers (Figure 3.8). 
The CERJ gene encodes a multifunctional antagonist that binds to Wnt, as well as 
Nodal and bone morphogenetic proteins (BMP), thus inhibiting the activity of these 
proteins in the extracellular space during embryogenesis.210 In Xenopus embryos, 
cerberus has the unique property of inducing ectopic head formation without trunk 
formation.223 Trunk formation relies on Nodal and Wnt signaling, whereas head induction 
requires inhibition of Wnt and BMP signaling. Studies of a mouse CERJ-related gene, 
designated as Cerr 1, have reported that Cerr 1 may play a role in anterior neural induction 
d . c . d . d 1 224 an som1te 1ormation urmg mouse eve opment. 
Recently, Swinkels and colleagues reviewed the clinical features, developmental 
characteristics, and cytogenetic aberrations in 13 patients presenting with a 9p deletion, 
caused by a constitutional monosomy of part of the short arm of chromosome 9. 225 The 
deletion 9p syndrome is clinically characterized by dysmorphic facial features (i.e. 
trigonocephaly), hypotonia, and mental retardation. The authors of this paper had 
narrowed down the critical region for the deletion 9p syndrome to an area approximately 
300 kb size, of which the CERJ gene is located just distally and appeared to be a prime 
candidate for mutation analysis. Intriguingly, speech development was delayed in all 
patients, with test records from speech therapists showing speech disorders ranging from 
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mild to severe. Other behavioural problems included low concentration span, temper 
tantrums with head banging, sleep problems, and delayed motor development. These 
behaviours have been commonly described in patients with autism. Indeed, two patients 
showed definitive characteristics within the autism spectrum. Although CERJ did not 
reveal any causative mutations, it may be hypothesized that altered gene dosages of 
CERJ can still impact developmental processes that require spatial and temporal 
sensitivity. As demonstrated by this study, the imprecise combination of FOXPl/2/4 
proteins can have indirect effects on the expression level of CERJ. 
To further cement the association of FOX-related genes in speech and language 
delays, another study pertaining to deletion 9p syndrome implicated the involvement of 
FOXD4, which was found to be deleted only amongst patients with speech and language 
deficits.226 Notably, in addition to significant speech delays, the 9p deletion patients also 
exhibited autism-related characteristics. The finding that thes~ 9p deletion patients have a 
heterozygous deletion of FOXD4 implies that this gene may also have a role in speech 
and language development. The FOXD4 gene belongs to the same winged helix/forkhead 
transcription factor gene family as FOXP2 and shares a crucial forkhead box (FOX) 
domain, which is indicative of DNA binding.227 Haploinsufficiency of FOX gene family 
members, such as FOXP2 and FOXD4, may cause dosage imbalance in its target genes, 
which leads to abnormal neurological development. 
With regard to brain development, altered expression of FOXPl/2/4 transcription 
factors may result in premature or delayed activation of multiple downstream targets that 
force biological processes out of step. Given the importance of WNT signaling during 
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embryogenesis, FOXPl/2/4 regulatory mechanisms that go awry during embryogenesis 
might lead to changed transcriptional outcomes that are potentially responsible for speech 
and language impairments. 
SFRP4 (Secreted frizzled-related protein 4) 
The results indicate that the expression of SFRP4 was downregulated by FOXPl 
and FOXP2 homodimers (Figure 3.5). Although FOXPl and FOXP2 demonstrated equal 
ability to repress SFRP4 expression, FOXP1/P2 heterodirners proved to be an even 
stronger transcriptional repressor. Moreover, a distinct role for FOXP4 homodimers in 
SFRP4 expression was discovered. FOXP4 homodimers may be the only FOXPl/2/4 
protein combination that causes SFRP4 upregulation. Further, the results suggest that 
FOXP4 proteins are unlikely to regulate SFRP4 expression via heterodimerization with 
FOXPl (Figure 3.6). FOXP2/P4 heterodimers produced a different transcriptional effect 
and caused increased repression in comparison to FOXP2 and FOXP4 homodimers 
(Figure 3.7). 
SFRP4 is another protein that has been demonstrated to be a Wnt antagonist, as 
well as a putative downstream target of FOXP2. SFRPs (secreted frizzled-related 
proteins) are structurally similar to FZD receptors but lack the transmembrane segment 
necessary for signal transduction.228 SFRPs inhibit the Wnt signaling pathway by binding 
to either the Wnt ligand or FZD receptor.229 The expression patterns of several SFRPs are 
complementary to that of Wnts when examined in developing mouse embryos.41 One 
emerging explanation is that SFRPs facilitate boundary definition by limiting the range of 
Wnt activity. The expression of SFRP4 in the embryo, particularly in the brain, makes 
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this an intriguing molecule to investigate.228 Given the diversity of Wnt signaling effects 
on the developing embryo, defining the expression patterns of SFRP4 and its modulator, 
FOXP2, is of potential significance in brain development. Dysregulation of SFRP4 by 
FOXPl/2/4 proteins is likely to impact Wnt signaling and lead to alterations in cell fate 
and migration. 
WISP 2 (WNT 1 inducible signaling pathway protein 2) 
The results of this study suggest that various FOXPl/2/4 protein combinations 
have different regulatory roles in WISP2 expression.For instance, even though FOXPl 
and FOXP2 homodimers caused downregulation of WISP2 expression, FOXP1/P2 
heterodimers proved to be stronger transcriptional repressors (Figure 3.5). The results 
indicate that although FOXPl and FOXP4 homodimers were comparable transcriptional 
repressors of WISP2, FOXP1/P4 heterodimers lead to WISP2 expression levels that more 
closely resembled the baseline (Figure 3 .6). This may represent a molecular mechanism 
whereby the strength of transcriptional repression is self-modulated. There were no 
differences between FOXP2 homodimers, FOXP4 homodimers, and FOXP2/P4 
heterodimers; perhaps indicating the functional redundancy of some FOXPl/2/4 dimer 
combinations in the regulation of WISP2 expression (Figure 3.7). 
WISP2, another component of the Wnt signaling pathway, belongs to the CCN 
gene family. The acronym CCN is from the first three reported members of the family, 
namely CYR61 (cysteine rich 61), CTGF (connective tissue growth factor), and NOV 
(nephroblastoma overexpressed), but has since grown to include the WISP genes (WISP 1, 
WISP2, and WISP3). 230 Over-expression of Wntl, either through retroviral infection or 
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transgenic mouse over-expression, was found to upregulate WISPs at both the mRNA 
and protein levels. 231 Although two independent experimental systems demonstrated that 
WISP2 induction was correlated with the expression of Wntl, it is not clear whether 
WISP2 is directly or indirectly induced by the downstream components of the Wntl 
signaling pathway. Thus, WISP2 expression could result from Wntl signaling directly 
through CTNNB 1 transcription factor regulation or alternatively through Wntl signaling 
activating a transcription factor, which in tum regulates WISP2.231 It is possible that the 
signaling machinery of the Wntl cascade may be engaged by FOXPl/2/4 transcription 
factors to modulate WISP 2 expression. In support of this hypothesis, it has been 
demonstrated in a fish experimental system that lefl, a member of the Tcf/Lef family of 
transcription factors activated by Wnt signaling, regulates foxP2 expression during CNS 
development.232 Additionally, as previously mentioned, WISP2 has been identified as a 
potential transcriptional target of FOXP2. 
The present work shows that various FOXP protein combinations have different 
regulatory roles in WISP 2 expression. The diverse roles played by the different 
combinations of FOXP proteins in WISP 2 expression points towards a complex 
regulatory mechanism. 
PRICK.LE] (Prickle homolog 1) 
The results indicate that FOXP2 homodimers have differential effects on 
P RICKLEJ expression than FOXP 1 or FOXP4 homodimers (Figure 3 .5 & 3. 7). 
P RICKLEJ was found to be transcriptionally activated by FOXP2 homodimers but 
transcriptionally repressed by FOXP 1 and FOXP4 homodimers. The results also indicate 
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that FOXP2 does not appear to regulate P RICKLEJ expression through heterodimeric 
interactions with FOXP4. 
PRICKLE 1 is a downstream Wnt signaling molecule that regulates gastrulation in 
the early embryonic stage.213 Mouse Prick/el, and its related gene Prickle2, are 
abundantly expressed in the developing brain and may play important roles in the 
positive regulation of neurite outgrowth. 233 Previous investigations using chromatin 
immunoprecipitation coupled with hybridization to promoter microarrays (ChIP-chip) to 
identify direct targets of FOXP2 have found that neurite outgrowth and synaptic plasticity 
are the most prominent biological themes associated with F oxp2 function in the 
embryonic CNS.234 These findings represent a starting point into the functional 
characterization of FOXP 1/2/4 regulatory mechanisms, in particular the modulation of 
networks involved in neurite outgrowth and other core aspects of neurodevelopment. 
3.5.3. Notch Signaling Modulation by FOXPl/2/4 Dimerization May Have 
Implications for Human Speech and Language 
Notch-mediated intracellular signal transduction, an evolutionary conserved 
pathway, is reported to play seminal roles in cell fate control,. influencing differentiation, 
proliferation, and apoptotic events, at all stages of development.235 Notch is a 
transmembrane protein containing multiple epidermal growth factor (EGF)-like repeats in 
the extracellular domain and Ankyrin repeats in the intracellular domain.236 Upon ligand 
binding, proteolytic cleavage of Notch near the transmembrane domain occurs, resulting 
in release of the Notch intracellular domain (NICD).237 NICD is then released into the 
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cytoplasm and translocated into the nucleus to regulate transcription of Notch target 
genes. Upon translocation into the nucleus, NICD bind to RBPJ (recombining binding 
protein suppressor of hairless) which is a constitutive repressor of Notch signaling. RBPJ 
represses Notch target gene expression by recruiting a co-repressor complex, which 
includes NCORl, NCOR2, SNWl, CIR, HDACl, SPEN, FHLl, and SAP30. NICD 
binding to RBPJ replaces the co-repressor complex with a co-activator complex, which 
includes MAMLl-3 and EP300. Transcriptional activation and repression mediated by 
sequence-specific DNA-binding factors underlie the binary decisions necessary for 
progression of cell determination events, and it is becoming increasingly clear that 
cofactors, including NCOR2 and SNWl, are indispensible for proper development in a 
variety of developmental systems. 
NCOR2 (Nuclear receptor co-repressor 2) 
The present study revealed that the expression of NCOR2 is activated not only by 
FOXP2, but also by other members of the FOXP subfamily. FOXP1/P2 heterodimers 
were found to elicit an upregulation of NCOR2 that far surpassed the expression levels 
produced by its respective homodimers (Figure 3.5). Likewise, FOXP2/P4 heterodimers 
also gave rise to an upregulation of NCOR2 that exceeded the expression levels produced 
by its respective homodimers (Figure 3.7). Interesting, FOXP1/P4 heterodimers had 
opposing actions and instead caused the downregulation of NCOR2 (Figure 3.6). These 
findings suggest that the relative levels of FOXPl/2/4 proteins, and thus the different 
combinations of protein dimers that may be formed, determine its ability to act as an 
activator or repressor. 
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A link between NCOR2 and Rett syndrome, a neurodevelopmental disorder 
included in the autism spectrum, has been previously established. Rett syndrome, caused 
by mutations in the methyl-CpG binding protein MeCP2, is characterized by reduced 
brain growth, regressive effects on motor, speech, and cognitive development, and 
stereotyped hand-wringing behaviour.238 A recent report demonstrates that MeCP2 
cooperates with the NCOR2 co-repressor complex to inhibit the expression a hairy-
related gene, a known target of the Notch signaling pathway that has significant effects 
on neurogenesis.239 Notch signaling can regulate many aspects of neuronal maturation, 
including dendritic branching. In Rett syndrome, decreased dendritic branching in 
neurons has been found, leaving open the possibility that subtle alterations in Notch 
signaling may contribute to the Rett syndrome phenotype. 240 
Intriguingly, even as NCOR2 is identified as a potential downstream target of 
FOXP2, a functional interaction between NCOR2 and FOXPl has been reported.241 
NCOR2/FOXP1 protein complexes have been found to regulate a program of gene 
repression essential to proper myocardial development. Moreover, NCOR2/FOXP1 co-
repressor complexes appear to mediate a more general strategy since NCOR2 and FOXPl 
proteins also appear to be a component of c-fms regulation in monocytes. The data 
indicate that NCOR2-mediated co-repression may be a common mechanism by which 
FOXPl and other FOXP proteins regulate gene expression programs in development of 
target organs. 
The present study found that FOXP2 homodimers led to the upregulation of 
NCOR2 and that a clear synergy was seen with FOXP1/P2 and FOXP2/P4 heterodimers, 
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where the cells expressing these combinations had a stronger NCOR2 induction than cells 
expressing them separately (Figure 3.5 & 3.7). Differential expression of NCOR2 in the 
developing brain may have profound consequences. NCOR2 mRNA is primarily 
expressed in the ventricular zone region, where multipotent• neural precursors reside.242 
NCOR2 has also been implicated in regulation of embryonic neural stem cell 
proliferation and differentiation, in which it may have an important role in controlling 
neural stem cell maintenance and lineage decisions, and pla)'IS a critical role in forebrain 
development.243 The data suggest that NCOR2 and FOXPl/2/4 proteins may comprise a 
functional biological unit required to orchestrate specific programs critical for 
mammalian CNS development. 
SNWJ (SNW domain containing 1) 
In this study, FOXPl/2/4 heterodimers were observed to cause SNWl 
downregulation but the homodimers demonstrated mixed regulatory roles. The data 
indicate that FOXP2 homodimers lead to the downregulation of SNWJ and that FOXP2 
proteins are unlikely to heterodimerize with FOXPl and FOXP4 in SNWJ regulation 
(Figure 3.5 & 3.7). FOXPl and FOXP4 homodimers were found to upregulate the 
expression of SNWJ to nearly equivalent levels (Figure 3.6). On the contrary, SNWJ 
expression as influenced by FOXP1/P4 heterodimers was significantly different and 
caused downregulation instead. 
In addition to participating in the Notch signaling pathway, SNWl has been 
identified as a key regulator of BMP activity in vertebrate embryos.244 BMPs are a family 
of morphogens that help direct early embryonic patteming.245 BMP gradients provide 
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positional information to direct cell fate specification, such as patterning of the vertebrate 
ectoderm into the neural plate, neural crest, and epidermal tissues, with precise borders 
segregating these domains. In Xenopus, it was demonstrated that SNWl is required for 
neural crest specification.246 Further in vivo and in vitro assays using cell culture and 
tissue explants concluded that SNWl acts upstream of the BMP receptors. BMP activity 
is normally concentrated in a tight horseshoe-shaped band ·that runs along the anterior 
edge and sides of the neural plate. Loss of SNWl expression in the neural plate caused a 
strong drop in BMP signaling levels within this band of cells. When BMP is lost, the 
border between the neural plate and neighbouring tissues was found to be blurred and the 
neural crest tissue did not form. Therefore, SNW 1 is an essential factor in determining 
proper embryonic development. Although the exact mechanisms by which SNWl 
modulates BMP activity as yet remains unclear, the identification of this connection 
opens new avenues to better understand embryonic development. 
3.5.4. FOXPl/2/4 Dimerization Regulates Nervous System Development and May 
Have Implications for Human Speech and Language 
NEUROD2 (Neurogenic differentiation factor 2) 
This study showed that the expression of NEUROD2 was upregulated by FOXP2 
and FOXP4 homodimers but downregulated by FOXPl homodimers. The fact that 
NEUROD2 expression by FOXPl homodimers was significantly different from that of 
both FOXP2 and FOXP4 homodimers indicates a distinct role for FOXP 1 homodimers in 
the regulation of NEUROD2. Although the results indicate that FOXP2 does not 
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heterodimerize with FOXPl, FOXP2 does appear to heterodimerize with FOXP4 where 
FOXP2/P4 heterodimers appear to cause transcriptional repression of NEUROD2 (Figure 
3.5 & 3.7). Additionally, FOXPl is not likely to influence NEUROD2 expression through 
interactions with FOXP4 (Figure 3 .6). The results indicate that the relative levels of 
FOXP2 and its interacting co-factors determine the transcriptional activity (either 
upregulation or downregulation) of downstream FOXP2 targets, such as NEUROD2. 
Transcription factors of the basic helix loop helix (bHLH) class have been shown 
to be essential for normal brain development in vertebrate species.247 The members of the 
NEUROD subset of neurogenic bHLH transcription factors are characterized as neuronal 
differentiation genes because they induce cell cycle arrest in neural precursors and induce 
transcription of genes that contribute to mature neuronal phenotype.248,249 Previous 
studies have shown that NeuroD2-null mice hav~ defects in thalamocortical development 
in that axon terminals fail to segregate, barrel : organization is disrupted, and synaptic 
transmission is defective.217 Other studies have found that mice deficient for NeuroD2 
experience excessive apoptosis in the CNS populations that normally express NeuroD2; 
in particular, immense granule cell loss was see~ in postnatal cerebellar development.249 
I 
These mice exhibit ataxia, motor deficits, postnatal premature death, and reduced seizure 
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threshold. Mice that were heterozygous for NeuroD2 exhibited the same deficits as 
NeuroD2-null mice, though not as severe. This haploinsufficiency phenotype in mice 
raised the possibility that NEUROD2 expressi~n levels may influence human brain 
development and function. Since NeuroD2 partic~pates in genesis of neurons involved in 
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learning, memory, motor coordination, and cranial nerve function, it is important to 
understand how this gene is regulated in the CNS. 
FOXP2 transcription during CNS development is found predominantly in neural 
circuits that have been implicated in motor c0ntrol, including the basal ganglia, the 
thalamus, the inferior olives, and cerebellum.94 These brain structures are intricately 
interconnected to subserve motor-related functio~s: the basal ganglia modulate activity of 
the premotor and prefrontal cortical areas through connections projecting through the 
globus pallidus, substantia nigra, and thalamus, while the cerebellum plays a role in 
regulating motor coordination, receiving input from the inferior olives.250 The data 
implicating FOXP2 in the development of motor-related circuits during embryogenesis 
may account for the oromotor difficulties of humans with FOXP 2 mutations. It is thought 
that the accompanying linguistic and grammatical impairments observed in individuals 
with FOXP2 mutations are secondary consequences of basic deficits in motor planning 
and sequencing.94 There is an intriguing level of concordance between NeuroD2 and 
I 
FOXP 2 mutations in that ·both are associated with significant structural abnormalities in 
the cerebellum. Studies of patients with acquired lesions have highlighted a cerebellar 
role in procedural learning, particularly in linguistic functions.251 Therefore, the 
expression data of the present study draws attention to a possible link between the 
olivocerebellar system and FOXP2-NEUROD2 regulation. 
PAX3 (Paired box 3) 
In this study, FOXP2 homodimers caused the upregu1ation of PAX3, as did the 
FOXPl and FOXP4 homodimers, although there was no significant difference in effect. 
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The FOXPl/2/4 heterodimers also did nc;>t demonstrate significantly different 
transcriptional outcomes of P AX3, perhaps indicating the functional redundancy of 
FOXP 11214 proteins in P AX3 regulation. 
I 
P AX3 encodes a transcription factor belonging to a family of paired-domain 
containing proteins and is specifically expres~ed in the dorsal and posterior neural 
tube.218 The importance of P AX3 in dorsal neural tube and neural crest patterning and 
differentiation is evident in human disorders a~sociated with P AX3 mutations, namely 
W aardenburg syndromes type I and type III. 252 Waardenburg syndrome is the most 
common inherited form of congenital deafness iand has been associated with cognitive 
delay and other neurological abnormalities as w~ll. 253'254 A case report of two individuals 
I 
with W aardenburg syndrome highlights the pre~ence of moderate to severe intellectual 
I 
disability, history of developmental delay, and kutism.254 It remains to be conclusively 
determined whether there is a higher prevalence of autism in individuals with 
I 
Waardenburg syndrome. If so, this association :would be of interest in relation to the 
autism susceptibility gene FOXP 2. 
EFNB3 (Ephrin-B3) 
The results of this study indicate that FqXPl/2/4 homodimers and heterodimers 
have differential effects on EFNB3 that, dependirg on the dimer combination, may lead 
to transcriptional activation or repression. Whereas FOXP2 homodimers caused 
transcriptional repression, FOXP 1 and FOXP.4 homodimers were responsible for 
transcriptional activation (Figure 3.5 & 3.7) .. FOXP1/P4 heterodimers led to the 
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downregulation of EFNB3 (Figure 3 .6). The results suggest that FOXP2 is unlikely to 
influence EFNB3 expression through heterodimerization (Figure 3.5 & 3.7). 
The Eph receptors are a family of growtli and guidance molecules that are widely 
expressed in the developing nervous system. These receptor proteins and their ephrin 
ligands have well-known roles in the establishment of neuronal connectivity by guiding 
axons to the appropriate targets and regulating the formation of synaptic connections. 255 
EphB receptors are known to be expressed iQ. dendrites and transducer postsynaptic 
forward signals that promote the assembly, m~turation, and plasticity of synapses.256 
Ephrin-B (EFNB) proteins are expressed in axons and dendrites and function to 
transducer reverse signals important for axon guidance and pruning, presynaptic 
development, and synaptic plasticity.219 
It has been proposed that at around the time of language emergence in humans, 
the amino acid composition in the human variant of FOXP 2: has undergone accelerated 
I 
evolution.257 Because FOXP2 has an important role in speech and language in humans, 
the identified differentially regulated targets between humans and chimpanzees may have 
a critical function in the development and evolution of language circuitry in humans. Of 
particular relevance, EFNB2 is a well-validated direct target of FOXP2 that has been 
identified as one of the genes that is differentially regulated between human and 
chimpanzee FOXP2 orthologues.234 Now, the related gene EFNB3 is proposed to be a 
downstream FOXP2 target as well. 104•105 Examining EFNB3 is a matter of particular 
interest because dysfunctional axon guidance signaling is thought to underlie the 
microstructural abnormalities in the brains of individuals affected with autism. 234 The 
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mRNA level of EFNB3 has been found to be significantly lower in the anterior cingulated 
cortex of brains from individuals with autism, compared to controls; this region has 
previously been implicated in the pathophysiology of autism.258 As mentioned 
previously, studies using ChIP-chip to identify direct targets of FOXP2 found that neurite 
outgrowth and synaptic plasticity are strongly represented biological themes associated 
with FOXP2 function in the CNS.234 
The present study found that FOXPl/2/4 homodim~rs and heterodimers have 
differential effects on EFNB3 that, depending on the dimer combination, may lead to 
transcriptional activation or repression. Genes controlling neurite outgrowth or axon 
guidance during embryonic development have crucial roles in the maturation and 
stabilization of synaptic connectivity. Hence, the strong impact of FOXP2 on EFNB3, a 
gene that influences neurite outgrowth and axon guidance, might reflect major FOXP2 
functions that are relevant to development and maintenance of neuronal networks. 
Dysregulation of this regulatory network might have implications for language abilities. 
SLITJ (Slit homolog 1) 
The current study revealed that FOXPl/2/4 proteins transcriptionally repressed 
the expression of SLITJ. There were no significant differences in transcriptional 
outcomes between FOXPl/2/4 dimer combinatiOns, suggesting that there is functional 
redundancy of these proteins in SLIT 1 regulation. 
To achieve the connectivity underlying normal brain function, axons grow to form 
pathways, taking directional cues at specific points in space and time. 259 These decisions 
depend on contacts of growing axons with guidance molecules, which are tightly 
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controlled. Slit proteins are secreted guidance molecules produced by midline glial cells 
that function as a chemorepellant to prevent the re-crossing of commissural axons. 260 
This effect is mediated by the Robo (Roundabout) receptors. In addition to acting as a 
chemorepellant for cortical axons, SLITl has been reported to regulate dendritic 
development.220 As mentioned previously, geJ?.eS that conitrol axon guidance during 
embryo genesis have essential roles in the development of neural circuits. 
3.6. Conclusions 
The development and functioning of brain circuits underlying human speech 
result from complex sequential processes that are tightly regulated. Deciphering the 
neural pathways that are associated with speech-related circuits of the brain has been a 
challenge considering that speech is a unique human trait. Nevertheless, progress has 
been made by studying families where impairment of speech-associated processes is 
inherited in a monogenic fashion. A gene that 1 predisposes individuals to spee~h and 
language disorders had not been conceived of until FOXP 2 was discovered. 82 Thus, the 
opportunity to pinpoint genes that signify key entry points into the molecular networks 
underlying speech-related processes was made possible. In addition to the 
characterization of FOXP 2 in various animal models, subsequent studies have focused on 
the identification of FOXP2-targeted promoter regions. 104'105 Given that FOXP2 encodes 
a transcription factor, the emerging picture is that some putative target genes in which it 
regulates in the brain are likely to represent important players in speech-associated 
pathways. 
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This study has provided novel information on the potential role of FOXP2, in 
relation to its cofactors FOXPl and FOXP4, in speech and language functions. Although 
the existing literature provides some evidence for the specific dimerization between 
FOXP proteins, this is the first study showing How dimerization of FOXPl/2/4 proteins 
can influence the expression of various target genes. Studies regarding FOXP2 and its 
cofactors will help uncover the regulatory influence of FOXPl/2/4 over genes that are 
potentially involved in the molecular mechanism underlyiQg language acquisition and 
contribute to the understanding of language-related deficits in neurodevelopmental 
disorders such as autism. Furthermore, understanding the genes and pathways that are 
regulated by FOXPl/2/4 might lead to the discovery of candidate autism susceptibility 
genes. 
3. 7. Limitations and Future Areas of Study 
The present study used an over-expression system to investigate the regulatory 
I 
I 
functions of FOXPl/2/4. Thus, the reported r~sults only pertain to the regulation of 
downstream target genes under artificial conditions of high-level expression of 
FOXPl/2/4 proteins. This may represent a study limitation because FOXPl/2/4 proteins 
may demonstrate preferential binding partners under varying levels of FOXPl, FOXP2, 
or FOXP4 expression. For instance, high levels ofFOXP2 may lead to homodimerization 
with itself but with decreasing amounts of FOXP2, there may be competition of FOXP2 
homodimers with FOXPl or FOXP4, possibly leading to changed preferential binding 
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partners and altered transcriptional outcomes. This speculation warrants further 
investigation. 
For future experiments, it would be interesting to determine the localization of 
downstream targets of FOXP2 in the developing brain to see if its expression coincides 
with that of FOXPl/2/4 transcription factors. T~e evidence obtained will likely continue 
to provide new insights into the neural mechanisms behind· speech and language. 
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